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Abstract
Particle therapy (PT) with scanned carbon ions has been shown to improve the treatment of stage IV
lung cancer patients through reduced dose exposure of critical organs. In order to maximize this effect,
the application of intensity modulated particle therapy (IMPT) is needed. However, PT is particularly
susceptible to internal dose gradients due to its range dependence. This challenge is exacerbated in the
presence of organ motion. Both, motion and internal dose gradients, can be addressed by dedicated
robust 4D optimization strategies. In addition, as IMPT needs congruent target volumes, only robust
4D optimization can incorporate field-specific range uncertainties and motion-induced range changes.
Hence, a ’worst-case’ method was implemented into GSI’s in-house treatment planning system TRiP4D
and adapted for different 4D optimization strategies, accounting for setup and range uncertainties.
The uncertainty scenarios of robust optimization increase the required computer memory, especially
when also motion states are explicitly considered, as for robust 4D ITV optimization. Several strategies
to reduce problem size and to increase the computation speed were implemented and tested, such as
splitting the optimization matrix by dose contribution or randomized voxel subsampling.
Plan robustness was tested by performing robustness analysis, where dose distributions were cal-
culated for a variety of uncertainty scenarios. By creating the superposition of patient setup errors
with particle range changes, uncertainty scenarios beyond the ones already used in the optimization
were tested. In a patient study with 8 complex lung cancer patients, it was possible to increase plan
robustness in the majority of patients using robust optimization.
For conventional optimization, especially the dose volume exposure of the smaller airways (SA) be-
came a limiting factor. Using the same 4D ITV planning strategy but with robust optimization enabled
the OAR constraint for the SA to be fulfilled in 98.8 % of the cases, up from 79.8 % for conventional
optimization. It is to note, that this increase in robustness could mean sacrificing target coverage in
some patients.
Furthermore, a robust implementation of conformal 4D optimization was developed, based on a library
of treatment plans for each motion phase of a 4DCT. The reduction of irradiated volume considerably
improved OAR exposure, but increased the need for robust optimization even further in order to maintain
robustness against deviations of the delivered dose distribution from the planned dose distribution.
For a lung cancer patient with large tumor motion, the robust conformal 4D optimization method
could be shown to generate treatment plans with increased robustness against range and setup errors.
As a result of the increased robustness, target coverage could be increased and dose exposure to the
OARs could be decreased at the same time.
In conclusion, both robust optimization methods for 4D treatment planning in PT yield promising
results, generating new options for robust, safe intensity modulated particle therapy and thus beneficial
treatment plans for lung cancer patients.
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Zusammenfassung
Die Partikeltherapie (PT) mit gescannten Kohlenstoffionen könnte die Behandlung von Patienten mit
Lungenkrebs im Stadium IV verbessern, indem die Dosisbelastung kritischer Organe reduziert wird.
Vorzugsweise wird hierbei die intensitätsmodulierten Partikeltherapie (IMPT) eingesetzt. PT ist aber
wegen ihrer Reichweitenabhängigkeit besonders anfällig für interne Dosisgradienten, insbesondere wenn
sich die betroffenen Organe bewegen.
Sowohl bewegungsinduzierte als auch interne Dosisgradienten können durch entsprechend robuste
4D-Optimierungsstrategien kontrolliert werden. Da IMPT kongruente Zielvolumina benötigt, kön-
nen nur mittels robuster 4D-Optimierung feldspezifische Reichweitenunsicherheiten und bewegungsin-
duzierte Reichweitenänderungen simultan berücksichtigt werden. Daher wurde in das GSI-eigene
Bestrahlungsplanungssystem TRiP4D eine "Worst-Case"-Methode, welche Fehler in der Patientenposi-
tionierung und Reichweitenunsicherheiten berücksichtigen kann, implementiert und an verschiedene
4D-Optimierungsstrategien angepasst. Die Unsicherheitsszenarien der robusten Optimierung erhöhen
den Bedarf an Arbeitsspeicher, insbesondere wenn auch Bewegungszustände explizit berücksichtigt wer-
den, wie bei der robusten 4D ITV-Optimierung. Mehrere Strategien zur Reduzierung von Problemgröße
und Rechenzeit wurden implementiert und getestet, wie z.B. das Aufteilen der Optimierungsmatrix nach
Dosisbeitrag oder randomisierte Reduzierung der in der Optimierung verwendeten Voxel.
Die Pläne wurden einer Robustheitsanalyse unterzogen, bei der Dosisverteilungen für eine Vielzahl
von Unsicherheitsszenarien berechnet wurden. Durch die Überlagerung von Positionierungs- und Re-
ichweitenfehlern wurden Szenarien getestet, die über die bereits in der Optimierung verwendeten hin-
ausgehen. In einer Studie mit 8 komplexen Lungenkrebspatienten konnte die Planrobustheit bei der
Mehrheit der Patienten durch robuste Optimierung erhöht werden. Für die konventionelle Optimierung
war insbesondere die Volumendosis der kleineren Atemwege ein limitierender Faktor. Mittels robuster
4D ITV-Optimierung konnte die Vorgabe für die kleineren Atemwege in 98.8 % der Fälle erfüllt wer-
den, gegenüber 79.8 % bei konventioneller Optimierung. Diese verstärkte Robustheit führte bei einigen
Patienten zu einem Verlust der Zielabdeckung.
Weiterhin wurde eine robuste Implementierung der konformen 4D-Optimierung entwickelt, die auf
einer Bibliothek von Behandlungsplänen für jede Phase eines 4DCTs basiert. Dieses Verfahren reduziert
das bestrahlte Volumen erheblich, erhöht aber auch die Notwendigkeit einer robusten Optimierung, um
weiterhin die Robustheit gegenüber Abweichungen der abgestrahlten von der geplanten Dosisverteilung
gewährleisten zu können. Für einen Lungenkrebspatienten mit großer Tumorbewegung konnte mittels
robuster konformer 4D-Optimierung die Zielabdeckung deutlich erhöht und gleichzeitig die Dosisbelas-
tung kritischer Organe reduziert werden.
Zusammenfassend lässt sich sagen, dass beide robusten Optimierungsmethoden für PT mit 4D-
Behandlungsplanung vielversprechende Ergebnisse liefern und neue Optionen für eine robuste, sichere
intensitätsmodulierte Partikeltherapie und damit vorteilhafte Behandlungspläne für Lungenkrebspatien-
ten schaffen.
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Motivation
As reported in a recent German national cancer report “Krebs in Deutschland”, about 19 300 women and
34 500 men were diagnosed with lung cancer in 2013–2014. Mortality rates for the same period were
reported to be 15 524 for women and 29 560 for men [Kaatsch et al., 2017]. At a 5-year survival rate
of 15 % for males and 20 % for females, lung cancer prognosis remains unfavorable (data collected in
Germany between 2013–2014 [Kaatsch et al., 2017]). More than half of these patients are not detected
until later stages, most commonly at stage IV, with non-small cell lung cancer (NSCLC) [Ramalingam
and Belani, 2008; Iyengar et al., 2014]. Since the rapidly growing and early metastasizing small cell lung
cancer (SCLC) is primarily treated chemotherapeutically [Kumar et al., 2004; Renz-Polster and Krautzig,
2008], the focus of this study is on NSCLC.
Several studies have shown that a dose escalation can significantly improve local tumor control rates,
in particular for NSCLC [Rosenzweig et al., 2005; Kong et al., 2005]. The occurrence of radiation-
induced normal tissue complications also depends significantly on the doses delivered to organs at risk
(OAR). For example, the probability for radiation side effects, such as acute esophagus toxicity increases
significantly depending on the esophagus volume receiving more than 35 Gy [Belderbos et al., 2005].
The choice of the radiotherapy protocol used also effects treatment outcome, where in particular the use
of stereo-tactic body radiation therapy (SBRT) has shown promising results for the treatment of early
stage NSCLC [Baumann et al., 2001; Fakiris et al., 2009; Grutters et al., 2010; Greco et al., 2011]. In
the majority of photon treatments, a high number of irradiation fields is necessary to provide sufficient
target coverage of deep seated tumors, while keeping normal tissue toxicity in the entrance channels
on an acceptable level. Considering that the absorbed photon dose is exponentially decreasing with
penetration depth, this comes at the cost of larger volume of surrounding tissue exposed with dose.
Ion therapy provides a promising solution for reducing doses to surrounding tissue. For these high-dose
applications, the beneficial depth dose profile of ion beams delivers low doses along the radiological path
and the majority of dose at the desired penetration depth. This is possible due to the “inverse” depth dose
profile with its distinctive Bragg peak, produced by fast charged particles decelerated in matter. Anderle
et al. have performed an in-silico comparative study for SBRT versus rescanned 4D optimized carbon ion
therapy showing promising results [Anderle et al., 2016, 2018]. For the majority of patients, the target
coverage was similar compared to SBRT while the OAR dose exposure was significantly reduced.
Compared to photons, scanned delivery of ion beams is much more sensitive to patient motion [Bert
et al., 2008]. The interference of the respiratory motion and the scanning of the pencil beam can lead
to interplay patterns, generating hot and cold spots within the planned dose distribution of the tumor
volume. The treatment of moving lung tumors with ion beams is, in particular, susceptible to motion
induced errors in delivery. One of the major issues is the large difference in density between the solid
lung tumor and the surrounding lung tissue with lower density, which could result in significant volumes
of dose delivered to healthy lung tissue, if the tumor is missed. To avoid high doses to normal tissue,
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especially if a treatment aims for high single fractionated target doses, motion mitigation strategies must
be implemented to ensure accurate dose delivery.
In addition to dose deteriorations induced by respiratory motion, further decrease of dose coverage
can be caused by imprecise patient positioning or range uncertainties. The latter two can lead to a
mismatch of internal dose gradients between treatment fields, in particular when intensity modulated
particle therapy (IMPT) is used. For the treatment of static targets with protons, robust optimization
approaches have been successfully developed to incorporate these uncertainties in patient positioning
and particle ranges during treatment planning [Unkelbach et al., 2007, 2009; Pflugfelder et al., 2008;
Fredriksson et al., 2011; Liu et al., 2012]. The majority of robust approaches include 9 scenarios into
the optimization: besides a nominal case, typically two range uncertainty scenarios are introduced, ac-
counting for under- and overshoots of the particles, next to 6 scenarios considering shifts of the patient’s
iso center. Eventually, the resulting treatment plan is optimal for several scenarios at the same time.
However, this could mean a deliberate decrease of plan quality for the nominal case.
In this study, the topic of robust optimization is investigated for treatment planning for moving targets
with carbon ions. Basically, the presented robust methods are an adaption of 3D robust optimization
for the use in time resolved plan optimization strategies, e.g. 4D optimization [Graeff, 2014]. This
optimization method makes use of the information about temporal changes in patient anatomy provided
by a 4D computed tomography (CT). The implementation of the robust 3D optimization algorithm into
the in-house treatment planning system is described in chapter 2.
The robust 4D treatment planning is tested on a set of 8 complex lung cancer patients with multiple
targets, which have been investigated by Anderle et al. using 4D optimization with rescanning [Anderle
et al., 2018]. The resulting robust plans are then compared with the carbon plans from Anderle et al..
To provide a high degree of comparability, the planning study presented in this thesis uses the same
planning parameters like in the study of Anderle et al., e.g. number of treatment fields, couch and
gantry angles, etc. The major quantities under consideration are target dose coverage and OAR dose
exposure. In contrast to [Anderle et al., 2018], these quantities are not only investigated for the nominal
case but for a variety of uncertainty scenarios, which are summarized in a robustness analysis. This
analysis gives deep insight about the plan quality under influence of different patient geometry between
the stage of planning and treatment. The major part of this thesis is dedicated to the investigation of this
robust 4D ITV method due to its high clinical relevance. The primary hypothesis of the presented study
is, that using robust optimization further increases OAR sparing while keeping sufficient target coverage
in the majority of considered uncertainty scenarios. As the implementation at centers like Heidelberg
or Marburg would require primarily changes to the treatment planning software, the described method
could be potentially used in a clinical environment in the near future.
Finally, a conformal 4D optimized treatment plan is presented for a selected patient. The conformal 4D
optimization creates a library of treatment plans for each motion phase of a 4DCT, minimizing the normal
tissue dose since only small safety margins are necessary for sufficient dose coverage. Though, a fast real-
time motion detection and a dedicated treatment control system is necessary for synchronization of the
treatment delivery to the respiratory motion of the patient. So far, this system has been only tested
experimentally in promising dosimetric experiments at GSI. However, this system has the potential to
improve carbon ion treatment in particular in combination with robustly optimized treatment plans.
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This chapter gives an introduction into the research background of this thesis. At first, an overview
about lung cancer in general is given in section 1.1.1. Section 1.2 briefly presents the history of radio-
therapy. In more detail, the mechanics behind the dose deposition of ionizing radiation are stated in
section 1.3, followed by a description of the biological effects caused by radiation. Section 1.5 described
the most common accelerators for particle therapy and the difference between passive and active deliv-
ery of treatment. Section 1.6 describes the fundamentals for treatment planning for scanned ions, also
looking at patient motion (section 1.6.4), its implications (section 1.6.6) and mitigation strategies (sec-
tion 1.6.7). Also the topic of 4D treatment planning (section 1.6.8) and image registration (section 1.6.9)
is addressed.
With the information presented here, the reader should be equipped with sufficient knowledge for
understanding the concepts and results in this work.
1.1 Lung cancer
As defined in [Renz-Polster and Krautzig, 2008] lung cancer, also called bronchial carcinoma, is a malig-
nant lung tumor originating from the bronchial epithelium. Currently, about 19 300 women and 34 500
men are diagnosed with lung cancer annually. Further, current annual mortality rates stand at 15 524
women and 29 560 men [Kaatsch et al., 2017, p. 56–59]. at the beginning of the 20th century, the
bronchial carcinoma was considered one of the rarest forms of cancer. Today it is the most frequent
malign tumor: Lung cancers represent about 25 % of all cancer deaths. Currently, men are inflicted with
bronchial carcinoma more frequently than women. However, since 1999, incidence rates are rising in
Germany’s female population (see figure 1.1). This can be correlated to the recently rising numbers of
female smokers [Renz-Polster and Krautzig, 2008].
At a relative 5-year survival rate of 15 % for males and 20 % for females, lung cancer prognosis remains
to be unfavorable (data collected in Germany between 2013–2014 [Kaatsch et al., 2017]).
1.1.1 Risk factors
The greatest risk factor for lung cancer is tobacco smoke [Kaatsch et al., 2017]. For males 90 % and for
females at least 60 % of lung cancer diagnoses can be traced back to active and regular smoking. Also
inhalation of second hand smoke increases the risk for lung cancer.
In the USA, the capita cigarette consumption from the beginning of the 20th century to the mid 2000’s
coincides with the male lung cancer incidence rates [MMWR, 2005; AACR, 2012]. The two graphs in
figure 1.2 show a lag of about 20 to 30 years between the rise of the cigarette consumption and the
cancer incidents. Following widespread US policy action against raising numbers of smokers within the
population, such as banning tobacco advertisements from broadcast in 1971 [Warner and Goldenhar,
1989], it took almost 20 years for the lung cancer rates to begin to decline.
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Figure 1.1.: Age standardized morbidity and mortality by gender for Germany 1999–2014/2015. Figure
adapted from [Kaatsch et al., 2017].
The effects of common pollution are also contributing to the overall lung cancer risk, although they are
less relevant compared to tobacco smoke. Nonetheless, about 15 % of patients suffering from bronchial
carcinoma are non-smokers. Cancerogenic substances like asbestos, polycyclic aromatic hydrocarbons,
quartz and nickel dust have caused about 9 % to 15 % of lung cancer incidents in Germany [Kaatsch
et al., 2017]. The exposure to radioactive substances such as natural radon gas also increases the risk
for lung cancer [Renz-Polster and Krautzig, 2008]. This is especially hazardous in basement levels of
buildings in areas with naturally high radon concentrations. Ongoing investigations are studying the
influence of pollution with fine dust like particles with grain sizes smaller 10 µm. Such particles originate
from transportation vehicles (combustion of diesel fuel, particles from tire and brake wear), power
plants, heating systems and industrial production. Due to their small size, the particles can sediment on
the mucosal tissue of the bronchial apparatus or even in the alveoli causing local inflammation. Over
time, this can lead to bronchitis or chronic coughing which encourages the development of bronchial
carcinoma [Renz-Polster and Krautzig, 2008].
1.1.2 Non-small cell lung cancer (NSCLC)
Since the rapidly growing and early metastasizing small cell lung cancer (SCLC) is primarily treated with
chemotherapy only [Kumar et al., 2004; Renz-Polster and Krautzig, 2008], the focus of this study is on
non-small cell lung cancer (NSCLC), which is primarily treated by surgery and subsequent chemotherapy
and radiotherapy, if the tumor is inoperable. NSCLC divides in four main stages I–IV with subdivisions
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Figure 1.2.: Correlation between per capita cigarette consumption and male lung cancer incidents from
1900–1999. Figure adapted from [AACR, 2012], cigarette consumption data from [MMWR, 2005].
(Ia/b, IIa/b, IIIa/b/c and IVa/b) [Goldstraw et al., 2016]. Table 1.1 showing the 5-year survival rates by
staging, emphasizes the poor prognosis for NSCLC, especially for stages III and IV. The categorization
depends on the size and number of lung tumors, the affection of lymph nodes as well as the occurrence
of metastasis outside of the lung (TNM staging).
Table 1.1.: 5-year survival rates of NSCLC patients by staging from worldwide data between 1999–2010
[ACS, 2017; Goldstraw et al., 2016].
Clinical stage 5-year survival in [%]
Ia1 92
Ia2 83
Ia3 77
Ib 68
IIa 60
IIb 53
IIIa 36
IIIb 26
IIIc 13
IVa 10
IVb 1
Figure 1.3 is an example of NSCLC stages Ia/b and IV. Stage Ia and Ib are primarily distinguished
by lesion size, whereas IV is distinguished by occurrence of metastases, lesions in the lining of lung or
heart or lesions in both lungs. In this thesis, the term of stage IV will primarily refer to the occurrence of
lesions in both lungs, which will be called multiple targets further on.
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Figure 1.3.: Panel (a) shows stage Ia and Ib which are primarily distinguished by lesion size; panel (b)
depicts stage IV which is distinguished by occurrence of metastases, lesions in the lining of lung/heart or
lesions in both lungs. In this thesis, the usage of stage IV refers primarily to the latter description. Figure
adapted from [CRUK, 2015].
Commonly the tissue affected by the tumor is surgically resected, either by removing segments or
whole lobes of the lung, and in some cases resecting the complete lung on one side of the thorax [Renz-
Polster and Krautzig, 2008]. Postoperative chemotherapy is often used, as data has shown it to increase
the 5 year survival rate from 40 % to about 45 % [Renz-Polster and Krautzig, 2008]. In cases where the
tumor is inoperable due to being in close proximity to or even infiltrating critical organs (e.g. esophagus
or the heart), radiotherapy may be selected as a final treatment option. Commonly, a fractionated dose
of 60 Gy is used for curative or palliative treatment [Renz-Polster and Krautzig, 2008]. As an example
of how NSCLC can look like, figure 1.4 shows a NSCLC lesion, specifically a squamous-cell bronchial
carcinoma. This cancer type is often related to smoking [Kenfield et al., 2008].
1.2 Radiotherapy – historical overview
The history of radiotherapy is basically beginning with W. C. Roentgen discovering X-rays in November
1895 [Röntgen, 1898]. After the discovery of the so called Roentgen radiation diagnostic applications
like radiographs quickly developed. These devices were used on battlefields to find bullets or broken
bones in wounded soldiers. There are also reported cases of the treatments of eczema or lupus with
X-rays [Connell and Hellman, 2009], including the Austrian physician Leopold Freund treating the birth
mark of a five year old girl with X-rays [Freund, 1897]. Further, only 7 months after Roentgen’s discov-
ery, X-rays were used by the French physician Victor Despeignes to treat a cancer patient with gastric
carcinoma who eventually benefited from radiotherapy [Sgantzos et al., 2014].
Limited by the available low X-ray energies and hence low penetration depths, most of the tumors
could not be treated without the infliction of normal tissue damage, such as skin burns [Connell and
Hellman, 2009]. The discovery of natural radioactivity, so called γ rays, by Antoine-Henri Becquerel
in 1901, as well as the discovery of radium by Marie and Pierre Curie improved the understanding of
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Figure 1.4.: Image of a squamous-cell bronchial carcinoma. The tumor (white tissue in the upper left
corner) is obstructing the bronchus. Beyond the tumor, the bronchus is inflamed and contains mucus. The
black and dark gray areas indicate, that the patient is a smoker. Image courtesy John Hayman [Hayman,
2007].
radioactivity, made radiation with higher energies available. At the same time, awareness of the risks of
ionizing radiation began to rise.
To reach deeper seated tumors, physicians and physicists worked improved the X-ray tubes by increas-
ing the available energies. In 1913, American physicist William Coolidge invented the hot-cathode X-ray
tube which produced X-rays with energies up to 200 keV [Coolidge, 1913]. Over the next few decades,
the X-ray tube was successively improved and higher energies became available through devices such as
the cascade tube which enabled energies up to 700 keV [Connell and Hellman, 2009]. New opportuni-
ties were enabled by Donald Kerst’s invention of the electron accelerator in 1940 [Kerst, 1940] and the
development of the U.S. version of the synchrotron by McMillan at Los Alamos Laboratory [McMillan,
1945]. This led to the development of compact linear accelerators mounted on 360° gantries, which
could deliver γ rays with energies of several MeV. These were the predecessors of modern photon
therapy technologies like intensity modulated radiotherapy (IMRT), SBRT or volumetric modulated arc
therapy (VMAT) which originated in the mid nineties [Connell and Hellman, 2009].
Although a depth dose curve of charged particles was described by W. H. Bragg back in 1903 for α-
particles in air [Bragg and Kleeman, 1904], it took until 1946 for the potential of charged particles in
radiation therapy to be seen. R. Wilson proposed the use of fast protons to treat deep seated tumors
due to their beneficial depth dose profile compared to photons and predicted "that precision exposures
of well-defined small volumes within the body will soon be feasible" [Wilson, 1946]. When, in 1948 the
synchrocyclotron became available for experiments at Lawrence Berkeley Laboratory (LBL), Berkeley
(USA), Tobias et al. investigated the physical and radiobiological properties of the proton beam [Tobias
and Todd, 1967]. Patient treatment started in 1954 with protons first and with helium beam later
[Schardt et al., 2010]. The use of heavier ions e.g. 20Ne started in 1975 at the Bevalac facility at LBL
18
with particle energies up to 670 MeV/u. In particle therapy the term "heavy ion" is used for every ion
heavier than a proton although only light ions up to neon are actually used in therapy. Until the closure
of the Bevalac facility in 1992, 443 patients have been treated with 20Ne ions delivered by passive beam
shaping systems.
In 1994 at National Institute of Radiological Sciences, Chiba, Japan (NIRS), a research program ded-
icated to carbon ions was launched. Based on the developments at Berkeley, the treatment delivery
system at the Heavy Ion Medical Accelerator (HIMAC) used a similar approach with passive beam shap-
ing [Hirao et al., 1992]. At around the same time, a project for the development of spot scanning for
protons was started at Paul Scherrer Institut (PSI) [Pedroni et al., 1995] and raster scanning for carbon
ions was developed at GSI Helmholtzzentrum für Schwerionenforschung GmbH (GSI) [Haberer et al.,
1993]. The goal of these therapy projects was to increase the conformity and the homogeneity of the
delivered dose distribution while increasing normal tissue sparing. These developments also eliminated
the neef for patient specific components such as compensators and collimators.
Following pilot studies done in Germany, Heidelberg Ion-Beam Therapy Center (HIT) started treating
patients in 2009, and Marburg Ion-Beam Therapy Center (MIT) in 2015. Both centers have been using
protons and carbon ions. In Europe, two more ion centers are in operation: National Center of Onco-
logical Hadrontherapy, Pavia, Italy (CNAO) since 2011, and MedAustron in Vienna, Austria since late
2016.
1.3 Ionizing radiation
In radiotherapy, the absorbed dose is one of the most important quantities. As reported in the 50th
report of the International Commission on Radiation Units and Measurements (ICRU), the absorbed
dose is defined as the mean energy dE deposited by ionizing radiation in a mass element dm [ICRU,
1993]. The absorbed dose is also called physical dose and is stated in the SI-unit Gray [Gy]. Introducing
the mass density ρ the dose becomes proportional to the quotient of mean energy dE and volume
element dV (see equation 1.1).
D =
dE
dm
=
1
ρ
dE
dV
[1Gy= 1J/kg]. (1.1)
The dose absorbed in matter is generated by two kinds of ionizing radiation: directly ionizing radiation
e.g. charged particles, like electrons or ions and indirectly ionizing radiation, like high energy photons
or neutrons. The different mechanisms behind the energy deposition are described for photons and and
ions in the following.
1.3.1 Photons
When photons interact with tissue, there are three major attenuation processes depending on the initial
energy: The photo electric effect, Compton scattering and pair production [Meschede, 2015, p. 838–
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839]. The attenuation I(x) of the initial photon intensity I0 is described by the absorption law introduced
by Lambert-Beer:
I(x) = I0 · exp(−µx), (1.2)
where x is the penetration depth and µ the material specific attenuation coefficient. Figure 1.5 shows the
depth dose curves for photon irradiation on a water phantom for three radiation sources: X-rays from a
cathode ray tube at 120 keV, gamma radiation from a 60Co source at about 1.25 MeV) and photons from
a linear accelerator at 18 MeV. The exponential decay is present for all three energy ranges, but it is
more pronounced for the X-rays. For the two higher energies, there is a buildup effect, which pushes the
initial dose maximum further into the tissue by some centimeters, before the exponential decay becomes
dominant. This initial buildup effect can be traced back to secondary Compton electrons which mainly
scatter in forward direction until they reach an equilibrium between dose deposition and creation of
further secondary electrons [Schardt et al., 2010]. This smaller dose deposition in the entry channel
makes the use of high energy photons (several MeV) more favorable, and is, therefor, common practice
in modern photon therapy. However, due to the exponential decrease of the deposited dose, photon
therapy typically requires several treatment fields to not exceed normal tissue constraints.
1.3.2 Ions
As the depth dose profile is inverse compared to photons, ion therapy is commonly used to treat deep
seated tumors, which typically requires particle ranges up to 30 cm. This corresponds to particle energies
of up to 220 MeV/u for protons and 430 MeV/u for carbon ions [Schardt et al., 2010]. To reach these
energies, particle velocities of about β ≡ v/c = 0.7 are required. The mechanism behind the energy
deposition of charged particles are mainly inelastic collisions with orbital electrons of the target atoms.
The Bethe-Bloch equation describes the energy loss of the charged particles dE per unit path length dx ,
also known as “stopping power” [Bethe, 1930; Bloch, 1933]
−dE
dx
= 4π
e4Z2
p
mev
2
· NAZtρt
At

ln
2mev
2
〈I〉 − ln
!
1− β2

− β2

. (1.3)
Zt and Zp denote the charge of the target and of the projectile, me and e are the electron mass and
the elementary charge, v is the velocity of the projectile, NA is the Avogadro number, ρt and At are the
density and the atomic mass of the target material and 〈I〉 is the mean ionization energy of the target
atoms, which is about 80 eV for liquid water [Schardt et al., 2010]. By increasing the initial kinetic
energy of the charged particles, the sharp dose maximum with its characteristic steep distal fall-off, the
so called Bragg peak, is shifted deeper into the irradiated tissue. This is illustrated in figure 1.5 for
carbon ions with energies of 250 MeV/u and 300 MeV/u.
Using the stopping power presented in equation 1.3, the expression for the dose from equation 1.1
can be written as
D[Gy] = 1.6 · 10−9 · dE
dx
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Figure 1.5.: Relative dose over depth in water in cm. The depth dose curve is shown for X-rays with
120 keV (cyan line), gamma rays with 1.1732MeV and 1.3325MeV from 60Co (blue line), 18MeV photons
from a linear accelerator (green line) and carbon ions with 250MeV/u and 300MeV/u (red lines). Figure
from [Schardt et al., 2010].
This formulation is valid for parallel beams with a particle flux F . In the context of radiobiology, a
similar quantity related to the stopping power is used: linear energy transfer (LET). LET is by convention
denoted in keV/µm, which refers to the energy deposited in the stopping medium by the slowing-down
particle [Schardt et al., 2010]. The LET is an important measure to assess the radio biological efficacy
of the ionizing radiation. It is especially used for the calculation of the relative biological effectiveness
(RBE), which is described in further detail in section 1.4.1.
1.3.2.1 Range straggling
The Bethe-Bloch equation describes the stopping power for a single particle. However, delivering clini-
cally relevant doses require thousands of particles to be slowed down within the tissue. As energy loss
by inelastic Coulomb scattering has statistical fluctuations, this results in a broadening of the Bragg peak
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and a degradation of the peak-to-entrance dose ratio. In the limit of many collisions, the law of large
numbers is valid and these statistical fluctuations can be described with a Gaussian distribution [Bohr,
1940; Ahlen, 1980].
From this distribution, the relative straggling ratio
σR
R
∝ 1p
M
(1.5)
can be derived, where σR is the straggling width, R is the mean range M is the particle mass [Schardt
et al., 2010]. Accordingly, this ratio becomes smaller for heavier ions. For example, carbon ions have
a factor 3.5 smaller relative range straggling than protons. However, in clinical treatment, the profile
of a Bragg is broader, which is primarily caused by the non-heterogeneity of the tissue of the patient,
especially when compared to initial measurements in water.
It can be advantageous to exploit this effect to reduce treatment duration. By deliberately extending
the longitudinal beam broadening, the number of particle energies necessary to cover a tumor volume is
reduced. Further detail is given in section 1.5.2, where the use of a passive range modulator build from
polymethyl methacrylate (PMMA) is described for the raster scanning method [Weber and Kraft, 1999].
1.3.2.2 Lateral scattering
As particles traverse through tissue, they experience small lateral deflections. These are mainly caused
by elastic Coulomb scattering interactions with the target nuclei, whereas scattering due to collisions
with the electron shell of the target atoms are much less significant and can be neglected. The analyt-
ical description of this lateral beam broadening by Molière [1948] is in good empirical agreement, as
measured e.g. for protons by Gottschalk et al. [1993]. Since laterally scattered particles can be further
scattered, the beam spread becomes larger with increasing penetration depth. Furthermore, the beam
spread is dependent on the material composition of the target. For a given thickness, targets consisting
of heavier elements cause greater lateral spreading of the incident ion beam [Schardt et al., 2010].
Similarly, heavier ions produce less lateral spread than protons [Weber and Kraft, 2009]. For a given
range of about 16 cm in water, the angular spread of protons is more than three times larger than for
carbons [Schardt et al., 2010]. The consideration of lateral scattering is also important for OAR sparing
during treatment planning, since sharp penumbras of the particle beams are necessary to reduce the
irradiation of surrounding tissue.
1.3.2.3 Nuclear fragmentation
Compared to the stopping power generated by Coulomb interactions of the projectiles with the electron
shell of the target atoms, the contribution of nuclear interactions to the overall stopping power is much
smaller. Nonetheless, for high energetic particles with long ranges, nuclear interactions (such as target
or projectile fragmentation) contribute significantly to the dose deposited in the irradiated tissue. For all
ions heavier than protons, target fragmentation has the highest dose contributions.
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Figure 1.6.: Schematic illustration of the abrasion-ablation model of peripheral collisions of high energy
ions as described in Serber [1947]. Figure from [Schardt et al., 2010].
For geometrical reasons, peripheral collisions are the most frequent nuclear reactions occurring along
the stopping path of the ions [Schardt et al., 2010]. The peripheral collision is a two-step process which is
well described with the abrasion-ablation model by Serber [Serber, 1947]. This process is schematically
illustrated in figure 1.6. During abrasion, the projectile abrades the partial overlap of the target nuclei
due to their geometrical cross sections and creates a reaction zone, the so called fireball. In the second
step, the ablation, the remaining projectile and target fragments deexcite by evaporation of a nucleus or
clusters. Detailed studies of these nuclear fragmentation reactions have been performed by Goldhaber
and Heckman [1978]; Hüfner [1985]; Lynch [1987].
For radiotherapy with high energy ion beams, fragmentation is important for two reasons: (i) The
nuclear reactions cause a loss of primary ions and produce a buildup of lower-Z fragments. The relevance
of these effects increases with increasing penetration depth. (ii) The secondary projectile-like fragments
travel at almost the same speed as the primary ions. Due to having about the same energy and smaller
mass than the primary ions, the fragments have a longer range than the primary ions [Schardt et al.,
2010]. This causes the dose tail behind the steep dose fall-off of the Bragg peak which is present for all
ions heavier than protons (see figure 1.5).
For carbon ions stopped in water, hydrogen and helium fragments are most abundantly produced
[Haettner et al., 2006]. Fragments heavier than boron are slowed down shortly after the Bragg peak.
Lighter fragments such as hydrogen and helium are the predominant ions in the dose tail [Schardt et al.,
2010]. For heavier ions the dose tail becomes more pronounced, until the depth profile of the deposited
dose becomes unfavorable for therapy. The distal dose fall-off becomes less sharp and the advantages for
a conformal dose deposition are lost [Kraft, 2000]. For this reason, ions heavier than neon are commonly
not used in ion therapy.
For the treatment of deep seated tumors, higher penetration depths are needed. However, the impact
of the fragmented ion species on the deposited dose increases with higher penetration depth. Especially
the relative biological effectiveness (RBE) differs for different ion species. Hence, accounting for frag-
mentation during treatment planning is in particular important for the calculation and optimization of
the biological dose. This is done by generating dedicated base data tables, e.g. particle spectra for dif-
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ferent depths in water. These tables are gained from analyzing fragmentation measurements, which has
been done at several centers [Maccabee and Ritter, 1974; Schimmerling et al., 1989; Llacer et al., 1990;
Schall et al., 1996; Haettner et al., 2006].
1.3.2.4 Track structure
From the microscopic point of view, the inhomogeneous spatial dose distribution generated by ions
(shown in figure 1.7) differs from the homogeneous dose distribution created by high energy photons
(see section 1.4). Ions lose their energy through electrical interactions with the Coulomb potentials of
target atoms or molecules. In this process, secondary electrons or so called δ-electrons are emitted.
Further on, these δ-electrons are frequently scattered within the target material, depositing energy in a
radial dose distribution around the ion track. This localized energy distribution of particles results in a
larger biological effect which is described in section 1.4.
The dominant ionization process through Coulomb interactions can be described by the binary-
encounter approximation which assumes that the projectile collides with a quasi-free electron [Kraft
and Krämer, 1993]. For electrons with energies below 50 eV, electron excitations are the dominant
process, while ionization is the major process for higher energies, creating further electrons which again
contribute to the deposited dose. The ionization cross section for electrons reaches its maximum at about
100 eV which corresponds to a mean free path length of a few nm. This increases the probability of two
ionization events occurring within 2 nm, which corresponds to distance of the two strands of the DNA
double helix [Schardt et al., 2010] (see figure 1.7).
The δ-electron track structures strongly depend on particle species and kinetic energy. Figure 1.7
shows the highly inhomogeneous energy distribution for protons and carbon ions with energies of
0.2 MeV/u, 1 MeV/u and 10 MeV/u. As the particles are slowed down and their energy decreases, the
number of liberated secondary electrons increases. Compared to protons, the density of secondary elec-
trons is higher for carbon ions. The radial dose distribution, which approximately follows an 1/r2
dependence, can be well described by analytical models [Chatterjee and Schaefer, 1976; Katz and Cu-
cinotta, 1999] and Monte Carlo simulations [Paretzke, 1986; Krämer, 1995]. It has also been confirmed
in experimental studies [Varma et al., 1977].
1.4 Radiobiology
The goal of radiotherapy is to irradiate the tumor, while minimizing normal tissue complications. In
order to achieve this, it is important to understand the radio-biological mechanisms behind radiological
damage.
In the energy regimes relevant for therapy, the energy of photons is predominantly transferred via
photo electric effect and Compton scattering. Due to the small cross sections of these processes, the
number of ionization events per incident photon within the cell volume is also small [Schardt et al.,
2010]. Hence, only few electrons are emitted from the target atom or molecule in the primary interaction
with the photon, which requires many photons to achieve a clinical dose. Due to the numerous random
interactions, the deposited doses are approximately continuous, creating a homogeneous dose, often
referred to as “dose bath”.
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Figure 1.7.: Track structure of secondary electrons for protons and carbon ions in water with 3 different
energies (0.2MeV/u, 1MeV/u and 10MeV/u) simulated with Monte Carlo code ’TRAX’. The schematic
figure of the DNA double helix is in scale. Figure from [Krämer and Durante, 2010].
Assuming that the deoxyribonucleic acid (DNA) molecule is the most sensitive target in a cell nucleus,
the radial dose distribution of an ion track creates more DNA damage than the homogeneous dose
deposited by photons. For carbon ion tracks, as depicted in figure 1.3.2.4, the area with the highest
deposited dose is on the order of some nanometers.
Typically, there are two pathways through which the radiation damage is propagated: A direct hit of
the DNA by the ion itself or a liberated secondary electron, or an indirect hit created by radiation induced
free radicals like hydroxyl (OH) from hydrolysis [Hall and Giaccia, 2012]. These radicals can travel for
a few nanometers and are able also able to damage the DNA. Both sorts of interaction are illustrated in
figure 1.8(a).
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The most common forms of damage are single strand breaks SSB and double strand breaks DSB of
the DNA molecule (as illustrated in figure 1.8(b)). single strand break (SSB) are easier to repair for the
cell, whereas double strand breaks (DSB) destroys the double helix of the DNA, which makes the repair
process more difficult and increases the susceptibility to errors during repair. This eventually leads to
cell inactivation in most cases. Therefor, the DSB is considered as the most hazardous damage for a
cell. Since more complex DNA damage does impair the cell’s repair capabilities, the radiation damage
induced by heavy ions is larger than for photons [Nikjoo et al., 1999].
Figure 1.8.: Schematic of interaction of ionizing radiation with DNA double helix. (a) differentiation
between direct and indirect interaction of radiation with DNA. (b) classification between single (SSB),
double strand break (DSB) and base loss of DNA. Figure adapted from [Hall and Giaccia, 2012].
In-vitro cell survival experiments are the most common way to analyze the damage caused by ionizing
radiation, as for example described by Puck and Marcus [1956]. After irradiation with photons or ions,
cell proliferation was analyzed over the course of two weeks. Cells which have built a colony with more
than 50 daughter cells were counted as survivors. After normalization to the number of initial cells, the
fraction of surviving cells (S) is parametrized with the linear-quadratic (LQ) model
S(D) = exp
!
−αD− βD2

(1.6)
where D is the absorbed dose and the experimentally determined parameters α and β [Hall and Giaccia,
2012, p. 39]. Schematic cell survival curves are shown in figure 1.9, where the survival fraction of
irradiated cells is depicted over the absorbed dose in Gy. The α/β ratio determines the shoulder of
the depicted cell survival curves. Compared to photons, the α/β ratio is typically higher for high LET
radiation like heavy ions. This results in a steeper, more linear shape of the survival curve for heavy
ions (dashed red line). This strong influcence on the shape of the survival curve makes theα/β ratio an
important quantity in radiation therapy [Fowler, 1989].
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Figure 1.9.: Schematic illustration of relative cell survival depicted over absorbed dose in Gy. Relative
biological effectiveness (RBE) values given for 1% and 10% survival rate. Figure from [Schardt et al.,
2010].
1.4.1 Relative biological effectiveness
The previous section described, how the damage to the DNA is caused by δ-electrons for both charged
particles and photon irradiation. Both modalities differ in their pattern of the microscopic dose, where
heavy ions show a higher radiobiological effect due to their higher LET. Since most knowledge about
the biological efficacy of radiation is gained from X-ray experiments, the concept of a relative biological
effectiveness (RBE) represents an elegant way to compare the biological effects of heavy ion radiation
versus photon radiation for a given biological endpoint. The RBE is defined as
RBEiso-effect =
Dref
Dion
, (1.7)
where Dion is the absorbed ion dose and Dref is the absorbed reference dose, typically X-rays. In figure 1.9
the RBE is stated for the 1 % and 10 % survival rates. Due to the linear shape of the survival curve for
heavy ions versus the more parabolic shape for photons, the RBE becomes larger for lower doses.
For heavy ions, the RBE depends on the biological endpoint, the dose, the LET, the tissue type and the
composition of the radiation field, which makes it a complex quantity to calculate. Hence, the RBE values
vary for different locations within the patient. To estimate the RBE value, different models have been
developed and validated. The aim of the carbon ion pilot project at GSI was to enable the optimization
of a homogeneous biological dose for patient treatment, for which the local effect model (LEM) has
been developed [Scholz et al., 1997; Krämer and Scholz, 2000, 2006]. Since its introduction, the LEM
has also received some revisions [Elsaesser and Scholz, 2007; Friedrich et al., 2012]. The LEM is used
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routinely at clinics in HIT and MIT within the proprietary treatment planning system (TPS) “Syngo” by
Siemens. LEM has also been licensed for implementation in the commercially available TPS “RayStation”
[RaySearch, 2013].
In the heavy ion community, the concept of considering variable RBE in treatment planning is widely
accepted. However, in proton therapy a fixed RBE value of 1.1 is still commonly used. The topic of a
variable proton RBE remains under heavy discussion [Underwood et al., 2017; Paganetti, 2018].
1.5 Accelerators & treatment delivery
In particle therapy, synchrotron or cyclotron accelerators are used to generate ions within the therapeutic
energy regime. In facilities which use heavy ions like HIT, MIT, CNAO or MedAustron synchrotron accel-
erators are used. These accelerators are capable of accelerating both protons and carbon ions. Facilities
using protons only, predominantly rely on cyclotron accelerators in order to reduce space consumption,
which is significantly less compared to a synchrotron accelerator with diameters from about 25 m to 30 m
versus approximately 3 m for typical cyclotrons.
Comparing synchrotrons and cyclotrons, there is also a major difference in the way particle energies
are generated. Cyclotrons are limited by construction in the maximum deliverable particle energy. By
design, this limitation is set to the maximum energy necessary to generate a range of 30 cm in water.
This corresponds to an energy of 220 MeV/u [Schardt et al., 2010]. To reach lower energies, a degrader
consisting of an absorbing material like PMMA is used. The cyclotron is capable of producing a con-
tinuous beam. If a degrader wheel with decreasing material thickness is used, fast energy changes are
possible.
This is in contrast to synchrotrons, where ion bunches of about 106 to 109 particles are accelerated to
the requested energy. In addition to their ability to accelerate heavier ions, synchrotrons are capable of
generating higher particle energies, depending on the size of the accelerator and is magnetic stiffness.
However, as each ion bunch is accelerated separately, the time to change the particle energy is not instan-
taneous, requiring a few seconds. Nonetheless, in the latest revision of the HIMAC synchrotron, there has
been a significant drop in the time necessary to change particle energy. The introduced multiple-energy
operation mode enabled energy transition times of 10 ms/step to 50 ms/step for corresponding energy
intervals of 1 MeV/u to 7 MeV/u [Mizushima et al., 2017]. Recent developments in the construction of
superconducting cyclotrons will enable the acceleration of helium or carbon ions with cyclotrons in the
near future [Jongen et al., 2010; Kang et al., 2012].
In the context of radiotherapy, the purpose of the delivery system is the transportation of the ion beam
into the patient, to cover the planning target volume accurately and homogeneously with the planned
dose distribution [Schardt et al., 2010]. For the interested reader, an overview of the variety of possible
solutions in treatment delivery can be found in Chu et al. [1993]. In the following sections, the two most
common approaches are presented: passive scattering and active scanning.
1.5.1 Passive scattering
In treatment delivery with passive scattering, a narrow and mono-energetic ion beam is shaped to cre-
ate a conformal and homogeneous dose distribution. Figure 1.10 schematically shows the required
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components. The process of the beam shaping can is divided into two parts, handling the lateral and
longitudinal shape of the dose distribution.
First, a pencil beam with a full width at half maximum (FWHM) of some millimeters is laterally broad-
ened from being irradiated onto a scattering system. This is usually done through a double scattering
system consisting of two metal targets from which the second one has a T-shaped geometrical cross sec-
tion. The scattering system broadens the beam diameter to be larger than the lateral cross section of the
tumor to irradiate. A brass collimator is used to reduce the penumbra of the lateral beam profile to a
sharp gradient. Additionally, the collimator has the lateral shape of the largest lateral extension of the
patient specific tumor volume in beam’s eye view (BEV). The beam shaping modifications can be seen in
the upper row of figure 1.10.	
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Figure 1.10.: Schematic of passive delivery of ion beams. The scattering system and the collimator are
used to shape the beam profile laterally. The range modulator, the range shifter and the compensator
are used to adapt the longitudinally dose distribution from a pristine Bragg curve to a SOBP. The com-
pensator is especially important to form the distal areas of the dose distribution enabling the sparing of
OARs. Figure from [Schardt et al., 2010].
The second part of the beam shaping modifications affects the depth dose distribution. Initially, there
is a quasi mono-energetic pristine Bragg curve. A ripple filter is used as a range modulator to broaden the
longitudinal dose profile to a flat and homogeneous dose distribution. Further, a range shifter consisting
of PMMA plates of different thicknesses is used to reach more shallow tissue areas by reducing particle
range. Since tumors typically are spherically shaped, a compensator, machined from PMMA, can be used,
to conform the distal part of the treatment volume. A compensator can also be applied for sparing OARs
in close proximity of the distal end of the target volume. However, it is important to note, that distal
dose shaping merely shifts parts of the dose distribution, which can also mean an increase of normal
tissue dose (see hatched area in figure 1.10). It is important to note that the collimator and compensator
are patient and field specific, and have to be built individually for each patient.
29
The approach was pioneered at Havard, especially the design of the range modulators and compen-
sators, as well as the optimization of range-compensated scattering systems [Koehler et al., 1975, 1977;
Gottschalk and Wagner, 1989].
1.5.2 Active scanning
Active scanning offers some distinctive advantages compared to passive scattering. First, no patient or
field specific components are necessary. The dose distribution is tailored to the patient within the TPS
only. Second, the ability to change the intensity of each grid spot within the tumor volume enables
the use of intensity modulated particle therapy (IMPT) with two or more irradiation fields, and thereby
superior OAR sparing. The IMPT technique was first developed for protons at PSI in the early nineties
[Lomax, 1999], but quickly transferred to the use for heavy ions at GSI.
Active scanning differs considerably from passive scattering, although both methods initially use nar-
row pencil beams with Gaussian shaped transversal profile. To cover the entire tumor volume using
active scanning, the tumor is divided into iso-energy slices (IESs) along the BEV axis. The irradiation
of these slices can be achieved by varying the particle beam energy, thereby changing the depth of the
Bragg peak. To cover the lateral extent of the IESs with dose, each of these IES is divided into a two
dimensional grid of typically 2 mm sized grid spots (see illustration in figure 1.11). Each of these grid
spots represents a position that a pencil beam spot will be delivered to during treatment. Two scanning
magnets are used to laterally scan the pencil beam to each of these spot positions on the grid: The first
magnet is used for horizontal, the second magnet for vertical scanning. A described method is called
“raster scanning” and has been developed at GSI. The required control system which is monitoring the
position, energy and intensity of the ion beam at any time during treatment has been developed by
Haberer et al. [1993]. Pioneering work for other scanning methods was done at National Institute of
Radiological Sciences, Chiba, Japan [Kanai et al., 1983] and Paul Scherrer Institut[Pedroni et al., 1995]. 	 
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Figure 1.11.: Schematic of active delivery of carbon ions. The raster scanning method uses two magnet
for vertical and horizontal deflection of the ion beam over the iso-energy slice (IES). The depth of the IES
is controlled by ion energy. Figure from [Schardt et al., 2010].
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In order to achieve a homogeneous dose over an IES, the FWHM of the Gaussian beam profile is chosen
with respect to the raster grid spacing ∆s (see figure 1.12(a)). Empirically, the beam spot size is usually
set to FWHM= 3×∆s provide a sufficient overlap.
Commonly, the narrow longitudinal dose profile of a pristine carbon Bragg peak is broadened to cover
a depth of 2 mm to 3 mm. This can be achieved by using a ripple filter as developed by Weber and Kraft
[1999]. A ripple filter consists of triangular grooves machined into a sheet of PMMA, creating a SOBP,
as seen in figure 1.12(b). Typically, the IESs are addressed in descending order, starting with the most
distal one (highest particle energy). Due to the dose already deposited in the proximal IESs by beams
traversing to deeper IESs, the intensity of the more proximal IESs must be reduced to create a flat and
homogeneous integral dose.
Figure 1.12.: Schematic view of lateral and longitudinal dose shaping. (a) lateral overlap of Gaussian
pencil beams and (b) pristine Bragg peak broadened by a PMMA ripple filter to create spread out Bragg
peak (SOBP). Figure from [Richter, 2012].
1.6 Treatment planning
This section provides an overview of the aspects of treatment planning: First, a brief description of the
pencil beam dose algorithm used in TRiP98 is presented in section 1.6.1, followed by the description
of the basic cost function used in treatment plan optimization (see section 1.6.3). A description of
internal organ motion (see section 1.6.4), their implications (see section 1.6.6) and how to mitigate
these effects (see section 1.6.7) are then described. Furthermore, the topic of 4D treatment planning is
addressed (section 1.6.8), including methods like image registration to process time resolved image data
for treatment planning (section 1.6.9).
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1.6.1 Physical dose calculation
The beam model used for the calculation of the physical dose is based on a pencil beam algorithm, which
has been developed at GSI during the carbon ion pilot project. The partial dose deposited in position ~r
by an pencil beam with energy Ebeam located in position ~r0 is described by [Krämer et al., 2000]:
D(Ebeam,~r)[Gy] = 1.6 · 10−8 · d(Ebeam, z)

MeV
g cm−2

︸ ︷︷ ︸
depth contribution
· 1
2πσ2 [mm2]
· exp

− r
2
2σ2

︸ ︷︷ ︸
lateral contribution
·N , (1.8)
where r =
p
(x − x0)2 + (y − y0)2 is the lateral distance from the beam center, σ the beam width of the
symmetrical Gaussian beam profile and N is the total number of particles. The energy loss distribution
d(Ebeam, z) of a given initial beam energy Ebeam as a function of the penetration depth z can be derived
from the Bethe-Bloch equation and is modeled for treatment planning (TP) by the YIELD transporta-
tion model (see [Krämer et al., 2000]). Apart from the single particle energy loss, the YIELD model
also describes energy straggling and projectile fragmentation processes, which is necessary to match
experimentally determined dose distributions measured in water [Krämer et al., 2000].
Treatment planning at GSI is, as in most other facilities, based on CT imaging of the patient’s internal
anatomy. Hence, the dose calculation is performed on a voxel-wise basis. A CT voxel is the three
dimensional representation of an pixel, describing a small unit of volume. In modern CT images, the
edge length of a voxel is typically between 1 mm and 2.5 mm.
A typical treatment plan consists of thousands of pencil beams with several energies and a spread of
lateral positions. Hence, the dose in a single voxel i consists of the contributions from many pencil beams.
These contributions include pencil beams which terminate within the voxel i, depositing a majority of
their energy at the voxel location, pencil beams j aiming at more distal location, which are traversing
through the location of voxel i and contributions of lateral scattering by neighboring beam spots j. The
dose contributions from all pencil beams j to voxel i are stored in a correlation matrix ci j which results
from the beam model presented in equation (1.8). Hence, the total dose of a single CT voxel with index
i is given as the sum over all contributing pencil beams
Diphys(
~N)[Gy] =
∑
j
ci jN j = ~ci
T · ~N . (1.9)
The dose Diphys can also be described as the scalar product of the i-th line of the correlation matrix ~ci
T
with the particle vector ~N , containing the particle numbers N j of each pencil beam.
1.6.2 Biological dose calculation
As described in section 1.4.1, the biological effect of ions is larger than of an equivalent photon dose.
This higher biological efficacy due to the microscopic track structure is described by the RBE value. In
previous projects at GSI, homogeneous biological dose optimization and biological dose calculation was
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implemented into TRiP98, based on the local effect model (LEM). The biological dose for a voxel i is
defined as
Dibio(
~N) = Diphys(
~N) ·RBEi( ~N), (1.10)
with the physical dose Diphys (see equation (1.9)), the relative biological effectiveness, RBE
i, and the
particle vector, ~N , containing the number of particles N j to be irradiated for each pencil beam [Krämer
et al., 2000; Krämer and Scholz, 2006]. Since the RBE is depending on many different quantities, such
as particle energy, particle spectra, tissue type, biological endpoint, LET, it varies for different locations
within the patient.
Using the low dose approximation as described by Krämer and Scholz [2006], the biological dose can
be analytically expressed as
Dibio(
~N) =
√√√αi · !~ciT · ~N+ βi · !~ciT · ~N2
βx
+

αx
2βx
2
− αx
2βx
, (1.11)
where αx and βx are the alpha and beta values of the photon survival curve, αi and βi the alpha and beta
values calculated for each voxel i from using the LEM [Elsaesser and Scholz, 2006; Krämer and Scholz,
2006]. Unlike the physical dose, the biological dose also depends quadratically on the particle vector ~N .
This behavior becomes important for the next chapter, which addresses the treatment plan optimization.
1.6.3 Plan optimization
The aim of plan optimization during treatment planning is to determine the optimal machine parameters
of the delivery system which generates the desired dose distribution within the patient, providing a
sufficient dose coverage for the tumor volume and acceptable OAR sparing. Namely, these machine
parameters are particle beam energy Ebeam, lateral pencil beam position ~r0 and the associated particle
number N . Since beam energy and lateral position are predetermined by the location of the target
volume within the patient, the particle number N j of each pencil beam remains as primary variable in
the plan optimization. Typically, the number of voxels and pencil beam spots are several ten-thousands.
The optimization is performed by minimizing a cost function. Following the approach of IMPT [Lomax,
1999], the cost function of a planning target volume (PTV) optimization is stated as the quadratic sum
over the difference between the calculated and the prescribed dose:
FPTV( ~N) =
∑
i∈PTV
wPTV·
!
Diact.(
~N)− Dpresc.
2
+
∑
j∈OARs
wOARs·Θ
!
D
j
act.( ~N)− Dlimit

·
!
D
j
act.( ~N)− Dlimit
2
, (1.12)
where wPTV and wOARs are weighting factors, allowing to influence the optimization result. D
i
act.(
~N) is
the actual dose of voxel i, which can be the physical or biological dose. Dpresc. is the dose to the tumor
as prescribed by a physician and Dlimit is the dose limit of an OAR which should ideally not be exceeded.
Θ(Dact.− Dlimit) is the Heaviside function which is unity if Dact. > Dlimit and zero if Dact. < Dlimit. By using
the Heaviside function, under dosage is neglected in organs at risk (OAR).
33
With equation (1.12), the optimization problem can be formulated as:
min FPTV( ~N) , (1.13)
s. t. N j ≥ Nmin ∀ j = 1, . . . , p , (1.14)
where p denotes the index of the last pencil beam of the raster grid [Horcicka et al., 2012]. The constraint
in equation (1.14) is due to the detector system used in the dose delivery system. A minimum particle
number, Nmin, is necessary per pencil beam spot for the treatment control system (TCS) to measure
position and energy of the corresponding pencil beam. At GSI, the default value of Nmin is set to 5000.
As the biological dose in equation 1.11 depends quadratically on N j, the cost function for a biological
dose optimization depends quadratically on N j likewise. Due to this nonlinearity the cost function cannot
be minimized using linear solvers. Hence, a conjugate gradient algorithm has been implemented in
TRiP98 [Krämer et al., 2000; Horcicka et al., 2012].
1.6.4 Patient motion in radiotherapy
Patient motion can generate huge deviations from the planned dose distribution. In radiotherapy, both
under- or over dosage can occur in the targeted volume, as well as accidental exposure of critical organs
to detrimental levels of radiation. There are different types of motion which will be briefly described in
the following section. Further information on methods to handle patient motion in radiotherapy can be
found in the review by Langen and Jones [2001].
Typically, three main types of patient motions are distinguished: patient positioning, interfractional
motion and intrafractional motion. In this thesis the focus is on respiratory motion in context with the
treatment of lung cancer.
• Patient positioning: The position of the patient can vary between the image acquisition for treat-
ment planning (in particle therapy typically a CT) and the treatment plan delivery. A shift occur-
ring in the internal patient anatomy during planning and delivery could result in changes to tumor
shape or position, including range changes due to different configurations of skin and fat tissue
in the entry path of the particle beam. To minimize the extent of this effects, immobilization is
commonly used, often accompanied with additional safety margins added to the clinical target vol-
ume (CTV) in the treatment planning phase (see section 1.6.10). Additionally, treatment centers
use dedicated treatment protocols, e.g. with pre-treatment position verification using orthogonal
X-ray projections or in-room CTs.
• Interfractional motion: Interfractional motion occurs between treatment sessions of fractionated
treatment protocols, due to changes in patient anatomy. The time scale of these changes is hours or
days. For lung cancer patients, this could mean tumor shrinkage or changes in lung tissue density
from scarring of inflammation [Mori et al., 2009]. Furthermore, changes in the patient’s breathing
pattern as well as a baseline shifts of the tumor motion amplitude can occur, deteriorating the
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planned dose distribution [Sonke et al., 2008]. The effects of interfractional motion can be reduced
by reimaging and replanning the remaining treatment.
• Intrafractional motion: Intrafractional motion occurrs on the smallest time scale. The motion
is primarily caused by respiration or the heart beat and is on the order of seconds. Peristaltic
movement of the bowel is also classified as intrafractional and occurs on the order of minutes.
The amplitude of the tumor motion caused by respiration is typically on the order of mm up
to a few cm [Shirato et al., 2004]. The major direction of the respiratory tumor motion is in
superior-inferior (SI) direction [Seppenwoolde et al., 2002; Britton et al., 2007; Liu et al., 2007].
1.6.5 Time resolved computed tomography (4DCT)
Patient motion, especially intrafractional motion caused by respiration, can be observed with a time
resolved computed tomography (4DCT). To generate a 4DCT image set, several 3DCT images of a free
breathing patient are recorded, while also the respiratory motion signal is continuously recorded, using
devices such as a stereoscopic camera or the ANZAI belt. During post processing, dedicated protocols are
used to assign the recorded CT images to specific motion phases of the respiratory cycle. Although those
CT scans are recorded over several respiratory cycles, the final 4DCT image set shows a single averaged
respiration cycle only.
For 4DCTs of the lung, usually a division into 10 motion states with equal phase duration is used. The
period of a respiratory cycle is the duration between two consecutive maxima or minima of the motion
curve, for example between two consecutive end inhale states of the lung, as shown in figure 1.13. The
typical duration of a respiratory cycle is in the range of 3 s to 5 s. In this thesis, the expressions motion
phase and motion state are used synonymously.
1.6.6 Consequences of patient motion
The impact of respiratory motion on the planned dose distribution can be especially detrimental, as the
scanning motion of the pencil beam occurs on a similar time scale as the period of the respiratory motion.
The interference between these two movements can lead to so called interplay effects and cause hot or
cold spots in den delivered dose distribution. All targets within the thorax region of a patient are affected
by the respiratory motion of the lungs, and their movement during treatment can impede the delivered
dose distribution.
The effects of interplay have been studied by Bert et al. [2008], for example in 2D dose measurements
where a moving film dosimeter was irradiated with a homogeneous dose distribution, using scanned
carbon ions. Figure 1.14 shows the resulting interplay patterns due to different motion directions. The
scanning motion is horizontal in all three panels, the target motion is sinusoidal. Panel (a) shows the
stationary case without any target motion. A homogeneous dose distribution is generated, depicted by
the uniform blackening of the film. Panel (b) shows the interplay pattern for a vertical target motion. The
zigzag shaped lines with overdose are typical for the case of orthogonal motion directions. In panel (c)
the motion direction is collinear with the scanning motion. This situation usually leads to “compression”
of the dose along the motion axis, here, creating cold spots on the left and right side of the target area.
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Figure 1.13.: Schematic illustration of a respiratory motion curve plotted over time. The respiratory mo-
tion period between two consecutive maxima (end inhale states of the lung) is typically divided in 10
motion phases of equal duration. As described by the Lujan function, the end exhale state of the lung is
most stable in its position [Lujan et al., 1999].
(a) (b) (c)
Figure 1.14.: Dose measurement with filmmaterial on static and moving targets with horizontal scanning
direction. (a) is the stationary case with no target movement. (b) shows the interference dose pattern
caused by interplay between the horizontal scanning and the vertical target motion, creating primarily
hot spots. (c) is the interplay pattern caused by a target motion collinear to the scanning motion, creating
cold spots. Figure from [Bert et al., 2008].
In case of lung cancer patients, the impact of the respiratory motion can be even more pronounced due
to the density gradient between solid tumor and lung tissue. If, during respiratory motion, inaccuracy
in pencil beam delivery results in tumor miss, a significant range overshoot occurs, potentially harming
critical structures behind the tumor in BEV.
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1.6.7 Motion mitigation
In this section, different motion mitigation techniques are presented, focusing on rescanning, gating and
tracking. However, there are many other methods, like abdominal compression or active breath control,
which are not presented in this thesis.
1.6.7.1 Rescanning
Rescanning, also called repainting, is a technique only used for scanned beam delivery and is based
on the concept of statistical averaging [Phillips et al., 1992]. Two major strategies exist: volumetric
rescanning and slice-by-slice rescanning. For both methods, the particle numbers of each beam spot in
an IES are divided by the number N of desired rescans. For volumetric rescanning, the entire tumor
volume is irradiated N times, while for slice-by-slice rescanning, each IES is irradiated N times. Since
interplay patterns depend on amplitude, period and starting phase of the respiratory motion, the basic
assumption is, that the exact same interplay pattern is unlikely to be generated in consecutive breathing
cycles. Hence, the superposition of N different interplay patterns will homogenize the dose distribution.
Figure 1.15 shows the effects of increasing the number of rescans on the dose homogeneity of a 2D dose
measurements using film material. The maximum number of rescans is limited by the detector system
used in the dose delivery system. At GSI, as described in section 1.6.3, at least 5000 particles are required
for the detector system to measure a beam spot’s energy and lateral position.
Several different rescanning strategies have been proposed and tested to address the inherent limita-
tions of rescanning. Random-delay rescanning introduces a random time delay between applied rescans
to avoid potential unfavorable temporal correlations between the scanning and respiratory motion [Seco
et al., 2009; Rietzel and Bert, 2010]. During Breath-sampled rescanning [Seco et al., 2009] and phase-
controlled rescanning [Furukawa et al., 2010] the rescans are equally distributed over the breathing cycle
to reduce the number of rescans and increase the robustness. Phase-controlled rescanning is in clinical
use at NIRS in combination with beam gating [Ebner et al., 2017].
Compared to beam gating or beam tracking, online motion detection is generally not required for
rescanning. However, to ensure that the tumor remains within the volume at any motion state within
the respiratory cycle, it is necessary to increase the treatment volume. This can result in significant
increases of OAR or normal tissue doses, representing the major disadvantage of rescanning.
1.6.7.2 Gating
The premise behind gating is to deliver the beam only when the moving target enters a predfined gating
window [Minohara et al., 2000; Lu et al., 2006]. For respiratory motion, the end-exhale portion of the
motion phase is typically chosen, as it is the most stable in its position [Lujan et al., 1999]. Motion
monitoring is necessary for gating to signal the control system for when the target is within the gating
window. When the signal is sent, the control system allows the treatment delivery. There is an additional
challenge for synchrotrons, which do not operate in a continuous mode. Instead, synchrotrons deliver
pulsed irradiation in spill cycles. So, the target may be within the gating window, while the synchrotron
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Figure 1.15.: Dose measurement with film material on a vertically moving target with horizontal scan-
ning direction. The interference between target and scanning motion causes an interplay pattern with
characteristic hot and cold spots. Increasing number of rescans mitigates the interplay pattern by super
position of different interplay patterns. This can be described as “statistical averaging”. Figure from [Bert
et al., 2009].
is between spills, further reducing the “effective gating window“, or the time the delivery system can
treat the tumor. Figure 1.16 shows an exemplary motion monitoring signal depicted over time with
a chosen gating window, showing the resulting extracted beam intensity, determined by the temporal
overlap with the beam availability of the synchrotron cycle.
It has been shown that optimization of the synchrotron cycle is possible and can considerably reduces
increases in treatment time [Tsunashima et al., 2008]. The use of knock-out extraction with RF cavi-
ties, has enabled the extraction of multiple beam gates per synchrotron pulse, which further decreases
treatment time with the beam gating method. This strategy has been clinically implemented at several
facilities, including at HIT [Heeg et al., 2004]. Nevertheless, a non-negligible residual motion of the
target can still persist. Depending on the chosen temporal size of the gating window, it can be in the
order of several millimeters, yet causing interplay.
Beam gating and fast rescanning can also be combined as done at NIRS for a small number of liver
and lung patients [Ebner et al., 2017]. This was made possible through the latest revision of the HIMAC
accelerator, providing fast and markerless pencil beam rescanning and fast changes of particle energy
[Mizushima et al., 2017].
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Figure 1.16.: Simplified diagram of the gating delivery mode with a synchrotron accelerator. The logical
gate signal is generated by applying the gating window to the motion monitoring signal. Irradiation is
only possible if the gate signal is active during beam availability. The amount of residual tumor motion
depends on the gating window size. Figure from [Richter, 2012].
1.6.7.3 Tracking
Tumor tracking is a combination of real-time motion monitoring with online corrections of the tumor
location from the original treatment plan due to patient motion. The idea was originally proposed for
IMRT [Keall et al., 2001] and is now used routinely in clinics, e.g. for X-ray radiosurgery with the
robotic Cyberknife Synchrony system (Accuray Inc., Sunnyvale, CA, USA) [Brown et al., 2007; Kilby
et al., 2010].
At GSI, a full tracking system has been implemented for the scanned delivery of carbon ion beams. For
the compensation of longitudinal range changes, a fast modulation of particle energies is required. Fast
energy modulation is provided by a system of opposing PMMA wedges mounted on a linear step-motor
[Weber et al., 2000]. For lateral compensation, the already existing scanning magnets were used, as
the schematic illustration shows in figure 1.17. The correction of patient movement was based on pre-
calculated look-up tables containing the compensation parameters and guided by a motion monitoring
signal. Important requirements for beam tracking were accurate 4DCT image data and a fast and pre-
cise motion monitoring unit for measuring the movement of internal organs. Dose measurements and
technical tests have shown the feasibility and high precision of the system [Bert and Rietzel, 2007; Bert
et al., 2010; Saito et al., 2009]. Besides the technical challenges in general, especially the longitudinal
beam tracking suffers from the finite size of the pencil beam diameter: high density gradients within
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the patient geometry can cause edge effect deteriorating the adapted dose distribution. However, beam
tracking is not yet clinically implemented primarily due to the complexity of the whole system.
Figure 1.17.: Schematic illustration of the tracking system. A motion monitoring unit (not depicted)
is necessary to determine the correction parameters for the control system. Lateral offsets in BEV are
compensated by a correction of the position of the scanning magnets. Range offsets are compensated
by a range modulator consisting of PMMA wedges mounted on a linear step-motor in front of the pa-
tient. In its nominal position, the wedges already overlap to enable also range reductions. Figure from
[Groezinger, 2004].
1.6.8 4D treatment planning
The goal of 4D treatment planning (4DTP) is to account for organ motion already during treatment
planning, to eventually increase the dose to a moving tumor while sparing normal tissue at the same
time. Compared to photon therapy, there is a greater challenge for 4DTP with charged particles, since
scanned ion beams are much more prone to motion induced errors like range changes or interplay (see
section 1.6.6). As proposed by Keall et al. [2004], 4DTP must account for temporal changes in patient’s
anatomy during the imaging, treatment planning and treatment delivery of radio therapy. In particle
therapy, this is especially important for single fractionated treatments, since tumor miss risks high doses
to normal tissue. Despite the risk, dose escalation can significantly improve local tumor control rates, in
particular for NSCLC [Rosenzweig et al., 2005; Kong et al., 2005], and is therefore desirable for treating
resistant lung cancers. The occurrence of radiation-induced normal tissue complications also depends
significantly on the OAR doses. The probability for treatment side effects such as acute esophagus toxicity
depends significantly on the volume of the esophagus receiving more than 35 Gy [Belderbos et al., 2005].
4D dose calculation
4D dose calculation allows for the quantification of dose heterogeneities caused by patient motion,
including interplay effects. In the field of particle therapy, different strategies to calculate 4D dose distri-
butions, exploiting deformable image registration (see section 1.6.9) and 4DCTs, are used. In the case of
scanned ions, the temporal correlations between the time-structure of the sequential plan delivery and
the patient motion have to be accounted for [Bert and Rietzel, 2007; Paganetti et al., 2004]. Currently,
there are two major approaches for calculating 4D dose distribution: transformation of the individual
dose contribution of each motion phase to a common reference frame [Bert and Rietzel, 2007] and de-
formation of the dose grid, as implemented into the GSI TPS [Gemmel et al., 2011]. The latter approach
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is advantageous for heavy ion therapy, since it enables biological dose calculation. For validation of
this algorithm, a dedicated phantom has been built and was successfully used in measurements. A dose
delivery simulation (DSim) tool used for temporal correlation between target motion and beam deliv-
ery sequence was revised, now capable of simulating synchrotron timings from GSI, HIT, MIT [Richter,
2012] and soon CNAO, Italy.
4D optimization
In 4D treatment planning, 4D optimization is used to account for temporal changes patient’s anatomy
due to patient motion. The 4D optimization strategies rely on the usage of the motion states of a 4DCT.
At GSI, the 4D treatment planning system is an expanded version of TRiP98, called TRiP4D. A detailed
description is given by Richter et al. [Richter, 2012; Richter et al., 2013].
Several 4D optimization strategies have been implemented into TRiP4D [Richter, 2012; Richter et al.,
2013; Graeff et al., 2012, 2013, 2014; Graeff, 2014]. More details on the 4D optimization algorithms
used in this thesis, are given in the first sections of chapters 3 and 4.
1.6.9 Image registration
By using different imaging modalities (CT, MRI, PET, etc.) or several images of the same modality
at different times (4D-CT, 4D-MRI, 4D ultra sound), the temporal changes of patient anatomy can be
observed. To gain processable data of patient or organ motion, it is necessary to generate a spatial
correlation between image sets. This can be done by using image registration techniques. For the
registration, two image sets are required: a fixed image set (as reference) and a moving image set.
The image registration process results in a voxel-to-voxel deformation map, which is a map of vectors
originating in the moving image voxel and are pointing to the corresponding fixed image voxel. The
two associated points x and x ′ in the fixed and the moving image, respectively, are represented in the
following formula:
x ′ = x + uri(x), (1.15)
where r indicates the reference state and i, the moving state. The deformation map is represented as
a vector field uri. The resulting vector field can be used for assessing quantities like motion amplitude
or for 4D dose calculation [Richter, 2012]. Figure 1.18 shows image registration applied on an axial CT
image of a patient’s thorax. Applying the deformation map to the moving image creates a warped image.
Ideally, the warped image is as close to the fixed image as possible.
Two main groups of transformations exist: The first group includes linear or rigid transformations
which describe translation or rotation by using 4 × 4 transformations matrices, affecting a CT image
globally. Typically, these transformations are used to describe non-complex motion of simple setups
such as dose simulations in water phantoms. The second group uses vector fields from deformable
transformations also capable of describing complex organ motion such as deformation (e.g. changing
volume of the lung lobe) or gliding motion between organs (e.g. between the chest wall and lung). There
is a variety of registration algorithms which are capable of generating these vector fields. The algorithms
have a high degree of complexity and further information is available [Hill et al., 2001; Brock et al.,
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(a) (b)
Figure 1.18.: Image registration for axial CT image of a patient’s thorax. Panel (a) shows overlap of a
fixed and a moving image and panel (b) the fixed and warped image after registration. Using inverse
colors in both CTs will result in gray colors where both images overlap perfectly. Figure courtesy Kristjan
Anderle.
2006; Rietzel and Chen, 2006]. Brock et al. have conducted a comprehensive multi-institutional study
on the accuracy of image registration algorithms. Despite large discrepancies, the majority of registration
algorithms have an accuracy on the order of typical CT voxel sizes (1 mm to 2.5 mm) encouraging the
further use of image registration to improve treatment planning and delivery [Brock, 2010]. Despite the
high level of accuracy, dedicated quality assurance protocol is still recommended [Anderle, 2016].
1.6.10 Treatment volumes and margins
Safety margins are already in use for treatment planning in radiotherapy with photons. The basic premise
is to increase robustness of the plan by increasing the treatment volume. This accounts for slight mis-
alignment during patient setup and marginal uncertainties to patient movement during treatment. The
common definitions of treatment volumes as recommended by the ICRU are stated below [ICRU, 1993,
1999].
• Gross Tumor Volume: The GTV is the gross palpable or visible/demonstrable extent and location
of malignant growth.
• Clinical Target Volume: The CTV is a tissue volume that contains a demonstrable GTV and/or
subclinical microscopic malignant disease, which has to be eliminated. This volume thus has to be
treated adequately in order to achieve the aim of therapy, cure or palliation.
• Planned Target Volume: The PTV is a geometrical concept and it is defined to select an appropriate
beam size and beam arrangements, taking into consideration the net effect of all the possible
geometrical variations, in order to ensure that the prescribed dose is actually absorbed in the CTV.
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• Internal Target Volume: The ITV is the margin that must be added to the CTV to compensate for
expected physio-logical movements and variations in size, shape and position of the CTV during
therapy.
• Organs At Risk: OAR are normal tissues whose radiation sensitivity may significantly influence
treatment planning and/or prescribed dose.
CTV
PTV
OAR
GTV
ITV
Figure 1.19.: Nomenclature of volumes
used in treatment planning, from inside
out: gross tumor volume (GTV), clinical
target volume (CTV), internal target vol-
ume (ITV) and planning target volume
(PTV). Critical structures are abbreviated
as organs at risk (OAR). Figure from
[Richter, 2012].
An illustration of a typical configuration of treatment volumes in case of a moving tumor is depicted in
figure 1.19. The CTV surrounds the GTV, including possible microscopic spread of tumor tissue. CTV and
GTV are typically contoured by experienced physicians. The ITV is generated by the union of all CTVs
in all motion phases. The PTV margins account for geometrical uncertainties and the sparing of critical
structures (OAR).
Due to the high spatial precision of the Bragg peak of protons or heavy ions, treatment plans are
more prone to errors during treatment delivery. Choosing appropriate safety margins is important and of
high relevance for particle therapy; however, safety margins should not be increased without restriction.
Assuming a spherical target with a diameter of 30 mm, additional PTV safety margins of 3 mm would
increase the treated volume by about 73 %. Since this additional volume is, in most cases, normal tissue,
extension of the margins must be carefully chosen. The topic of safety margins in robust optimization is
further discussed in chapters 2 and 3.
1.7 Summary
An introduction on lung cancer was given, stating the poor prognosis of the disease, potential risk factor
such as tobacco consumption in particular, and giving an overview about non-small cell lung cancer
(NSCLC) as the lung cancer subgroup which will be primarily addressed in this thesis. Further, the
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rationale for the clinical application of ion beams was given and the physical and biological properties
of ion beams were introduced. The second half of this chapter looked at treatment planning with ions,
also presenting the two concepts of treatment delivery. Further, the implications of patient motion were
addressed, where the raster scanning approach is especially prone to dosimetric errors due to moving
targets. In the following section, mitigation strategies to overcome the issue of respiratory patient motion
were presented, including rescanning, beam gating and beam tracking. In the following section, 4D
treatment planning was introduced, describing the potential benefits and requirements using 4DCTs
and image registration for treatment planning. Details on the implementation of robust optimization
methods for 3D and 4D treatment plan optimization will be introduced and discussed in the upcoming
three chapters.
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2 Introduction to robust optimization
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2.1 Introduction
In contrast to photon therapy, particle therapy is much more prone to range uncertainties due to the high
precision of the energy deposition provided by the Bragg peak. While traversing heterogeneous tissue,
unplanned density variations can alter the range of particles on the order of several millimeters.
Range or setup uncertainties can eventually lead to a deterioration of the delivered dose distribution,
in particular for multiple field optimization (MFO) when a mismatch of inter field dose gradients occurs.
This is illustrated in figure 2.1, where the increasing color gradients represent internal dose gradients.
These dose gradients can for example occur in situations, where a critical organ which is in close prox-
imity to the target volume needs to be spared. In the depicted example, the dose deterioration is caused
by a range undershoot which can be due to a higher CT density of the traversed tissue.
The topic of accounting for range uncertainties with robust optimization was first addressed by Unkel-
bach et al. [2007]. He proposed a probabilistic approach which handles range uncertainties as a random
variable. The cost function becomes a random variable too and the expectation value is then optimized.
For protons, the resulting robust cost function depends linearly on the particle vector ~N and it can be
minimized using linear optimizing algorithms.
As described in section 1.6.2, biological dose calculation for heavy ions relies on variable RBE. Due
to the variable RBE, the biological dose depends nonlinearly on ~N (see equation (1.11)). For the opti-
mization of a biological dose, this nonlinearity is passed on to the cost function in equation (1.12). To
minimize this “biological” cost function, which now also depends nonlinearly on ~N , a nonlinear solver
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Field 1
Field 1
Field 2 Field 2
Target Target
Figure 2.1.: Sketch of target irradiated by two orthogonal IMPT fields. Color gradients illustrate internal
dose gradients due to IMPT. Left: both fields are irradiated exactly as planned. Right: the dose dis-
tribution is deteriorated because of reduced particle ranges. Figure adapted from [Graeff et al., 2012].
is required. Therefore, TRiP98 uses the implementation of a conjugate gradient algorithm [Krämer
et al., 2000; Horcicka et al., 2012]. In contrast to robust optimization of proton treatment plans, the
probabilistic approach is less suited for robust optimization of carbon treatment plans.
2.2 Worst-case method
The worst-case approach for the robust optimization of a cost function described by Pflugfelder et al.
[2008] demonstrates a method which is more suitable for the nonlinear biological dose calculation.
Besides the nominal scenario, the robust cost function F˜( ~N) includes an additional term for a worst-case
dose scenario:
F˜( ~N) = F(Dnom( ~N)) + pworst case · F(Dworst case( ~N)), (2.1)
which is steered by a worst-case penalty weight pw. For pworst case = 0 the original nominal case is
obtained. The worst-case dose distribution Dworst case is calculated by initially assessing the expected
range uncertainties for all pencil beams included. Since it is most likely that the pencil beams and
their range uncertainties are not independent, a minimal and maximal range uncertainty is estimated
[Pflugfelder et al., 2008]. This will result in two possible dose distributions. In the proposed approach
of Pflugfelder et al., setup uncertainties are accounted for by shifting the dose distribution in lateral
directions in BEV. For the worst-case approach two simplifications are made: the laterally shifted dose
distributions are calculated for only the nominal pencil beam range and dose distributions for minimal
and maximal range are considered for the unshifted nominal case only. This results in seven different
dose distributions.
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If the reference frame for the setup uncertainty is changed from BEV to the patient system, this results
in six possible scenarios, which are described in section 2.2.0.1.
In this study an approach similar to the one proposed by Liu et al. [2012] has been implemented. This
methods differs from Pflugfelder et al. in the less prominent role of the nominal case as it is handled as
on of the possible uncertainty scenarios only.
2.2.0.1 Modeling of setup uncertainty
xCT
yCT
zCT
x'CT
y'CT
z'CTBEV
yrst
xrst
BEV,y
 BE
V
,x
BEV,z
CT
CT
Couch
Gantry
Figure 2.2.: Projection ∆BEV of the setup error ∆CT onto the coordinate system of the BEV system of an
arbitrary raster point resulting from shifting the patient during setup. Here the ∆CT consists of a x and y
component in the CT system.
Patient setup errors are modeled by shifting the patient’s isocenter in the direction of the major
anatomical axis (SI, anterior-posterior (AP) and left-right (LR) direction) by a few millimeters.Since
a field specific set of pencil beam spots of a treatment plan is optimized with water equivalent path
lengths (WEPLs), the shift ∆CT in the CT system is transformed to this coordinate system (see figure
2.2). In the WEPL system, also referred to as BEV, the transformed shift ∆BEV can be divided into two
lateral parts ∆BEV,x and ∆BEV,y as well as a part collinear to the BEV axis, ∆BEV,z.
This is in contrast to the method by Pflugfelder et al. [2008], where the patient setup shifts are directly
applied as lateral shifts in the WEPL coordinate system and no collinear shift is applied. The rationale
is that, due to the high difference between mass density of air and of human tissue (a factor of about
1000), the particle ranges are only marginally affected by traversing an additional distance through a
layer of air.However, the approach of Pflugfelder et al. ignores that the setup error originally occurs in
the patient coordinate system and, hence, overestimates the resulting setup errors in the BEV system.
This can be solved by only accounting for the relevant projections of the setup error in the BEV system
as shown in figure 2.2. In case of collinearity between the field angle and one of the major anatomical
axes, the orthogonal projection of the shift becomes zero and effectively turns the respective setup error
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scenario into the nominal one. For all other field angles, the described approach yields the relevant shift
in the WEPL system.
2.2.0.2 Modeling of range uncertainty
nominal
WEPL + 3.5%
WEPL - 3.5%
-1000 0 1000 2000 3000
0.0
0.5
1.0
1.5
2.0
CT value in HU
W
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P
L
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g
/c
m
2
Figure 2.3.: HLUT used for translation of geometric length to WEPL space. Black: nominal HLUT, blue:
WEPL + 3.5%, red: WEPL - 3.5%.
A straightforward approach to globally shift the particle ranges of a treatment plan is to scale the
Hounsfield unit (HU) values of a CT cube. This will change the tissue density of the patient and inversely
change the particle ranges.
Since the particle numbers for all pencil beams in a treatment plan are optimized in the space of
WEPLs, it is also possible to scale the function which translates the CT coordinates into WEPL space.
Compared to the approach of storing two additional CT cubes with scaled HU values in addition to
the nominal CT cube, no additional memory is needed. To convert geometrical distances into WEPL
space, a simple Hounsfield unit lookup table (HLUT) is required. The HLUT correlates the HU values
of a CT with its equivalent path length in water. The WEPL for water, which corresponds to a HU
value of 0, is normalized to 1.0. Hence, by reading the CT value of a traversed voxel, the geometrical
intersection length between a pencil beam and the voxel can be translated to the WEPL space by scaling
the geometrical distance with the corresponding scaling factor from the HLUT. Since the HU values
depend on the CT machine, the HLUT has to be experimentally determined by evaluating CT images
with a variety of tissue equivalent materials. The nominal and the shifted HLUTs are shown in figure
2.3.
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Figure 2.4.: Spread out Bragg peak along the BEV axis for one of two opposing fields irradiating a sphere
in water. Solid lines represent biological dose and dashed lines represent physical dose. SOBPs are shown
for three ranges: nominal range (black lines), reduced range with CT density increased by 3.5% (blue
lines) and increased range with CT density decreased by 3.5% (blue lines).
The impact on the range of a SOBP in BEV is shown in figure 2.4 for one of two opposing fields
irradiating a sphere in a water phantom with a diameter of 50 mm. The biological and physical dose is
plotted over the z-direction of the raster system in CT coordinates in mm. Shifting the WEPL values by
3.5 % increases the CT density which results in a shortened range (solid blue line), whereas shifting by
−3.5 % yields a prolonged range (solid red line) due to the decreased CT density.
WEPL shift [%] 80% range [mm] ∆range in [mm] ∆range rel in [%]
-10.0 144.8 14.5 11.1
-3.5 135.1 4.7 3.6
nominal 130.3 - -
3.5 125.9 4.4 3.4
10.0 118.5 11.8 9.1
Table 2.1.: 80% ranges and deltas to nominal range of SOBPs shifted by ±3.5% (depicted in figure 2.4)
and ±10.0%.
Table 2.1 presents the range shifts due to scaling the CT density by ±3.5 % and ±10.0 % for the above
mentioned example of a sphere in water. The table states distal 80 % ranges, and the absolute and
relative differences between the nominal range and the two scenarios with higher and lower CT density.
Shifting the WEPL values of the HLUT by ±3.5 % results in a comparable range shift of approximately
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∓3.5 %. It’s important to note that the relationship between WEPL and range shift is not linear, due to
the Bethe-Bloch equation. For larger shifts, such as a WEPL reduction by −10 % the range is prolonged
by 11.1 %. However, in the desired order of a few millimeters, the difference in range shifts between
scenarios with low and high density is negligible.
2.2.1 Implementation of the robust optimization algorithm
Robust field setup
Whether for single or multiple field robust optimization, the setup procedure per treatment field is
identical. Figure 2.5 summarizes the process of the field setup for robust optimization. First, the same
parameters as for a “normal” field setup are used, namely couch angle, gantry angle, isocenter, target
contours, pencil beam width, pencil beam grid spacing, thickness of ripple filter, etc. Here, the original
implementation of the field setup algorithm in TRiP4D is used, which results in an initial RST grid for
the nominal case. The target volume is transformed to the WEPL space in reference to the BEV axis
which is determined by couch angle, gantry angle and the patient’s isocenter. To find the proximal and
distal limits of the target volume, CT↔RST intersections are calculated using a ray-tracing algorithm.
During the ray-tracing process, the geometrical intersections of the pencil beams traversing the voxels of
a CT cube are calculated. By scaling the geometrical distance with the WEPL, which corresponds to the
HU value of the intersected CT voxel, the range in water can be estimated. The transformed volume is
divided in IES determined by the thickness of the ripple filter and the available primary particle energies.
The slice with the largest extension is used as a starting point for the remaining slices. The resulting three
dimensional RST grid is cubical in shape and contains all necessary pencil beam spots to cover the target
volume.
As mentioned in section 2.2.0.1, there are two primary input parameters for robust optimization: the
patient setup uncertainty (in mm) and the range uncertainty (in percent). From here, nine uncertainty
scenarios are initialized. Since changing the CT density affects the particle ranges, the corresponding
shifted Hounsfield lookup tables are also stored, as well as the patient-to-gantry and gantry-to-patient
transformation matrices which are changed when shifting the patient’s isocenter.
The goal of the robust field setup is to further extend the initial RST grid to contain all possible pencil
beam spots resulting from the 9 uncertainty scenarios. To achieve this, a loop over the uncertainty
scenarios is repeated to find the lateral, proximal and distal limits of the target volume. This process
can result in additional proximal and distal IES; however, the final result is an extended RST grid (see
figure 2.5).
Initially, all RST points of the final cubical RST grid are valid beam spots and their particle numbers
would be optimized to deliver the planned target dose to the entire volume of the RST grid. Typically,
tumors are more or less of spherical shape and beam spots which are outside of the treatment volume
need to be discarded. In the original algorithm this is done looping all RST points and recheck, whether
they are inside of the treatment volume. Since the position of the treatment volume changes within the
patient for different uncertainty scenarios, an additional loop over all scenarios is required for each beam
spot from the final RST grid.
In case of the robust field setup, the order of these two loops is commutable. Hence, the loop over
the uncertainty scenarios can be performed first. The target contours are shifted, corresponding to the
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Figure 2.5.: The flowchart schematically shows the setup of a RST grid for a field used in robust opti-
mization. Inputs are the basic field parameters like couch angle, gantry angle, isocenter, target contours,
pencil beam width, pencil beam grid spacing, thickness of ripple filter, etc. These are not explicitly shown
in the chart, but the resulting initial, nominal RST grid. Further inputs are the uncertainty parameters
for the robust optimization e.g. ±3.0mm for patient setup error and ±3.5% shift of CT density to model
range uncertainties.
robust parameters of each scenario and the WEPLs are recalculated. This is followed by the loop over all
RST points, rechecking if the RST point is within the target contours. This procedure ensures, that all
relevant RST points are considered for the robust optimization.
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Robust optimization
The two basic inputs for the subsequent robust optimization are the extended RST grid per treatment
field as described in the previous section, and the CT image. Both inputs are needed to calculate the
entries of the field dose correlation (FDC) matrices for each uncertainty scenario. For each scenario,
the CT voxels corresponding to the shifted target volume are correlated to the dose contribution of each
field. The lateral and depth dose contributions result from the pencil beam model used for physical and
biological dose calculation, which has been presented in sections 1.6.1 and 1.6.2. Since the lateral and
longitudinal shifting of the target volume within the CT image addresses different voxel, the resulting
9 FDC matrices are also differing, describing different dose distributions. In figure 2.6 the setup of the
FDC matrices is shown as a flowchart. The FDC matrices are schematically visualized as two dimensional
false color plot. As described in section 1.6.1, the dose of an voxel i results of the scalar product between
the particle vector ~N and the i-th line of the FDC matrix. For the robust optimization, there are nine
different dose values for each voxel (see also equations (1.8),(1.9) and (1.11)).
An optimal solution for the particle numbers for each pencil beam spot N j (within the particle number
vector ~N) is found by minimizing the cost functions presented in the following sections 2.2.2 and 2.2.3.
As described in section 1.6.3 a conjugate gradient algorithm is used for solving the minimization prob-
lem. For determination of step width and search direction in each iteration of the conjugate gradient
algorithm, the calculation of the particle vector gradient ∇F( ~N) is necessary, as described explicitly in
Horcicka [2011]. Since this gradient has contributions of each voxel considered in the optimization,
these contributions can differ depending on the uncertainty scenario chosen by the worst case optimiza-
tion algorithm. As the entries of FDC matrix are used for the calculation of this gradient, all FDC matrices
have to be held in memory over the complete course of the optimization, which increases the amount of
memory required for the execution of a 3D robust optimization by a factor of 9. A detailed description
of the used conjugate gradient algorithm can be found in Horcicka [2011].
2.2.2 Difference between conventional and robust cost function
The robust cost function used in this thesis, based on the worst-case method proposed by Liu et al.
[2012], is defined as
FRobust( ~N) =
∑
i∈CTV
wCTV ·

min
{k∈KScen.}

Diact.(
~N , k)

− Dpresc.
2
+
∑
j∈OARs
wOARs ·Θ

max
{k∈KScen.}

D
j
act.( ~N , k)

− Dlimit

·

max
{k∈KScen.}

D
j
act.( ~N , k)

− Dlimit
2
, (2.2)
where the minimum and maximum dose is taken from a set of KScen. possible dose scenarios per voxel.
In this thesis, 9 uncertainty scenarios are used for lateral and longitudinal displacement of the target
volume, as described in section 2.2.0.1. The Heaviside function, Θ(Dact. − Dlimit), is unity when Dact. >
Dlimit and zero when Dact. < Dlimit. By using the Heaviside function, under dosage is neglected in the
organs at risk (OAR).
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Figure 2.6.: The flowchart schematically shows the setup of field dose correlations matrices for the robust
3D optimization. Based on the 9 uncertainty scenarios (fromfig. 2.5) and the field dose correlations (FDC)
for each pencil beam are calculated and stored. For this approach this results in 9 FDCmatrices fromwhich
different dose scenarios are calculated. Eventually, the expanded RST grid is then robustly optimized.
Choosing the actual dose, Dact., from a set of KScen. possible dose scenarios per voxel is the major
difference between the conventional definition of the cost function, FPTV, in equation (1.12) and the
robust definition, FRobust, presented above. Following the worst-case approach, the minimal dose is
assigned to CTV voxels, while the maximum dose is assigned to OAR voxels.
The formulation of the optimization problem is identical with equations (1.13) and (1.14), except that
FRobust( ~N) is used as cost function.
The robust cost function uses the CTV without additional margins around the target structure. This
is unlike the conventional definition, where the treatment plan is optimized on the PTV. By running on
several uncertainty scenarios, the presented robust optimization method intrinsically creates patient and
case specific margins, eliminating the need for the standard safety margins of the PTV.
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2.2.3 Robust cost function with maximum dose term
The maximum dose term (MDT) is an optional and additional contribution to the robust cost function
(2.2) introduced by [Liu et al., 2012]. The original purpose of this term was to reduce hot spots in
dose distributions for proton therapy by including the maximum dose scenario from each target voxel
in the robust cost function. The maximum dose term has its own penalty weight, pCTV, max, which is
independent from the CTV contributions shown in equation (2.2). This results in the following cost
function
FRobust, MDT( ~N) =
∑
i∈CTV
wCTV ·

min
{k∈KScen.}

Diact.(
~N , k)

− Dpresc.
2
+
∑
i∈CTV
wCTV, max ·

max
{k∈KScen.}

Diact.(
~N , k)

− Dpresc.
2
+
∑
j∈OARs
wOARs ·Θ
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D
j
act.( ~N , k)
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− Dlimit

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
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j
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
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.
(2.3)
For proton therapy, the robust cost function with the maximum dose term is used optionally only,
whereas for carbon ion therapy the maximum dose term is mandatory to avoid an increase in target
doses far beyond the prescribed dose. The impact of the maximum dose term is shown in figure 2.7 for a
50 mm diameter sphere in a cubical water phantom, optimized to a biological dose of 10 Gy(RBE). When
no maximum dose term is applied (MDW=0.0, black line), the dose volume histogram (DVH) shows a
massive overdosage, reaching maximum doses of 126 %. By increasing the maximum dose penalty
weight, the overdosage can be reduced to 101 % for MDW=1.0 (cyan line). For a simple volume such as
a sphere in water, increasing the maximum dose penalty weight above 1.0 leads to slight degradation of
the DVH; however, for patient cases, and maximum dose weight (MDW) of 1.0 is sometimes insufficient
to control overdosage within the target volume. Empirically determined MDW values up to 1.2 have
shown to decrease the maximum delivered dose to an acceptable level below about 110 % of the planned
dose.
2.2.4 Robustness analysis — Conventional vs. robust optimization
In this section, a comparison between conventional and robust optimized treatment plans will be made
for the simplified case of dose delivery to a spherical target inside of a water phantom. For this setup
IMPT with two opposing fields was used. The plans were optimized to a biological dose of 10 Gy(RBE).
In case of the conventional optimization, a PTV with 5 mm isotropic safety margins on the CTV was
chosen as the target volume. For robust optimization, the CTV was chosen as target with MDW value of
1.0.
The treatment plan quality was assessed using a robustness analysis (RA), which involves calculating
21 different dose distributions from 21 different uncertainty scenarios, namely from a manipulation
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Figure 2.7.: DVH for a sphere with a diameter of 50mm in a water phantom, showing the influence of
the maximum dose term in the robust cost function for different penalty weights (MDW).
of the CT density, and shifts to the patient’s isocenter. Even the superposition of density changes and
position shifts are considered in the RA. The scenarios used in optimization and robustness analysis are
described in more detail in table 2.2.
nominal density low density high density
no shift Opt. & RA Opt. & RA Opt. & RA
pos. x shift Opt. & RA RA RA
neg. x shift Opt. & RA RA RA
pos. y shift Opt. & RA RA RA
neg. y shift Opt. & RA RA RA
pos. z shift Opt. & RA RA RA
neg. z shift Opt. & RA RA RA
Table 2.2.: The scenarios used in the robust optimization (9 in total) are denoted with ’Opt.’, the ones
used for the robustness analysis (21 in total) are denoted with ’RA’, i.e. for the RA also superpositions of
position and density shifts are used.
Figure 2.8 illustrates the average dose curve (solid line) and the corresponding uncertainty band
(light color) resulting from 21 DVHs for four treatment plans. The uncertainty band is the envelope of
the minimum and maximum volumes from all 21 scenarios for each dose value on the horizontal axis of
the DVH. In the conventional case (fig. 2.8(a)), the biggest uncertainty occurs at the region of the dose
fall-off which around 100 % of the target dose. For plans where the robust optimization was applied, the
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uncertainty band has been reduced to a small area, located directly on the shoulder of the dose fall-off
(feg. 2.8(b)).
In order to measure the robustness of a plan, the dose spread (DS) is used, as follows:
DS= max
{k∈KScen.}
D50%(k)− min{k∈KScen.}
D50%(k), (2.4)
where k is from the set of KScen. uncertainty scenarios. Table 2.3 summarizes DS, values for the min-
imum dose delivered to 99% of volume (D99%), minimum dose delivered to 50% of volume (D50%),
the homogeneity index (HI) and the maximum dose delivered to a single voxel (DMax) from a RA with
KScen. = 21 uncertainty scenarios. Using robust optimization, the DS is shown to be reduced by a factor
of approximately 8; however, this reduction of the uncertainty band comes at the price of a smaller D99%
and an increased DMax. Therefore, the planned dose must be increased by 2 % recovers the D99% value
while maintaining the reduced DS. This will come at the cost of an additional increase to the maximum
dose.
conventional robust robust* robustHC
D99 [%] 98.2 ± 2.0 96.9 ± 1.6 99.1 ± 1.7 99.4 ± 1.6
D50 [%] 100.01± 1.45 100.03± 0.18 102.05± 0.20 102.48± 0.04
HI [%] 2.9 ± 1.0 2.2 ± 0.5 2.1 ± 0.4 2.7 ± 0.3
Dmax [%] 101.1 ± 1.6 102.0 ± 1.5 104.0 ± 1.5 105.0 ± 2.0
DS [%] 3.63 0.44 0.47 0.13
D99≥ 100% [%] 33.3 0.0 47.6 47.6
Table 2.3.: Average values and standard deviation for dose measurements from robustness analysis for a
sphere in water phantom for conventional and robust optimization. The robust plan with the increased
planned dose (DP = 10.2Gy(RBE)) is denoted with a
∗. The robust plan optimized with a hard constraint
of 10Gy(RBE) is denoted with a HC. The last line states the percentage from 21 uncertainty scenarios in
which D99% is ≥ 100%.
Instead of increasing the planned target dose manually, in order to increase the D99% of the robust plan
to values comparable to the conventional plan, it is possible to repeat the optimization several times
until the desired goal is accomplished. This strategy is called “objective optimization” and has been
implemented into TRiP4D by Anderle et al. [2018]. As this strategy is independent of the optimization
algorithm itself, only minor adaptations were necessary to use it for the robust optimization kernel. For
the presented case, the chosen “objective” is a D99% ≥ 100 %, which corresponds to a hard constraint
dose value of 10 Gy(RBE). As this objective sets a strict limit to the D99% value, it will be further on
called “hard constraint” (HC).
The procedure of the objective optimization starts with assessing the fraction of under-dosed voxels
after an initial optimization with the number of iterations reduced by a factor of 2. The underdosage is
the difference between the actual dose of a voxel and the predefined hard constraint dose value. For the
robust optimization kernel, the algorithm of the objective optimization always chooses the dose of the
nominal scenario as actual dose for each voxel. A voxel is counted as under-dosed if its actual dose is
below the hard constraint dose value. The algorithm then increases the planned dose, voxel by voxel,
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(a) Conventional PTV optimization. (b) Robust CTV optimization.
(c) Robust CTV optimization with a planned dose
of 10.2Gy(RBE).
(d) Robust CTV optimization with hard constraint
of 10Gy(RBE).
Figure 2.8.: DVHs with uncertainty bands resulting from robustness analysis for a sphere in water with a
diameter of 50mm. Figure shows the difference between (a) conventional, robust optimization with (b)
default and (c) by 2% increased planned dose and (d) robust optimization using adaptive planning with
an hard constraint on the CTV of D99 > 100%. Solid lines: average DVH, light colors: uncertainty band
(min/max envelope). All DVHs are normalized to a target dose of 10Gy(RBE).
for each under-dosed voxel, up to 0.1 Gy additional dose. The increase of the planned dose is restricted
to a maximum of 110 % of the hard constraint dose value.
Comparing the robust HC plan (figure 2.8(d)) with the other two robust optimized plans (figures
2.8(b) and 2.8(c)), the fall-off of the average DVH curve is not as linear. Furthermore, compared to the
robust plan with the planned dose increased by 2 %, the maximum dose in the DVH of the robust HC
plan is slightly increased (see also table 2.3).
If objectives, such as D99% ≥ 100 % of the planned dose, are required during treatment planning,
there are only few qualitative differences between the simple robust optimization with an empirically
increased planned dose by 2 % and these of an objective optimization with a hard constraint. For both
plans, the constraint is fulfilled in 10 of the 21 scenarios considered in the RA only.
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2.3 Robust RBE variation
Since the RBE plays an important role in calculating the biological dose for carbon ions, it was postulated
that varying the RBE during robust optimization could potentially improve the treatment plan robust-
ness against biological uncertainties. A sensitivity analysis by Friedrich et al. [2013] of the parameters
determining the RBE estimated an uncertainty for the RBE value in the SOBP of about 10 %; however,
the given RBE uncertainty served as a guiding value only and also depends on patient geometry, the
choice of beam angles, and the α/β ratio of the tissue. Nonetheless, the findings from [Friedrich et al.,
2013] support the hypothesis that introducing an RBE uncertainty scenario into the robust optimization
will reduce the susceptibility of carbon ion treatment plans to manipulated RBE values.
The conception of the robust RBE scenario was to describe the worst case for target and OAR voxels
in a single scenario. This is possible as the biological dose is proportional to the RBE value and reducing
the RBE means reducing the biological dose and vice versa. Given that underdosage is the worst case
for target voxels and overdosage the worst case for OAR voxels, scaling the RBE value depending on the
voxel type will cover the RBE uncertainty in a single scenario.
During each iteration step of the optimization, the biological dose is calculated for all target and OAR
voxels. First, the physical dose is determined and the RBEiinitial value for a each voxel i is calculated from
particle spectra and the αi and βi values of the corresponding voxel. The biological dose is computed
by multiplying physical doses with RBEiinitial values. At this point, the RBE
i
initial value must be scaled by
±10 % depending on the voxel type.
Since the RBE value is always larger or equal than unity by definition, following scaling function is
used:
RBEifinal =
!
RBEiinitial − 1

·
!
1.0± 0.1

+ 1. (2.5)
For OAR voxels, the 10 % values are added on the initial RBE value RBEinitial, increasing the biological
dose, and for target voxels, the 10 % values are subtracted to decrease the dose. This strategy ensures
that RBE values are always ≥ 1.0.
The robust optimization with an additional RBE scenario was tested on a lung cancer patient. For
simplification, only 3D optimization was used to create the treatment plans, where the planned target
dose was 25 Gy(RBE). The robust RBE plan was compared to a robustly optimized plan (as described in
section 2.2.2) and a conventionally optimized PTV plan.
To observe the influence of the RBE shift, plan quality was initially assessed by evaluating the CTV
coverage for the aforementioned nine basic scenarios (the nominal, two range error and six position
error scenarios); the corresponding DVHs, including uncertainty bands, are shown in the left column of
figure 2.9. The 27 error scenarios of the superposition of the 9 basic uncertainty scenarios with RBE
shifts of ±10 % are presented in the right column of figure 2.9. The results of the RA are summarized in
table 2.9. Target coverage is assessed with dose measurements such as D99, Dmax HI, DS and the dose
exposure of the smaller airways (SA) with Dvol and Dmax.
As the left column of figure 2.9 shows, all three plans were robust against the basic nine error scenarios
as almost no uncertainty bands are present for the target dose measures. Compared to both robust plans,
the conventional PTV plan unexpectedly had the lowest dose spread, a factor of about 2 smaller than for
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9 uncertainty scenarios
(a) Conventional PTV optimization.
(b) Robust CTV optimization.
(c) Robust CTV optimization incl. RBE scenario.
27 uncertainty scenarios incl. RBE shifts
(d) Conventional PTV optimization.
(e) Robust CTV optimization.
(f) Robust CTV optimization incl. RBE scenario.
Figure 2.9.: DVHs with uncertainty bands resulting from robustness analysis for a lung cancer patient
irradiated with a 3D treatment plan with two orthogonal fields on the reference CT phase for 3 dif-
ferent plans from conventional optimization (a,d), default robust optimization (b,e) and robust RBE
optimization (c,f). Left column shows results for the 9 basic uncertainty scenarios. Right column the
superposition with an RBE shift of ±10% resulting in 27 error scenarios. Solid lines: average DVH, light
colors: uncertainty band (min/max envelope). All DVHs are normalized to a target dose of 25Gy(RBE).
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conventional robust robust RBE
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D99 [%] 98.4 ± 0.1 98.2 ± 0.0 99.1 ± 0.0
Dmax [%] 101.0 ± 0.0 103.4 ± 0.7 103.7 ± 0.7
HI [%] 2.0 ± 0.1 2.4 ± 0.1 2.5 ± 0.0
DS [%] 0.04 0.07 0.15
SA: D0.5cc [%] 25.6 ± 0.5 11.8 ± 7.0 12.9 ± 8.9
SA: Dmax [%] 50.0 ± 0.0 42.8 ± 3.3 44.0 ± 5.6
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ts D99 [%] 98.5 ± 1.0 98.2 ± 1.0 98.6 ± 1.1
Dmax [%] 101.3 ± 1.2 103.7 ± 1.4 103.7 ± 1.4
HI [%] 2.1 ± 0.2 2.5 ± 0.1 2.4 ± 0.2
DS [%] 2.32 2.50 2.81
SA: D0.5cc [%] 25.6 ± 1.0 11.9 ± 7.1 12.2 ± 7.8
SA: Dmax [%] 50.0 ± 0.8 42.8 ± 3.4 43.1 ± 4.2
Table 2.4.: Average values and standard deviations of dose measurements from robustness analysis of a
3D treatment plan for conventional, robust and robust RBE optimization for a lung cancer patient. SA =
smaller airways.
robust plan and of about 4 for the robust RBE plan, respectively. Even the homogeneity index was about
20 % smaller for the conventional plan. Hence, for the basic uncertainty scenarios, the conventional plan
provided the highest robustness.
When the additional 18 dose scenarios with a superposition of the basic nine scenarios with an RBE
shift of ±10 % were also taken into account, the uncertainty bands increased for all three plans. The
conventional plan still maintained lower homogeneity index and dose spread values than for both robust
plans.
Despite the reduced robustness of the target coverage, both robust plans have been shown to generate
superior OAR sparing. Independent of including RBE shifts to the RA, the volume dose for the SA was a
factor of about 2 smaller for both robust plans compared to the conventional plan. Also the maximum
dose was about 20 % smaller for both robust plans. As the uncertainty bands for the target coverage
are only marginally differing, the default robust plan is the more favorable plan due to the shape of
dose curve for the SA, generating the lowest volume dose and maximum dose. Additionally, the more
symmetrical distribution of the uncertainty band around the average dose curve of the CTV is more
favorable for the robust plan, especially for doses larger than 100 % of the target dose.
Discussion
For the tested lung patient case, the conventional PTV plan and the two robust plans seem to be
inherently robust against the integrated RBE uncertainty. For all plans, the uncertainty band around the
average dose curve of the CTV increased similarly, when RBE errors of ±10 % were included. Using
an additional worst-case scenario during the robust optimization which considers a shifted RBE value
does not improve the resulting dose distribution. Instead, the resulting target coverage becomes slightly
worse than for the conventional or robust treatment plan.
As introducing an RBE shift during the dose calculation produces a global increase to the dose if the
shift is positive and a reduction to the dose if the shift is negative, the initial approach to include RBE
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uncertainty into the robust optimization was different. Two RBE uncertainty scenarios were added to the
nine basic uncertainty scenarios of the robust optimizer, one decreasing and the other increasing the RBE,
resulting in 11 error scenarios. These two scenarios proved to overshadow the other scenarios during op-
timization and, being potentially incongruous, prevent the optimizer from finding any optimal solutions.
This conclusion was the rationale for the approach described in section 2.3, unifying the worst-case RBE
values for target and OAR voxels in a single uncertainty scenario. Enabling the robust optimizer to suc-
cessfully minimize the cost function, the RBE uncertainty scenario did not show the expected improve
in robustness against RBE uncertainty. Surprisingly, the dose distribution with the highest robustness for
target coverage was generated by the conventional plan. Possibly, even the unified RBE error scenario
is still incongruous to the remaining uncertainty scenarios, more impeding the optimizer from finding
optimal solutions, than helping to generate robust treatment plans.
Conclusion
Since the RBE calculation is highly complex and depending on numerous quantities, a simplified ap-
proach has been developed to implement the RBE uncertainty scenario into the robust optimizer. As
a simplification, a single scenario, unifying the worst-case RBE values for target and OAR voxels, was
added to the already existing nine uncertainty scenarios. Depending on the voxel type, the RBE value was
scaled by ±10 %. As the resulting DVHs show, the anticipated improvement of robustness against RBE
variation during dose calculation could not been accomplished by using an additional RBE uncertainty
scenario in the robust optimization. Possibly, the chosen approach oversimplified the source for RBE un-
certainty. Against the initial assumptions, a more complex approach is probably needed. However, due
to the numerous quantities influencing the RBE, the potential degree of complexity could again impede
the optimizer from finding optimal solutions. Since the RBE is a quantity afflicted with uncertainties as
described by Friedrich et al. [2013], it would be still of high relevance to consider RBE uncertainties
within a robust optimization.
2.4 Discussion
In this chapter, an algorithm for the robust optimization of carbon ion treatment plans has been pre-
sented. The algorithm was based on a voxel-wise worst-case approach as described by Pflugfelder et al.
[2008] and Liu et al. [2012]. From a set of potential range or patient setup errors resulted a set of
different possibly dose distribution. In each iteration step of the robust optimization, the scenario with
the lowest dose is selected for target voxels and the scenario with the highest dose is selected for OAR
voxels. Since this selection is done on a voxel-wise basis, the resulting treatment plan will consist of
mixed contributions from different uncertainty scenarios, which can not be realized at the same time in
a real patient. For example, if a real patient is shifted to the right during setup, a simultaneous shift to
left is not possible. With the current implementation, the optimizer can not account for these illogical
combinations of uncertainty scenarios, resulting in “unphysical” treatment plans. However, the resulting
plans could also be described as overly conservative, anticipating the incidence of errors impeding the
delivered dose distribution.
The treatment plans generated with the robust optimizer, were tested on a spherical target in a water
phantom without the presence of critical structures. Conventional plans optimized on a PTV and the
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robust treatment plans were compared for plan quality and robustness against different uncertainty
scenarios. This was done by performing a robustness analysis (RA). During this RA, dose distributions
for different error scenarios were calculated. The RA considered the nine basic uncertainty scenarios,
as well as the superposition of range and setup uncertainties resulting in additional 12 error scenarios,
which adds up to 21 uncertainty scenarios in total. Thus, the RA is enabled to see beyond potential error
scenarios, which have already been accounted for during the robust optimization.
Comparison between the RA for the conventional plan (as seen in figure 2.8(a)) and the robust plan (as
seen in figure 2.8(b)) has revealed a considerable increase in robustness as seen in the large reduction to
the uncertainty bands around the average CTV dose curves. The dose fall-off of the robust plan intersects
the 100 % dose value at around 50 % of the volume, inevitably leading to a reduction in target coverage.
The average D99 value is reduced from 98.2 % to 96.7 %. An additional method for recovering the
target coverage is then necessary. In this work, two options for recovery of the target coverage were
investigated. First, an empirical approach of globally increasing the planned target dose by 2 % was
investigated. Second, a more elaborate method involving the usage of an existing objective optimization
strategy was used. By repeating the optimization several times while adapting weights and planned
target dose on a voxel-wise basis after each optimization run, this method enabled the consideration of
dose volume and hard constraints.
The resulting DVH for the case of globally increased planned dose is shown in figure 2.8(c). The
average DVH curve as well as the uncertainty band has nearly the same shape as the DVH curve of the
robust plan (as seen in figure 2.8(b)), but is shifted to higher dose values by an offset of about 2 %.
This can also be observed in the D99%, D50% and DMax values in table 2.3 which are likewise increased
by approximately 2 %. The steep and narrow fall-off of the DVH curve of the robust plan with globally
increased planned dose enabled a recovery of the target coverage.
A similar result could be obtained by using an objective optimization approach which sets a hard con-
straint for the target of D99% ≥ 100 %. The objective optimization algorithm successfully adapted the
planned dose for underdosed voxels and produced a similar plan as the robust optimization with globally
increased target dose. Compared to figure 2.8(c), the DVH in figure 2.8(d) has an even narrower uncer-
tainty band than robust plan with globally increased target dose, but the fall-off is less steep resulting in
slightly more overdose of (104.0± 1.5) % vs. (105.0± 2.0) %. The percentage of uncertainty scenarios,
in which the constraint of D99% ≥ 100 % is fulfilled, is about 48 % for both, the robust plan with globally
increased planned dose and the robust plan using objective optimization.
In this chapter, treatment planning was limited to cases with no consideration of critical structures.
The influence of OARs on plan quality of robust treatment plans will be investigated in chapter 3. The
relevance of an objective optimization will change for complex patient cases, especially with dose volume
constraints for OARs in close vicinity to the target. To be fulfilled, a dose volume constraint requires a
certain fraction of the OAR volume to not exceed a given dose value. Compared to objective optimization,
the empirical method of increasing the planned dose globally by some percent during robust optimization
only works for hard constraints on target dose, but not for dose volume constraints.
The impact of the maximum dose term in the robust cost function was an unexpected finding. For
robust proton treatment planning, the maximum dose term was proposed to minimize the occurrence of
hot spots in the target volume [Liu et al., 2012]. For carbon ions, this term not only reduced hot spots
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(compare figure 3.4 (a) and (b)), but more importantly, the maximum dose term helped to attenuate
an unrestricted growth of the maximum dose (see 2.8(d)). A maximum dose penalty weight around 1.0
was, therefore, recommended. For values larger than about 1.5, the maximum dose was even further
reduced, at the cost of sacrificing target coverage around the D95 region. Using penalty weights below
1.0, basically deactivated the efficacy of the maximum dose term in avoiding overdosage, resulting again
in unfavorable high maximum dose values.
The reason for this behavior may be that the robust optimizer uses only the minimal dose scenario to
determine the new particle numbers for all possible scenarios. During the optimization, particle numbers
get adapted in the manner that every scenario is as close as possible to the prescribed dose. However,
without the maximum dose term, there is no correcting momentum in the robust cost function which
stops the optimizer from exceeding the planned dose.
As described in section 2.2.1, field dose correlation matrices are set up for each uncertainty scenario,
which increases the used working memory by a factor of about nine. Optimizing simple target structures
in a water phantom does not pose a big challenge to the optimizer, but robust treatment planning of
patient CT scans does. As will be described in chapter 3, the use of randomized subsampling of voxels
becomes necessary during robust optimization to enable that the robust optimizer can handle the robust
optimization’s problem size at all. There are other potential methods to decrease memory consumption
which have yet to be explored, such as deleting FDC matrices describing similar scenarios. This is
the case for patient setup error scenarios, whose lateral projection on the BEV axis is zero, generating
a FDC matrix which is identical to the one of the nominal case. Having two identical FDC matrices
present during optimization dose not further contribute to the process of finding a robust treatment
plan. Therefore, the uncertainty scenario in question, including its corresponding FDC matrix, can be
deleted. Due to the current implementation of the robust optimization in TRiP4D, such a scenario cannot
simply be deleted. However, the potential of this method to save memory may be used by a more modular
implementation of the error scenarios for the robust optimization with TRiP4D.
2.5 Conclusion
The presented robust optimization algorithm, which uses a voxel-wise worst-case approach, provides
a suitable method to account for uncertainties such as patient setup errors and range changes during
treatment delivery for carbon ions. The increase in robustness could be seen in the resulting set of
DVH curves from a robustness analysis and was characterized by an reduced uncertainty band, a steeper
fall-off of the average dose curve of the CTV and a more homogeneous plan. Due to the shape of the
robust DVH, the increased robustness was achieved by a minor decrease to the target coverage. This can
be solved by globally increasing the planned target dose by approximately 2 % or by using an objective
optimization with an hard constraint on the target volume. Using one of the aforementioned approaches
for a simple spherical structure in a water phantom, average dose measurements for target coverage,
such as D99, became comparable to the results of a conventional PTV plan.
The presented robustness analysis (RA) not only uses error scenarios already applied in the robust op-
timization, but additionally considers the superposition of setup errors and range uncertainty scenarios.
This approach is favored, as it accounts for combinations of scenarios which are likely to occur during
treatment, but which are not explicitly considered during the robust optimization process.
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Finally, the importance of the maximum dose term on the quality of robust treatment plans using
carbon ions, was studied. For treatment planning with protons, this additional term of the robust cost
function is used optionally, in order to avoid hot spots in the delivered dose distribution. For robust
optimization with carbon ions this term is not optional,as without it overdosage in the target volume is
certain. It is strongly recommended to use the maximum dose term in robust optimization for carbon
ions. If the cost function’s worst-case term has a penalty weight of 1.0, the suggested range for the
penalty weight of the maximum dose term is 1.0 to 1.2.
The influence of the presence of OARs during robust optimization will be investigated in the following
chapter within.
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3 Robust 4D optimization
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3.1 Introduction
One of the major issues encountered during carbon ion radio therapy of lung tumors is the density
gradient between lung and surrounding tissue. This density difference can lead to significant range
changes from nominal targeting accuracy, which not only deteriorates the delivered dose distributions,
but also harms surrounding normal tissues. For moving tumors, such as those of the lung, the main
source of range uncertainties is caused by the periodic tumor motion, leading to changes in the WEPLs
over time.
Figure 3.1 exemplarily shows the dose distribution of a single field uniform dose (SFUD) plan, opti-
mized on the end inhale phase of a 4DCT, and the same plan applied on the end exhale phase of the same
4DCT without any adaptations. In the end exhale phase, the tumor has moved about 2 cm in superior
direction, causing a deterioration of the inferior part of the dose distribution. Due to the lower density
of the surrounding lung tissue, considerable range overshoots occur which increase the dose exposure to
the heart.
The changes in tumor depth due to respiratory motion can be addressed by creating a WEPL ITV. To
create a WEPL ITV, the target volumes from all motion states of a 4DCT are transformed to the WEPL
space, then the union of these transformed target volumes is generated. The resulting volume, the WEPL
ITV, accounts for ranges changes which are caused by respiratory tumor motion. As the transformation to
the WEPL space strictly depends on field parameters like couch and gantry angle, the resulting WEPL ITVs
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Figure 3.1.: Left panel: dose distribution of a SFUD plan, optimized on the end inhale phase of a 4DCT
of lung cancer patient without safety margins. Right panel: same SFUD plan applied on the end exhale
phase. Due to periodic tumor motion and the density gradient between tumor and surrounding lung
tissue, considerable range changes are generated for the end exhale phase, causing dose deteriorations
which increase the dose exposure to the heart.
are likewise field specific, only allowing to be used in SFUD optimization. Graeff et al. [2012] proposed a
solution to this limitation by moving the part of algorithm calculating the field specific WEPL changes to
the part of the optimization algorithm which transforms geometrical path lengths to WEPL space. With
this approach, a MFO IMPT optimization can be performed, which is based on the geometrical ITV, not
requiring field specific increases to the target volume. Though this method works, it is highly complex
and the internal transformation of the geometrical ITV to the WEPL space is not a unique mapping.
A more elegant approach is the 4D ITV optimization introduced by Graeff [2014], where an influence
matrix is set up for each motion state, correlating all target voxels from a specific motion state to the
grid of beam spots of a single treatment plan. This method has been successfully adapted for multiple
targets and used in an in-silico patient study with carbon ions presented by Anderle et al. [2018]. In
the corresponding study, the results were compared to actual treatments done with SBRT and showed
that the 4D ITV approach could meet strict dose constraints for critical organs (defined by Benedict et al.
[2010]) without compromising the prescribed target dose. Although different interplay patterns were
assessed on four motion patterns with different combinations of respiration periods and starting phases,
the study only looked at a single nominal dose scenario, not considering any further range changes or
patient positioning uncertainties.
The dose distribution of a 4D IMPT carbon ion plan differs from the an 3D SBRT plan as shown in
figure 3.2. The SBRT dose distribution shows an inevitable low dose bath of X-rays, which is delivered to
the complete thorax. In contrast, carbon ion therapy with the 4D IMPT approach significantly decreases
the low dose exposure of the thorax, due to both, the usage of less treatment fields and the favorable
depth-dose profile of ions as shown in figure 1.5. Compared to photons, not only the dose to surrounding
tissue but also the dose deposited in entry channels is considerably reduced for the usage of carbon ions.
A robustness analysis, as described in chapter 2, was performed for the same patient cohort used in
Anderle et al. [2018]. The treatment plans used for this analysis are the same 4D ITV plans as used
in the study conducted by Anderle et al. The RA reveals that for some critical structures, like smaller
airways, the strict dose constraints (as described in Benedict et al. [2010]) could not be met any longer
in the majority of considered uncertainty scenarios.
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Figure 3.2.: 4D IMPT and SBRT treatment plans for two patients. First row: patient 13 with 5 tumors and
no nearby critical organs. Second row: patient 22 with 4 tumors, from which 2 are next to the heart. For
the 4D IMPT plans, the doses are calculated on 4DCTs, whereas the SBRT plans are calculated on static
CTs. The targets are outlined in white, the heart in red. Figure adapted from [Anderle et al., 2018].
To account for range changes and setup uncertainties, a robust version of the 4D ITV approach was in-
troduced, based on the worst-case method presented in chapter 2. This algorithm has been implemented
into TRiP4D, and a more detailed description can be found in section 3.2.
The following hypotheses are established and will be examined later in this chapter:
1. Robust 4D ITV optimization leads to a general increase in robustness against range changes and
patient positioning uncertainties.
2. Robust 4D ITV optimization enables a superior OAR sparing in the majority of considered uncer-
tainty scenarios.
3. Although the nominal dose distribution from the robust plan might degrade, robust 4D optimiza-
tion still maintains the advantage in OAR avoidance over photon therapy.
3.2 Optimization method
The 4D ITV optimization strategy used in this chapter is based on the method developed by Graeff
[2014]. In order to handle multiple targets, the optimization algorithm has received further extensions
by Anderle et al. [2018]. The cost function for 4D-ITV-based IMPT, as used by Anderle et al., is described
by
F4D ITV( ~N) =
∑
m∈M


∑
T
wT
∑
i∈Target
!
D
i,m
act.( ~N)− Dpresc.
2
+
∑
j∈OARs
wOARs ·Θ
!
D
j,m
act.( ~N)− D jlimit

·
!
D
j,m
act.( ~N)− D jlimit
2

 , (3.1)
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where M is the set of all motions states of a 4DCT. For patients with multiple tumors, T represents the set
of all targets included in the optimization. Dpresc. denotes the dose prescribed by a physician and Dlimit
is the dose limit for the surrounding critical structures considered during treatment planning. Values
for Dlimit which depend on organ and fractionation according to Benedict et al. [2010] can be found in
table B.1. The formulation of the optimization problem is identical with equations (1.13) and (1.14),
except that F4D ITV( ~N) is used as cost function.
One should note, that this approach, though it considers all motion states of a 4DCT, only generates
a single treatment plan (single RST grid) which is valid for all motions states accounting for motion
induced range changes from all phases. In order to ensure that the tumor is within the treatment
volume at all times, the final 4D ITV can be considerably larger than the geometrical ITV. Further motion
mitigation, using slice-by-slice rescanning, is addressed in section 3.4.
A robust version of the 4D ITV approach was realized by a straightforward implementation of the
worst-case method into the existing 4D ITV algorithm. The same implementation as presented in chap-
ter 2.2.1 was used for the setup of the robust IMPT fields. The further procedure of the robust 4D ITV
optimization is described in figure 3.3. As in figure 2.5, the result of the robust field setup is an expanded
RST grid which is large enough to contain all pencil beam spots corresponding to the uncertainty scenar-
ios under consideration. The nine stored uncertainty scenarios per field containing shifted HLUT tables
and shifted patient to gantry and gantry to patient transformation matrices are stored in the working
memory for the setup of the field dose correlation (FDC) matrices.
Following the non-robust implementation of 4D ITV optimization method, the dose contributions from
each pencil beam spot from the RST grid are calculated and stored in the FDC matrices for all target
and OAR voxels from all motion states from a 4DCT (typically 10 motion states). For the non-robust
implementation, this typically results in 10 FDC matrices. For the robust implementation, a FDC matrix
for each of the nine uncertainty scenarios is calculated at each motion state. This additional dimension
can be seen in the k = 9 dose scenarios Di,mact.( ~N , k) used in the cost function for the robust 4D ITV
optimization:
FRobust 4D ITV( ~N) =
∑
m∈M
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, (3.2)
where m is the current motion states from a set of M motion states. During the optimization, the
minimum or maximum dose scenario k from a set of dose scenarios is chosen, depending on the voxel
being target or OAR for each voxel i and j. This means that for each motion state, 9 FDC matrices are
set up, creating a total of 90 influence matrices in the working memory during the plan optimization.
The formulation of the optimization problem is identical with equations (1.13) and (1.14), except that
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Figure 3.3.: The flowchart schematically shows the setup of field dose correlations matrices for the robust
4D ITV optimization. The field dose correlation (FDC) matrices for each pencil beam are calculated and
stored, based on the 9 uncertainty scenarios from fig. 2.5 and the 10 motion states of a 4DCT. This results
in 90 FDC matrices from which different dose scenarios can be calculated. The expanded RST grid can
finally be used for robust optimization.
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FRobust 4D ITV( ~N) is used as cost function. Depending on the size of the target(s) and critical structure(s),
a calculation could require up to hundreds of gigabyte of working memory. To handle the work load,
machines with suitable computational power are necessary. Alternatively, smart software solutions might
reduce the needed matrix size.
3.3 Patient data
The robust 4D ITV algorithm was tested on a set of 8 patients with 2 - 5 tumor lesions in the lung. In
total there were 24 metastases. This set of patients represents a subset of the most complex cases of a
patient cohort presented in Anderle [2016]. The patient numbering from Anderle is preserved in this
thesis to maintain consistency.
For each patient, 4DCTs with 10 motion states (0-9) were obtained, where the end inhale phase is
defined as the reference state (0). Additionally, a deformable image registration (DIR) is performed for
each 4DCT which is used to transform all structure like CTVs and OARs from the reference state to the
remaining motion states.
The average tumor volume was 28.8 cm3, with a range of 0.4 cm3 to 139 cm3 for the reference state.
The peak-to-peak motion was estimated from the 4DCTs to be 6.2 mm on average, with a range of
0.5 mm to 17 mm. A more detailed overview of the patient cohort is shown in table 3.1.
3.4 Treatment planning
In the study of Anderle et al., treatment planning was done on the geometrical ITV, which is generated
by the union of the CTVs from all motion phases, extended by 3 mm PTV margins. In case of an overlap
between target volumes and critical structures, the overlap is subtracted from the corresponding CTV
in all motion phases. The original SBRT plans, which have been used for the radiotherapy treatments
of these patients at Champalimaud Center for the Unknown (FC), also used 3 mm PTV margins. In
comparison to both, the conventional 4D ITV approach by Anderle et al. and the SBRT photon treat-
ment, the robust optimization is performed on the CTV(s) only. As described in chapter 2, the robust
optimization algorithm generates safety margins by considering several uncertainty scenarios during op-
timization, namely errors in patient positioning and uncertainties in particle ranges. These uncertainties
are described by two parameters, the setup uncertainty parameter and the range uncertainty parameter
(see section 2.2.0.1 for more details). Hence, the extension of the safety margins depends on these two
uncertainty parameters used during robust optimization. To maintain comparability with the 3 mm PTV
margins used in Anderle et al., the setup uncertainty was chosen to be ±3 mm and the range uncertainty
parameter was set to ±3.5 % for the robust optimization algorithm.
As described in chapter 2, errors in patient positioning can be modeled by shifting the patient’s isocen-
ter during treatment planning, more precisely by shifting in direction of the six major axis of CT coordi-
nate system. Since treatment plan optimization is performed in the BEV coordinate system, the effective
shift is obtained by calculating the lateral projections of the shifts in the CT coordinate system.
Like the BEV coordinate system itself, the effective shifts in the BEV system also depend on couch and
gantry angle; however, in the BEV coordinate system, only planes orthogonal to the BEV axis are affected
by the shifts in the CT coordinate system. The particle ranges are only marginally affected by adding or
70
Patient Target
Volume
[cm3]
Peak-to-peak
motion [mm]
Fractions
[Gy(RBE)]
Dplan
[Gy(RBE)]
N◦ of IMPT
fields
Adjacent OAR
1 a 10.2 3.4 1× 24.0 25.5 2
b 14.4 2.8 1× 24.0 25.5 2
3 a 136.0 12.0 1× 27.0 28.5 3 Heart
b 12.4 2.5 1× 20.0 21.0 2
c 123.0 14.0 1× 27.0 28.5 2 Heart
d 80.7 17.0 1× 22.0 23.1 3
e 86.7 6.6 1× 20.0 21.0 3 Smaller airways
11 a 2.3 12.0 1× 24.0 24.5 2
b 0.4 11.8 5× 7.0 7.9 3 Heart, stomach,
esophagus
13 a 3.8 5.8 1× 24.0 24.5 2
b 4.3 0.8 1× 24.0 24.5 2
c 2.7 3.4 1× 24.0 24.5 2
d 3.1 2.1 1× 24.0 24.5 2
e 0.5 0.5 1× 24.0 24.5 2
20 a 139.0 0.6 1× 24.0 25.0 3 Smaller airways
b 9.2 2.0 1× 24.0 25.0 3
21 a 4.0 9.0 1× 27.0 27.5 5 Smaller airways,
heart, esophagus
b 0.8 7.8 1× 24.0 24.5 2
22 a 3.4 5.0 1× 24.0 24.5 3
b 2.4 4.4 1× 24.0 24.5 2
c 2.0 6.3 1× 24.0 24.5 2 Heart
d 2.4 6.4 1× 24.0 24.5 2 Heart
23 a 20.6 7.4 1× 24.0 24.5 4 Smaller airways
b 27.1 6.0 1× 24.0 24.5 3 Smaller airways,
heart
Table 3.1.: Characteristics of the patient cohort, showing target volumes, peak-to-peak motions, dose
fractions used, number of fields used in IMPT and OARs closer than 15mm to CTV. Dplan = planned dose
used in robust optimization.
subtracting an additional 3 mm of air while traversing patient tissue in BEV; however, manipulating the
CT density by ±3.5 % creates significant particle range changes, as shown in figure 2.4.
The resulting average lateral, proximal, and distal extension of the applied RST grids are stated in
table 3.2. These values are averaged over all 61 fields from all 8 patients found in table 3.1. It was
found that shifting the patient’s isocenter resulted in an average lateral extension of about ±3.0 mm on
the RST grids. More precisely, the average shift was ±3.0 mm on the horizontal BEV axis and ±2.8 mm
on the vertical BEV axis. Modifying the CT density effectively introduced shifts to particle ranges and
extended the average RST grid by −2.5 mm in proximal and 4.1 mm in distal directions of the BEV axis.
It should be noted that the proximal and distal extensions to the RST grid in the BEV system are stated
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in [mmH2O]. This is in contrast to table 2.1, where the range changes are stated in the CT coordinate
system in mm.
Lateral left
[mm]
Lateral right
[mm]
Lateral down
[mm]
Lateral up
[mm]
BEV proximal
[mmH2O]
BEV distal
[mmH2O]
Average −3.0 3.0 −2.8 2.8 −2.5 4.1
Stddev 0.1 0.1 0.3 0.3 0.9 1.3
Median −3.0 3.0 −3.0 3.0 −2.4 4.1
Min −3.0 2.3 −3.0 2.1 −5.4 1.7
Max −2.3 3.0 −2.1 3.0 −1.1 6.8
Table 3.2.: Average lateral, proximal, and distal extension of the RST grids in BEV system due to the un-
certainty parameters used in the robust optimization algorithm (±3mm setup uncertainty, ±3.5% range
uncertainty). The values are averaged over all 61 fields from all 8 patients (see table 3.1).
The treatment plan optimization was performed separately for each of the lung lobes since the entry
channels did not overlap. As in the study from Anderle et al. [2018], due to the low density of lung
tissue, an 80 mm PMMA bolus was used to account for the short particle ranges for targets in close
proximity to the chest wall. In order to reduce the size of the calculation problem, large OARs, such
as the heart or the lung, were each cropped to the volumes intersecting with the treatment fields only.
In this study, the same OARs as used in Anderle et al. [2018] were used for the robust optimization.
Only for one case, patient 20, which had been originally optimized without OARs, it was necessary to
introduce 10 mm shells of lung tissue around the CTVs to reduce the increased normal tissue dose close
to the CTVs which was caused by the robust optimization algorithm.
In order to maintain comparability, treatment planning parameters such as number of fields, couch and
gantry angles, target points, spacing of RST grid, and size of ripple filter were taken from the treatment
plans created in the study by Anderle et al. [2018]. As in the study by Anderle et al., the number of
fields per target was selected, depending on the presence of adjacent OARs: (i) two opposing fields were
used in absence of an OAR, (ii) two or more opposing or oblique fields were used in presence of critical
structures in close proximity.
The RBE was calculated by applying LEM IV [Friedrich et al., 2014; Elsaesser et al., 2010], using the
low dose approximation presented in Krämer and Scholz [2006]. Alpha-beta ratios of 6 and 2 were
selected for target and normal tissue, respectively [Anderle et al., 2018].
The weight for the max dose term introduced in section 2.2.3 was set to 1.0 for all patients except for
patient 1, where the value was set to 1.1. This was necessary in order to account for a higher normal
tissue dose, since this patient was optimized without consideration of OARs.
Unlike in Anderle et al. [2018], the use of objective optimization was only necessary for patient 23.
Here, a hard constraint was chosen for the smaller airways of the lung in order to reduce the maximum
dose which prevented compliance with the dose volume limit defined in Benedict et al. [2010].
Voxel randomization
For further reduction of the calculation problem, random voxel sampling has been used throughout
this study. Firstly, the volume V of a structure was split into an interior part Vinterior and a boundary
shell Vboundary by using a distance transformation. For both portions of the volume, random sampling
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parameters xinterior and xboundary were chosen. During the setup, all voxels considered were assigned the
probability of 1/xinterior and 1/xboundary, respectively, to be selected for the actual optimization, more
precisely, only the fraction of 1/x × 100 % of all voxels in V is considered in the optimization. In this
study, the random sampling parameters were typically chosen to include more boundary than interior
voxel (xinterior > xboundary), due to their close vicinity to the dose gradients.
Quasi-random numbers were used to perform the random voxel sampling. Since these numbers de-
pend on seed numbers, the resulting set of randomly chosen voxel only changes between executions
of the same optimization in cases where the seed has changed. In order to maintain comparability be-
tween the resulting treatment plans of several executions of the same optimization, always the same
seed numbers were used.
Since P3 and P20 both have CTVs larger than 100 cm3, only a subset of states were considered for the
optimization to further reduce the number of optimization voxels. To cover the target motion properly,
two extreme states, 0 and 5 (end inhale and end exhale), as well as an intermediate state (7) were
considered for the robust 4D ITV optimization. For all other patients, all 10 motion states were used.
For all 24 CTVs, a median of 50 % of all boundary target voxels (range of 25 % to 100 %) and 25 % of all
interior voxels (range of 6.25 % to 100 %) were taken into account for the treatment plan optimization.
For OARs, less voxels were considered for optimization: For boundary voxels, a median of 25 % with a
range of 1.25 % to 50 % and for interior voxels a median of 6.25 % with a range of 1 % to 25 % were
selected for optimization.
3.5 4D dose calculation
4D dose distributions were calculated for the robust and the conventional treatment plan from Anderle
et al. [2018]. The 4D dose calculations were performed with TRiP4D using a patient specific DIR, to
transform all partial state doses to the reference phase (0). Temporal correlations between patient’s
respiratory motion and the beam delivery was simulated with a dose delivery simulation tool (DSim)
[Richter, 2012]. Machine parameters, including average spill duration and spill structure, were taken
from the synchrotron accelerator at Heidelberg Ion-Beam Therapy Center (HIT). The DSim also simu-
lated the dynamic intensity control (DIC) beam extraction method implemented at HIT, which creates
a step sized spill structure with a flat intensity over time [Schömers et al., 2011]. Compared to the
extraction method at GSI, this enables a more homogeneous particle extraction. Breathing motion was
modeled with a periodical Lujan function using to different periods T (3.5 s and 5 s), each combined
with two different starting phases φ (0° and 90°), resulting into four respiratory motion patterns. The
Lujan function is
sin2n(t/T +φ), n ∈ N, (3.3)
as presented in Lujan et al. [1999].
For each of these four respiratory motions patterns, 21 4D dose distributions were calculated, corre-
sponding to 21 uncertainty scenarios as described in section 2.2.4, consisting of a combination of the
nominal range scenario and over- and undershooting ranges, with shifts to the patient’s isocenter in 6
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major anatomical directions. In total, this results in 84 different 4D dose distributions per treatment
plan.
3.6 Analysis
To evaluate the treatment plan quality, a RA, as described in chapter 2, was performed. For the RA, dose
volume histograms (DVHs) have been calculated for each of the 84 4D dose distributions. From this
set of DVHs, average values for different dose measurements can be determined. The target coverage
was evaluated by considering the dose distribution for the CTV and calculating V95, D95, D99, the D50
spread and the homogeneity index (HI).
For critical organs, the volume dose Dvol and the maximum dose Dmax, corresponding to the dose
limits defined for different fractionation schemes in Benedict et al. [2010] were calculated. The V5 value
was additionally calculated to assess the low dose exposure to OARs. The Dvol and Dmax values were
normalized to the limits stated in Benedict et al. [2010]. If a value exceeded 100 %, the constraint was
counted as violated.
3.7 Example patient
To evaluate the performance of the robust 4D ITV optimization in a more comprehensive manner, pa-
tient 23 is presented in more detail in the following section.
3.7.1 Results
Although patient 23 has only one tumor per lung lobe, this case posed a challenge for the conventional
and the robust optimizer, due to the close vicinity between the CTV and the smaller airways in each lung
lobe. At some locations, the distance between targets and smaller airways is less than 10 mm, generating
a competitive situation between providing sufficient target coverage and adequate OAR sparing. Both
the original SBRT treatment plans and the conventional 4D ITV carbon ion plans from Anderle et al. tried
to find a compromise between these two opposing objectives. In case of doubt, OAR sparing was favored
over target coverage. For the conventional treatment plan, there was the need to sacrifice target coverage
of the CTV in the left lung lobe to spare the smaller airways adequately already in the “nominal dose
scenario”, which does not consider any additional range or setup errors. The result of this compromise
can be seen in figure 3.4(a,c) as an axial dose cut for both the conventional and robust treatment plan.
The dose distributions of both plans show a cold spot in target coverage for the medial area of the left
CTV, which will further on be called “low dose area”. For the robust plan, the low dose area between
the left CTV and smaller airways was already larger than for the conventional case, and in the right
lung lobe, the low dose area in the CTV is even more pronounced than for the conventional plan. For
the robust treatment plan, this means an additional sacrifice of target dose coverage in order to provide
improved sparing of the SA.
The ideal treatment plan would generate a DVH, where the CTV dose curves converge to the ideal
step-shape for all considered uncertainty scenarios, and where the CTV dose curves provide a steep dose
fall-off shortly after 100 % of the target dose is reached. This would result in a narrow uncertainty bands
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CTV R
CTV L
(a) conv. 4D ITV, nominal
(c) robust 4D ITV, nominal
(e) robust 4D ITV LOW, nominal
(b) conv. 4D ITV, hd
(d) robust 4D ITV, hd
(f) robust 4D ITV LOW, hd
Smaller
airways
Spinal cord
Aorta
Esophagus
Figure 3.4.:Axial view of 4D dose distribution overlaid on CT reference phase for patient 23 in the nominal
(nom) and high density (hd) scenario with Lujan period of 3.6 s and starting phase of 0°. Panel (a) and
(b) show the dose distributions resulting from the conventional optimized plan with right and left CTVs
(white) as well as the smaller airways (black) and heart (brown) as critical structures. Panels (c) and (d)
shows the dose distributions from the robustly optimized treatment plan and panels (e) and (f) show the
robust plan with low OAR weights (LOW). Dose is shown in Gy(RBE).
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around the average DVH curves and that the CTV objective of D99%≥ 100 % is fulfilled in the majority of
cases. At the same time, the ideal plan would meet the DVH constraints for both the volume dose and the
maximum delivered dose for each OAR in all uncertainty scenarios under consideration. In the following
three figures, the dose volume constraint for the smaller airways is indicated in the DVHs with stars. For
the DVH of the ideal treatment plan, all OAR curves would stay left and below of the corresponding star
symbols.
Figure 3.5 shows the result of the RA for the plan optimized with conventional IMPT using the 4D ITV
approach. The desired target coverage for the right CTV (D99%≥ 100 %) was fulfilled in 4 of 84 scenarios
as the average D99% is only (93.1± 6.7) %. The target coverage was limited by the competing constraint
for smaller airways of D0.5cc ≤ 12.4 Gy(RBE) which was met in 31.0 % of the uncertainty scenarios.
For the left lung lobe, there was a large uncertainty band around the average DVH curve of the CTV.
This exemplifies the situation of the conventional optimization failing to provide adequate certainty for
delivering the planned dose distribution under the presence of patient setup or range uncertainties. The
smaller airways in the left lung lobe benefit from the reduced target coverage (D99% is (63.0± 8.1) %),
since the corresponding dose volume constraint is fulfilled in 63.1 % whereas the CTV constraint is not
met in any uncertainty scenario.
Figure 3.5.:DVH of the conventional treatment plan for patient 23. The bold lines are average DVH curves
and the light colored areas are uncertainty bands, depicting the envelope of all 84 4D dose distributions.
Star symbols indicate the dose volume constraints for the smaller airways (D0.5cc ≤ 12.4Gy(RBE)). The
SA constraint is fulfilled in 31.0% and 63.1% of all uncertainty scenarios for the right (blue) and the left
smaller airways (green), respectively.
Using robust optimization with similar voxel weights as for the conventional plan can help to meet
the desired OAR objectives. The DVH from the RA for the robust plan is shown in figure 3.6. The dose
volume constraint of D0.5cc ≤ 12.4Gy(RBE) for the smaller airways was fulfilled in 75.0 % of the cases for
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the right SA and in 100.0 % for left SA. This constraint reduced target coverage for the both CTVs. The
D99 objective for the CTVs could not be accomplished in any of the considered uncertainty scenarios.
Figure 3.6.: DVH of the robust treatment plan for patient 23. The bold lines are average DVH curves
and the light colored areas are uncertainty bands, depicting the envelope of all 84 4D dose distributions.
Star symbols indicate the dose volume constraints for the smaller airways (D0.5cc ≤ 12.4Gy(RBE)). The SA
constraint is fulfilled in 75.0% and 100.0% of all uncertainty scenarios for the right (blue) and the left
smaller airways (green), respectively.
The DVH for the robust plan with low OAR weights (further on called “robust LOW” plan) is shown in
figure 3.7. For the robust LOW plan, the OAR weights were chosen to be smaller than the CTV weights
during robust optimization. This enabled an improvement of the robustness to the target coverage by
increasing OAR doses, in this case the dose to the smaller airways. In addition to the improved target
coverage, the uncertainty band was reduced and the average homogeneity index was increased. Though
the DVH of the robust LOW plan almost showed the ideal step-shape, the CTV objective of D99%≥ 100 %
was only met in 2.4 % for the right CTV and in 6.0 % for the left CTV. Figure 3.4(e) shows the axial view
of the dose distribution for the robust LOW plan.
The right column of figure 3.4 shows the axial cuts of the dose distributions of all three plans where CT
density is increased by 3.5 %. The high density (hd) scenarios exemplary demonstrates the performance
of the robust optimization algorithm under the presence of uncertainties. Since increasing CT density
will result in a range undershoot of the planned treatment fields, the impact on the dose distribution can
be drastic as seen in the increased number of hot and cold spots. When comparing the nominal and the
hd dose distribution for the conventional plan, both CTVs contain hot spots. Especially the left target
sustains extensive cold spots which is in the order of several Gy(RBE) in some areas.
Apart from the deliberately created cold spots close to the smaller airways, the robust dose distribu-
tion is much more homogeneous and only contain small hot spots, as seen in the dose distribution in
figure 3.4(c) and (d).
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Figure 3.7.: DVH of the robust LOW treatment plan for patient 23, where the OAR voxel weights were
smaller than CTV voxel weights during optimization. The bold lines are average DVH curves and the light
colored areas are uncertainty bands, depicting the envelope of all 84 4D dose distributions. Star symbols
indicate the dose volume constraints for the smaller airways (D0.5cc ≤ 12.4Gy(RBE)). The SA constraint is
fulfilled in 0.0% and 28.6% of all uncertainty scenarios for the right (blue) and the left smaller airways
(green), respectively.
The major difference between the robust LOW plan and the robust plan can be seen around the
boundary areas of the target volume, next to the smaller airways. Since the weights for the target voxels
were set to be larger than the weights for the OAR voxels for the robust LOW plan, the cold spots in the
target vanish. A similar effect can be seen in the presence of uncertainties, which can be exemplarily seen
in figure 3.4(f) for the axial dose distribution with an increased CT density by 3.5 %. Especially when
compared to the conventional and the robust plan, the robust LOW plan shows almost no deterioration
of the dose distribution for the hd scenario.
CTV coverage
The results for all the dose measurements of the target, including all 21 uncertainty scenarios and
all 4 patient motions, are summarized as boxplots in figure 3.8, resulting in 84 values per boxplot. In
the boxplots, the black lines indicate the median values, and the black X’s symbols denote the average
values. The boxes describe the 1st and 3rd quantiles, and the whiskers represent 3 standard deviations,
including approximately 1 % to 99 % of all values in the distribution of a dose measurement. Outliers are
represented by crosses. Since the distribution of these values is not Gaussian, statistical significance has
been calculated by using an unsigned rank test. The resulting p-values are divided into three different
classes: ∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001.
The boxplots for the conventional, the robust and the robust LOW plan are presented adjacent to
each other. Both robust plans show distributions of dose measurements V95, D95 and D99 which are
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significantly different from the conventional plan, having p-values smaller 0.001. Considering the plan
quality, the robust LOW plan leads to the best target coverage, followed by the conventional and the
robust plan in descending order. These results are in agreement with the results described in previous
paragraphs and the DVH figures. The objective of D99% ≥ 100 % is fulfilled in 4.2 % of the uncertainty
scenarios for the conventional plan, in 0.0 % of the scenarios for the robust plan and in 10.7 % for the
robust LOW plan.
Figure 3.8.: CTV coverage of patient 23 shown as boxplots of V95, D95, D99, D5 and HI for the conven-
tional, the robust and the robust with low OAR weights plan. The black line indicates the median value
whereas the black X denotes the average value. The boxes represent the 1st and 3rd quantiles, while the
whiskers represent the environment of 3 standard deviations. Statistical significance is tested between
the conventional and the two robust plans and is indicated by a p-value calculated with an unsigned rank
test (∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001).
The width of the D50 distribution describes the width of the uncertainty band around the 100.0 %
target dose level. As described in chapter 2, it is a suitable measure to assess plan robustness. Hence, the
width of the D50 distribution is more important to assess plan robustness, than the median or average
value of the D50 distribution. For both robust plans, the D50 width was considerably reduced. For the
robust plan, the complete distribution of D50 values lies around the median value of 103.1 %, and falls
within an interval range of 2.3 %. For the robust LOW plan, the total width of the distribution is further
reduced to 1.3 % around a median value of 104.0 %. The conventional plan has a D50 median value of
104.7 % with a interval width of 16 %.
In an ideal DVH, with a step-shaped target dose distribution, values for the homogeneity index would
be very small, almost approaching zero. The values for homogeneity index are significantly worse for the
robust plan than for to the conventional plan, whereas the robust LOW plan yields significantly better HI
values. The p-values, in both cases, are smaller than 0.001.
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OAR exposure
The evaluation of the dose measurements for treatment targets must always be considered with the
dose delivered to surrounding critical organs. Values for dose exposure to the most important organs
(smaller airways, heart, esophagus, spinal cord, aorta and ipsilateral lung) are summarized for all 84
uncertainty scenarios in figure 3.9 as boxplots. The ipsilateral lung consists of the volume of the affected
lung lobes subtracted by the volumes of the corresponding CTVs. Both, patients 20 and 22, have only
one lung lobe which is affected by a tumor. For theses two cases, the corresponding ipsilateral lung
volumes do not include the healthy lung lobes. The values for the dose volume, Dvol, and the maximum
dose delivered, Dmax, are all normalized to their corresponding limits from Benedict et al. [2010]. This
means that a constraint is violated if the Dvol or Dmax values exceeds 100 %.
The presented patient cohort was originally treated with photons using a stereo tactic radio therapy
(SBRT). For SBRT, almost the entire patient is covered by the huge number of photon treatment fields,
also generating areas of tissue volume which receive low levels of photon radiation dose. As in Anderle,
the V5 value is used here to assess the amount of low dose delivered to the OARs .
For patient 23, the boxplot of the smaller airways includes the dose values of the smaller airways of
the right and left lung lobes. In this plot, the average dose volume, Dvol, for the conventional plan was
102.6 % with a range of 84.2 % to 129.7 %. The constraint for the SA of D0.5cc < 12.4Gy(RBE) was only
fulfilled in 38.1 % of the 84 uncertainty scenarios. For the robust plan, the Dvol is 84.8 % with a range
of 66.8 % to 101.6 % which met the SA constraint in 96.4 % of the scenarios. The Dvol for the robust
LOW plan is 117.6 % with a range of 97.7 % to 144.2 %, which fulfilled the SA constraint in 10.7 % of
the uncertainty scenarios.
As for the Dvol values, the robust plan yielded the smallest Dmax values. The distribution of the maxi-
mum dose values of the conventional plan were significantly higher than for the robust plan. The highest
Dmax values were generated by the robust LOW plan. For all three plans, the limit for the Dmax value
was exceeded for all uncertainty scenarios; however, according to Anderle [2016], the maximum dose
constraint had already been deliberately violated for the actual photon treatment with SBRT. The V5
values, which were used to assess the low dose exposure, were significantly lower for the robust and
robust LOW plan compared to the conventional plan. As the V5 values of both robust plans were even
smaller than for the conventional plan, they were considered as uncritical.
For the remaining OARs, the dose measurements did not show a noticeable pattern. Nonetheless, the
dose values all fell within the constraints.
The Dvol values for the heart were significantly higher for the two robust plans. For the conventional
plan, the median Dvol was 15.0 %. In contrast, the median Dvol was 19.5 % and 30.0 % for the robust
and the robust LOW plans, respectively. However, the maximal doses were significantly smaller for the
two robust plans. While the conventional plan had a median Dmax of 76.3 %, the robust and the robust
LOW plans yielded median Dmax values of 52.4 % and 62.7 %, respectively. The V5 values were below
5 % for all plans and therefore uncritical. The corresponding p-values were smaller 0.001.
The volume dose and maximal dose of the esophagus were below 20 % for all plans. Nonetheless,
the values of Dvol were significantly smaller for both robust plans. The Dmax values of the robust plan
were significantly smaller than those of the conventional plan, but for the robust LOW plan, they were
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Figure 3.9.: OAR doses of patient 23 shown as boxplots of Dvol, Dmax, V5 as well as Dmax, V20 and V90
for the ipsilateral lung. Results are shown for the conventional, the robust and the robust with low
OAR weights plan. The black line indicates the median value whereas the black X denotes the average
value. The boxes represent the 1st and 3rd quantiles, while the whiskers represent the environment of 3
standard deviations. Statistical significance is tested between the conventional and the two robust plans
and is indicated by a p-value calculated with an unsigned rank test (∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→
p < 0.001).
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significantly higher. The V5 values were below 10 % for all plans, but the two robust plans yielded
significantly smaller V5 values. The p-values were all less than 0.001.
Larger variations can be seen for the spinal cord. The Dvol values for the conventional plan were
significantly lower than for the two robust plans where median values were 31.2 % for the conventional
and 36.0 % for the robust plan. Additionally, the Dvol values of the robust LOW plan were even higher
than for the two remaining plans, with a median value of 57.6 %. The Dmax values for the robust LOW
plan were significantly higher than for the conventional or the robust plan. The median value was 59.9 %,
whereas the median values for the conventional and robust plan were 39.3 % and 38.3 %, respectively.
The statistical significance between the distribution of Dmax values of the conventional and the robust
plan was less pronounced (p-value < 0.05).
The volume dose values for the aorta were below 10 % for all three plans. The Dvol values for the
robust plan were slightly lower than for the conventional plan, but differed significantly with a p-value
below 0.01. The maximal dose for the conventional plan was significantly smaller than for the two robust
plans. The median value was 17.1 % for the conventional plan, and for the robust and robust LOW plan,
the median values were 23.3 % and 25.3 %, respectively. Concerning the V5 values, the situation was
opposite here; the median values for the robust and the robust LOW plan were significantly smaller at
20.1 % and 21.7 %, and the conventional plan had a median V5 at 28.2 %.
As there was no limit stated for the maximal point dose for the lung, the Dmax value was normalized
to the target dose of the tumor in the affected lung lobe. All dose measurements for the lung were
evaluated for the volume of the lung lobe minus the clinical target volume(s). V20 and V90 values were
calculated to assess the low and the high dose exposure of the ipsilateral lung lobe, respectively. For both
robust plans, the median maximal dose was significantly smaller, measuring at 109.6 % and 110.8 %
for the robust and the robust LOW plans, respectively, as compared to 123.7 % maximal dose for the
conventional plan. The V20 values lied around 25.0 % for all three plans. Nonetheless, compared to
the conventional plan, the V20 distribution was significantly smaller for the robust plan and significantly
larger for the robust LOW plan. The V90 values were smaller than 5.0 % for all three plans, and the
robust plan was significantly smaller than the conventional plan. The p-values were all smaller than
0.001.
3.7.2 Discussion
Low dose area
The dose areas, as exemplarily shown for the robust plan in figure 3.4(c & d), are a consequence of
the choice of voxel weights and the current implementation of the optimization algorithm. Overlaps of
the target volume with adjacent critical organs, result in both structures sharing the same voxels in the
CT image. The implementation of the voxel-based optimizer in TRiP4D requires that any give voxel may
only be assigned as a target or an OAR exclusively. The decision whether to classify a voxel as target or
OAR is determined by the voxel weights which are a manual input of the treatment planner. If the OAR
weights are larger than the target weights, the corresponding overlap voxels between target and OAR
are counted as OAR, and vice versa.
During the robust optimization, uncertainty scenarios such as shifting the patient’s isocenter, do not
exclusively affect the CTV(s), but also critical organs such as the smaller airways in case of patient 23,
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are shifted. Having adopted the same relation between target and OAR weights as described in Anderle
et al., moving the CTV in direction of an OAR and an OAR in direction of the CTV, will result in at least a
low dose area of about the doubled size as compared to conventional plan. The extension of the low dose
area depends on the setup uncertainty parameter initially used in the robust optimization. In this study,
a shift of ±3 mm resulted in a extension of the low dose area in the order of about 6 mm. Depending
on the choice of the beam angles, the shift caused by setup error scenario and the shift due to range
overshoot may superpose, resulting in a even larger extension of the low dose area.
This situation occurred in patient 23 for the right CTV (see figure 3.4(c)). As described above, the
emergence of these low dose areas can be interpreted as an inherent effect of the current implementation
of robust optimizer with its exclusive assignment of voxels as target or OAR; however, the voxel-wise
worst-case optimization also generates unrealistic dose distributions consisting of different uncertainty
scenarios for adjacent voxels, which are highly unlikely to occur at the same time. For example, a setup
error which shifts the patient’s isocenter in direction of the OAR can not at the same time shift the OAR in
the opposite direction. An extension to the worst-case method which can discriminate unrealistic cases
could be implemented, which would neglect one of the two shifts and would result in a low dose area of
just 3 mm.
CTV coverage
The low fulfillment rates of the D99% objective for all three plans are due to several factors. First,
for the conventional and the robust plans the focus was to find a balance between target coverage and
OAR sparing (in case of patient 23 the adjacent smaller airways). To achieve this, overlapping areas
of the target and the smaller airways were cropped from the CTV volume and higher voxel weights
were used for the smaller airways than for the target voxels. Compared to the robust algorithm, the
conventional IMPT algorithm only optimized a 4D ITV plan on the nominal scenario. As the robust
optimizer functions by trying to fulfill the OAR objective in all 9 uncertainty scenarios, sacrificing target
coverage is inherently necessary. This also explains why the robust plan cannot meet the CTV objective
at all, whereas the conventional plan can fulfill it in at least 4.2 % of the uncertainty scenarios.
Compared to the conventional and robust plans, using the robust LOW plan led to an average DVH
curve which converged more to the ideal step-shape and to a considerable reduction of the uncertainty
bands, as can be seen in figure 3.7. Nonetheless, with 10.7 % of all uncertainty scenarios, the CTV
objective was fulfilled in less scenarios than expected. This is due to the usage of the same planned
target dose values during optimization as for the robust plan. Since the dose fall-off in the DVH for the
robust LOW plan was steeper than for the two other plans, the fulfillment rate for the CTV objective
could be straightforwardly improved by increasing the planned target dose at the cost of additional dose
to normal tissue.
Robustness of CTV coverage
The gain in robustness is best described by the reduced whisker lengths in the boxplots for the D50
values of the two robust plans (as seen in figures 3.6 and 3.7). The whiskers contain all values within
the 3σ-interval from approximately 1 % to 99 %. Compared to the conventional plan, the whiskers were
very close to the median value for both robust plans. In combination with small HI values, this describes
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a considerable reduction of the uncertainty band around the dose fall-off in the DVH, as can be seen for
the robust LOW plan. For the robust and the conventional plans, the HI values were increased due to
the close proximity of the tumor and the smaller airways. Although the uncertainty band was smaller for
the robust plan, than for the conventional plan, this reduced HI values caused, that the D99 constraint
could not be fulfilled; however, when voxel weights are increased to favor the target voxels during the
optimization, the HI value improves appreciably for the robust LOW plan, as described above.
Increased robustness of the robust and robust LOW plans was also expressed in dose distributions
which were less prone to hot or cold spots compared to the conventional plan. This is due to the smooth-
ing of internal dose gradients by the robust optimizer. Compared to the robust LOW plan, this refers to
the portion of the CTV dose distribution of the robust plan which was not deliberately reduced due to
the choice of target and OAR voxel weights in order to increase OAR sparing. Expressed mathematically,
the robust dose distributions can be described as more convex on the 100 % iso-dose value.
OAR exposure
Since the OAR exposure differs for each organ in consideration, it is not possible to universally describe
one of the three plans as superior to the others. The advantages and disadvantages of each plan type
must be carefully weighed against each other on a case by case basis.
When considering the heart, none of the three plans violated the volume or maximal dose constraint.
For the robust or robust LOW plans, the volume dose was slightly increased compared to the conventional
plan, but the maximal dose was therefore significantly reduced. The difference between the conventional
and the two robust plans was most pronounced in the overall reduction of the maximal point dose
measurements. Although the heart has not been considered during the treatment plan optimization, the
robust plans yield reduced maximal point heart doses as described above, which prefers the robust plans
over the conventional plan.
For the spinal cord, all three plans likewise do not violate the given constraints. As for the heart,
the spinal cord was not explicitly considered as an OAR during optimization. The robust LOW plan
consequently produces significantly more volume and maximal dose. Between the conventional and
robust plan, in this situation the conventional plan is preferred. Hence, in cases where the spinal cord is
critical, the robust LOW plan is less preferable.
Interestingly, there was a large reduction in maximal dose to the healthy lung tissue for both robust
plans. Although the robust LOW plan yielded a superior target coverage, it did not increase the dose
delivered to the lung. The Dmax stayed more or less at the same level as the maximal dose distribution of
the robust plan. This could be due to the higher convexity of the dose distributions for the robust plans,
as described above for the increased robustness of the CTV coverage. When less hot spots are produced,
less hot spots can lie outside of the CTV in healthy lung tissue.
The creation of cold spots in close vicinity to the OARs was an inherent consequence of the robust
optimization when target weights were chosen to be smaller than the OAR weights. This choice of voxel
weights ensured meeting the dose volume constraints in the majority of considered uncertainty scenarios.
For patient 23, the difference between the conventional and robust plan was very pronounced for the
smaller airways. Averaging the smaller airways in both lung lobes, the robust plan fulfilled the DVH
constraint in 96.4 % of the uncertainty scenarios, whereas the conventional plan only in 38.1 % of the
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scenarios. The robust LOW plan ensured a superior dose coverage, as compared to the conventional and
robust plans, but did so by neglecting smaller airways sparing. The conventional plan is a compromise
between the two extremes of the robust plan, which focused on OAR sparing, and the robust LOW
plan, which focused on target coverage. However, the conventional plan quality was reduced by large
uncertainty bands, especially for the left CTV. Apart from the nominal case, safe delivery of the planned
dose distribution could not be ensured in presence of uncertainties. As patient 23 is the most complex
patient from the cohort, there is no clear indication on which plan is the most beneficial. Further changes
would need to be made to the robust optimization algorithm to produce dose distributions more like that
of the conventional plan. Potentially, voxels which represent both target and critical organ would need
to be assigned as target voxel and OAR voxel during robust optimization. This capability is currently not
available in TRiP4D.
In conclusion, robust optimization enables a reduction of uncertainty of the delivered dose distribution
also for a wide range of different optimization weights. This also enables a range of clinical choices which
can be personalized to each patient.
3.8 Results — patient study
CTV dose coverage
In this section, the resulting robust treatment plans are compared against the conventionally optimized
plans for all eight patients. Figure 3.10 describes the target coverage for all 24 tumors as boxplots of
different dose measures. For each patient 21 uncertainty scenarios and 4 different patient motions are
considered, resulting in each boxplot consisting of 24·21·4= 2016 values. In the boxplots, the black lines
indicate the median values, and the black X’s symbols denote the average values. The boxes describe
the 1st and 3rd quantiles, and the whiskers represent 3 standard deviations, including approximately 1 %
to 99 % of all values in the distribution of a dose measurement. This environment will further on be
referred to as 3σ-interval. Outliers are represented by crosses. Since the distribution of these values is
not Gaussian, statistical significance has been calculated by using an unsigned rank test. The resulting
p-values are divided into three different classes: ∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001.
The dose coverage of the CTVs is described by V95, D95 and D99 values. Considering the volume
receiving 95 % of the target dose (V95), there was no significant difference between the robust and
the conventional 4D ITV plan. Nevertheless, it is worth noting that the 3σ-interval contained values
down to 28.2 % of the volume for the conventional plan, compared to the robust plan, where the lower
limit of this environment was 60.0 % of the volume. The D95 distribution, which describes the dose
given to 95 % of the CTV volume, looked similar for both optimization types, but was slightly in favor
of the conventional plans. For the D99 values, the median values were identical at 98.0 %, but the
average values were slightly different with (93.1± 12.1) % for the robust and (94.0± 11.6) % for the
conventional plans, respectively. The bottom limit of the 3σ-interval was 6.0 % lower for the robust
plans, and with a p-value smaller than 0.001 in favor of the conventional 4D ITV plans. Additionally, the
conventional plans could fulfill the objective of D99 ≥ 100 % in 38.5 %, whereas the robust plans could
only fulfill the objective in 31.9 % of cases.
The D50 and HI values are used to measure plan robustness against patient setup errors and range
uncertainties. The width of the 3σ-interval is used to determine the width of the D50 values, as it also
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Figure 3.10.: CTV coverage summarized for all patients, shown as boxplots of V95, D95, D99, D5 and HI
for the conventional and the robust plan. The black line indicates the median value whereas the black X
denotes the average value. The boxes represent the 1st and 3rd quantiles, while the whiskers represent
the environment of 3 standard deviations. Statistical significance is indicated by a p-value calculated with
an unsigned rank test (∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001).
describes the width of the uncertainty bands at the steep dose fall-off in the DVHs around 100 % mark of
the target dose. For the conventional plans, the D50 width was 37.9 % whereas for the robust plans this
width was reduced to 9.7 %. The width of the D50 3σ-interval must be considered in conjunction with
the HI value, as the HI describes how close the dose fall-off in the DVH is to the ideal step-shape. The
median values for the HI were 5.6 % for the robust and 7.4 % for the conventional plans, respectively.
The distribution of the HI values for the robust plans was significantly different from the conventional
plans.
OAR exposure
The results for the dose measurements for the most important critical organs are summarized for all
8 patients in figure 3.11. For smaller airways, heart, esophagus, spinal cord, aorta and trachea, the
volume dose Dvol, the maximal dose Dmax and V5 values are shown. The values for Dvol and Dmax were
normalized to their corresponding limits as stated in [Benedict et al., 2010]. Due to the normalization, a
constraint was counted as violated, when the value exceeded 100 %. Since the volume dose to the lungs
is low for all cases and the constraint was never violated, the Dvol lung data is not shown. As lung tissue
is counted as parallel tissue and Benedict et al. [2010] states no limit for the maximal lung dose, in this
study, the maximal lung dose was normalized to the target dose. To asses the low dose and high dose
exposure, V20 and V90 values were stated for the affected lung lobes. Except for trachea and smaller
airways, each boxplot consists of 672 values. The numbers correspond to all 8 patient dose distributions
for 4 different breathing motions combined with 21 uncertainty scenarios. Due to missing contours for
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trachea in patient 13 and for smaller airways in patient 22, the corresponding boxplots consist of only
588 values.
For heart, esophagus, spinal cord and aorta, Dvol, Dmax and V5 were significantly smaller for the robust
plans. The corresponding p-values were below 0.001, apart from Dvol and Dmax values for the spinal
cord, where the p-values were only below 0.01. It is to mention that for both kinds of treatment plans,
the maximal dose for the heart was violated in 9.1 % and 8.3 % for the robust and the conventional
plans, respectively. Similarly for the esophagus, the Dmax constraint was violated in 2.8 % and 10.1 % of
scenarios for the robust and conventional plans, respectively.
In case of the trachea, all dose measurements were very low and no constraints were violated. Dmax
and V5 values were significantly lower for the robust plans with p-values below 0.05 and 0.01, respec-
tively. Concerning the volume dose, the median value was 0.0 % for both plans. Due to the upper limit
of the whiskers being higher for the robust plans (41.6 % vs. 32.2 %), the unsigned rank test resulted in
a statistical significance in favor of the conventional plans.
As already described by Anderle et al. [2018], the smaller airways were the most critical organ for this
patient cohort. The differences between the three dose measurements were statistically significant, and
p-values were far below 0.001. The robust plans yielded smaller values for Dmax and V5, since median,
average and upper whisker limits were always lower than for the conventional plans. There is no clear
trend for the Dvol distributions: the median Dvol value was smaller for the conventional plans (52.1 %
vs. 55.9 %) whereas the average Dvol value was larger (57.1 % vs. 50.4 %). The largest difference could
be found in the height of the whiskers with the upper limit at only 100.6 % for the robust plans but
at 126.9 % for the conventional plans. Given that the OAR constraints were counted as violated if the
dose value is above 100 %, and the upper limit of the whiskers was much closer to the 100 %, the robust
plans met the dose volume constraint in many more uncertainty scenarios than the conventional plans.
For robust optimization, this constraint was fulfilled in 98.8 % of the uncertainty scenarios, whereas, for
the conventional plans, it was only fulfilled in 79.8 % of cases. For the maximal dose constraint, the
robust plans were below the limit in 62.4 % of uncertainty scenarios, compared to 46.3 % of cases for
the conventional plans.
Dose exposure of the lung is shown in figure 3.12. Since in patients 20 and 22 only the left lung
lobes were affected by tumors, the healthy right lung lobes were neglected for the evaluation of the lung
exposure. In the remaining patients both lung lobes were affected. Thus, the affected lung lobes are
further referred to as the ’ipsilateral lung’. For carbon ion therapy, the number of treatment fields is less
than those needed for IMRT and the entry channels receive less dose, so the volume dose constraint from
Benedict et al. [2010] was always fulfilled for the lung and is therefore not shown. To assess the high
and low dose exposure, Dmax, V90 and V20 were evaluated. As the lung is considered as a parallel tissue,
which can tolerate partial radiation induced damage without directly affecting the function of the lung,
no maximal dose constraint is stated in Benedict et al. [2010]. In order to allow reasonable evaluation,
the maximal dose was normalized to the planned target dose.
For the ipsilateral lung, all three dose measurements were significantly smaller for the robust plans
with p-values far below 0.001. The difference was greatest for the maximal doses, where the median
value was reduced from 113.8 % to 110.2 % of the target dose. More importantly, there was a reduction
to the upper limit of the whiskers from 147.4 % to 122.9 %.
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Figure 3.11.: OAR doses summarized for all patients shown as boxplots of Dvol, Dmax and V5. Results are
shown for the conventional and the robust plan. The black line indicates the median value whereas the
black X denotes the average value. The boxes represent the 1st and 3rd quantiles, while the whiskers rep-
resent the environment of 3 standard deviations. P-values of unsigned rank test. Statistical significance
is indicated by a p-value calculated with an unsigned rank test (∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p <
0.001).
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Figure 3.12.: Dose exposure of the ipisilateral lung as boxplots of Dmax, V20 and V90. Results are shown
for the conventional and the robust plan. The black line indicates the median value whereas the black X
denotes the average value. The boxes represent the 1st and 3rd quantiles, while the whiskers represent
the environment of 3 standard deviations. P-values of unsigned rank test. Statistical significance is indi-
cated by a p-value calculated with an unsigned rank test (∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001).
3.9 Discussion — patient study
Robustness
The summarized results for the CTV coverage in figure 3.10 show that the robust optimization leads
to a gain in robustness against patient setup errors and range uncertainties. This is described by the
considerable reduction to the width of the 3σ-interval for the D50 values and by significantly smaller
HI values. So, even if the dose delivery was influenced by shifting the patient’s isocenter and/or manip-
ulating CT density, the robust treatment plans provided a more homogeneous dose distribution with a
narrower uncertainty band. This confirms the first hypothesis that the robust 4D ITV optimization leads
to a general increase in robustness against range changes and patient positioning uncertainties. The
same holds true for the robust LOW plans.
Nevertheless, in some cases, the homogeneity of a plan was compromised by the objective of increasing
robustness of OAR sparing. This can be seen for the case of patient 23 (see section 3.7). Although there
was a considerable drop in target coverage, when focus was set on robust sparing of the smaller airways,
the uncertainty bands of the DVH curves of the CTV remained narrow on the dose fall-off around 100 %
of the target dose. This can be interpreted in such a way, that even the robustness of an unfavorable
dose distributions can be increased. As desired, robust optimization allowed the dose distribution for
the smaller airways to become more robust. In contrast to the impact of the robust optimization on the
CTV, the increased robustness does not become apparent through a reduction of the uncertainty band.
The uncertainty bands of the DVH curves for the smaller airways stayed more or less the same (as seen
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in figures 3.5 and 3.6). The only visible difference was that the both DVH curves for the smaller airways
were shifted to lower dose values, converging towards the dose volume constraint (indicated by stars
in the DVH plots) for the robust plans. So, the robust plan allowed meeting this constraints in more
uncertainty scenarios than the conventional plan allowed. In the case of patient 23, the dose volume
constraint for the smaller airways was fulfilled in 96.4 % of the considered uncertainty scenarios for the
robust plan, averaged over the smaller airways in both lung lobes. This is in contrast to the conventional
plan, where the same constraint was fulfilled in only 38.1 % of cases.
It is important to note that the current implementation of the worst-case for the robust optimization
can increase general robustness for either the target volume or critical organs. The objectives of in-
creasing robustness for the target volume and the OARs are prohibitively opposing to lead to a optimal
solution. In the case of close distances between targets and OARs (smaller than 10 mm to 15 mm),
the conventional optimization may more effectively unify the two opposing objectives. This may occur
because the conventional optimization takes into account a single nominal scenario only, whereas the
robust optimizer currently accounts for nine uncertainty scenarios simultaneously.
The described behavior of the robust optimizer not being able to find solutions which can fulfill op-
posing objectives is potentially owed to the utilization of the worst-case method and might be avoided
with the probabilistic approach proposed by Unkelbach et al. [2007] or the minimax approach proposed
by Fredriksson et al. [2011]. For the latter approach, cost functions are evaluated for each uncertainty
scenarios, minimizing the cost function with the highest value in each iteration step. This ensures that
only scenarios are considered which can occur in reality. Such a discrimination is not possible for the
voxel-wise worst-case method.
The way how the different motions phases are considered in the implementation of 4D optimization
in TRiP4D [Graeff, 2014], as used in the patient study presented in this chapter, could serve as a new
implementation of robust optimization. For the conventional 4D optimization, there is typically a set of
10 FDC matrices, one for each motion phase (see section 3.2). However, all FDC matrices are referring to
the same beam spot grid, representing different motion scenarios. A similar approach should be feasible
for robust optimization by considering the uncertainty scenarios as independent possibilities with equal
weights. This approach should be still compatible to 4D optimization, since it would expand the set of
FDC matrices per motion state only.
Target coverage
Target coverage must be considered in the context of the dose exposure to the OARs. Since, in fig-
ure 3.10, the summarized results for the 24 CTVs for the entire patient cohort are presented, suboptimal
results of individual patients are not visible. Patient 23, which was selected to be described in more de-
tail, is a good example of this as there is a significant loss in target coverage for the robust plan as seen in
the distributions of the V95, D95 and D99 values in figure 3.8. As for the robust and conventional plans,
the sparing of the smaller airways were prioritized, the loss of target coverage is a direct consequence of
the superior sparing of the smaller airways provided by the robust treatment plan (see figure 3.9).
Although, there was no significant difference in the distribution of the V95 values, the robust opti-
mization is preferable, as the interval width of the whiskers was narrower for the robust plans than for
the conventional plans. Disregarding outliers, the absolute difference in the lower limits of the whiskers
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was more than 30.0 %, favoring the robustly optimized plans (see figure 3.8). For the D95 values, the
discernible difference between robust and conventional plans was less distinct, but slightly higher av-
erage and median dose values than for the robust plans, and the absence of a statistically significant
difference, favor the conventional plans.
The statistical significance of the D99 values was more evident in the boxplots. Apart from the identi-
cal median D99 values, the average values were higher for the conventional plans. In combination with
both the lower and the upper whisker limits being higher than for the robust plans, the conventional
plans were favorable. However, accomplishing the objective of D99 ≥ 100.0 % posed a challenge to
both optimization approaches, especially when aiming to fulfill this objective in large number of uncer-
tainty scenarios. Though the focus of the robust treatment planning was set on sparing adjacent OARs,
the percentage of scenarios which fulfilled the CTV objective was still comparable to the results of the
conventional plans (31.9 % and 38.5 % for robust and conventional plans, respectively).
Despite the low dose areas of the robust plans, the remaining portions of the dose distributions are
more convex than for the conventional plans, resulting in less hot and cold spots. This can be explained
by the reduced internal dose gradients, which reduces the susceptibility to interplay patterns for the
robust dose distributions. In the most extreme case, patient 23 presents strongly enhanced interplay
patterns, which result from increased CT densities. This is illustrated in the transversal dose cuts of
patient 23 for nominal and HD scenarios in figure 3.4.
OAR exposure
When comparing the robust and conventional 4D ITV optimizations, it is clear that critical organs
do, in general, profit from the robust approach, as they receive less dose. The differences in OAR dose
exposure between the robust and the conventional plans were not as pronounced as between SBRT and
carbon ion therapy, as described in Anderle et al. [2016, 2018]. In fact, for most critical structures,
the differences between the results of the conventional and robust plans were marginal but the dose
exposure is reduced for the robust plans in most cases. Although, there are patients where the OAR
doses were higher for the robust plan than the conventional plan, the volume and maximal doses were
still within the limits stated by Benedict et al. [2010]. Hence, the robust plan should be still selected, if
the objective is to improve target coverage.
For the robust optimization, the exact same number of treatment fields with the same beam angles
and similar voxel weights as in the conventional optimization were used, so the improvement to OAR
sparing was quite small. During treatment planning, the largest difference between both optimization
types, was the choice of increases planned target doses for the robust optimization, as stated in table 3.1.
This step was necessary to reach acceptable D99 values, since the shape of the dose fall-off region of the
robust DVH curve was narrow in width but less steep than the conventional DVH curves.
Using the objective optimization, introduced into TRiP4D by Anderle et al. [2018], was only necessary
the robust optimization of patient 23. This is a remarkable result, since conventional planing required the
use of objective optimization in 4 of the 8 patients in order to create treatment plans with sufficient OAR
sparing (see [Anderle et al., 2018]). The remaining patients were optimized with only the basic robust
4D optimization algorithm and still yielded a small improvement in OAR exposure. Less computational
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effort was needed to meet the required OAR constraints, and the robust optimizer generally performed
well in sparing critical structures.
The enhanced performance was especially true for OARs which are further from the CTVs (distances
larger than 10 mm to 15 mm). The OARs were also spared with robust optimization, although they
were not explicitly considered in the optimization. This behavior may result from the more convex and
compact dose distributions to the target which avoid unnecessary margins. This effect was especially
prominent for the heart, though it has been only considered in optimization for 2 of 8 patients; for all
patients slight improvements to the volume doses, and significant reductions to the median maximal
doses were seen. As reported by Gagliardi et al. [2010], reduced heart doses are beneficial as they
reduce the relative risk for radiation induced heart diseases, such as pericarditis. Also in Benedict et al.
[2010], the recommended limit values for the dose volume constraint and the maximal delivered dose
to the heart for single fraction treatments are considerably lower then for 3 or 5 fractions (see table B.1),
which further emphasizes the importance of reduced heart doses for high dose single fraction treatments
as investigated in this thesis.
For critical structures in close vicinity to the target, such as the smaller airways, robust optimization
can also provide beneficial results. The smaller airways can be particularly close to lung tumor lesions, as
they are found as smaller bronchial ramifications in the lung. As mentioned, the robust plan optimization
was generally conducted with the same voxel weights as used for the conventional plan optimization by
Anderle et al. When during robust optimization the OAR voxel weights were larger than the CTV voxel
weights, this led to low dose areas between the target and the critical organ. As described in section 3.7,
this was an intrinsic consequence of the current implementation of the robust optimization in TRiP4D.
Although the dose exposure of the smaller airways is significantly reduced, the superior OAR sparing
causes a reduction to the target coverage. By changing the weights to be larger for CTV voxels than for
the OAR voxels, dose distributions like those of the robust LOW plan for patient 23 would be created.
These reversed voxel weights create a significantly more robust target coverage but also significantly
increase the OAR dose exposure.
As discussed for patient 23, the strict assignment of voxels as OAR or target voxel strongly contributed
to the decrease of target coverage, especially when target volumes overlapped with critical organs in
the planning image set and the OAR voxel weights were chosen to be larger as the CTV voxel weights.
Without changing the implementation of the optimization algorithm, it would be challenging to create
a plan which does not sacrifice as much target dose but is still robust against uncertainty scenarios.
Compared to robust optimization, the conventional optimization considers a single scenario only. Hence,
the RST grid is not laterally and longitudinally shifted as for robust optimization, and tumor and OAR
overlaps consequently produce only small low dose areas. The conventionally optimized plan can be
considered as an intermediate plan, between the robust and the robust LOW plan. For more complex
cases, such as patient 23, However, for patient 23, the conventional planning has a lack in plan robustness
and robust planning should be considered to create acceptable plans.
A notable result of the robust plannin was that, although the plan robustness was increased, the
maximal dose exposure to the lung was significantly reduced for all patients. The initial expectation
was that a gain in robustness to target coverage would create higher doses to the lungs, since features
present in the robust optimization, such as accounting for range uncertainties, could increase the created
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margins. The reduced maximal lung dose shows, that the manner in which robust optimization increases
plan robustness is not only done by creating patient and field specific margins. In addition, the robust
plan avoids large internal dose gradients which could lead to hot and cold spots under presence of
position or range uncertainties. In summary, plan optimization on set of several uncertainty scenarios
simultaneously creates an averaged mixture of all possible plans for each corresponding uncertainty
scenario.
General remarks on treatment planning
While, for the conventional optimization, it was not necessary to explicitly account for normal lung
tissue during the optimization, the case can be different for the robust optimization. Since the RST grid
is effectively shifted laterally and longitudinally within the patient geometry by accounting for patient
setup errors and range uncertainties, and the difference in density between the solid tumor and the lung
tissue is high, this can lead to unrestricted dose exposure to the lung. This effect was seen in patient 20.
A straightforward approach to reduce normal lung dose exposures was to add the lung as a critical
organ to the optimization. It was sufficient to simply add a shell of lung tissue around the tumor to the
optimization with a thickness of about 10 mm. The OAR voxel weights were chosen to be smaller than
the CTV voxel weights, in order to avoid a cropping of the CTV volume due to the strict assignment of
voxels as OAR or target. Further, it was sufficient only to consider every 80th voxel of the considered
’lung shell’. With this approach, the normal lung dose exposure could be reduced to acceptable levels.
The results of this patient study have shown that a robustness analysis is a very powerful tool. Al-
though, a ’robustness’ analysis with respect to patient motion was performed by Anderle et al., by
evaluating the 4D dose distributions of the conventional plans for 4 respiratory curves, the RA pre-
sented here which analyzed patient setup errors and range changes, revealed considerable lacks in plan
robustness for the conventional optimization. For example, interplay was visibly higher in patient 23 for
the left CTV when the CT density was increased by 3.5 %.
3.10 Conclusion
The main goal of introducing robust optimization methods into TRiP4D was to improve OAR sparing
while maintaining sufficient target coverage. With the help of the robustness analysis (RA), the impact
of various uncertainty scenarios on target coverage and OAR sparing for both robustly and convention-
ally 4D optimized plans was investigated. For the RA, 84 uncertainty scenarios have been taken into
consideration, accounting for patient setup uncertainties, range changes and various respiratory motion
patterns.
For the patient cohort presented in this chapter, the smaller airways stood out has the most critical
OAR. As described by Anderle [2016], the smaller airways are limiting factor for the treatment planning
for photon 3D SBRT plans. During the treatment planning at Champalimaud Center for the Unknown,
in Portugal, the OAR constraints presented in Benedict et al. [2010] were used strictly. For the treatment
plans using scanned carbon ions, it was possible to significantly reduce the dose exposure of the smaller
airways using robust 4D ITV optimization, and the overall CTV coverage was still comparable to 4D ITV
treatment plans, as seen in Anderle et al. [2018].
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For the target coverage, a general improvement to the robustness due to the robust 4D optimization
was most visible through the reduced width of the D50 distributions, which represent a small uncertainty
band in the DVH curves for the targets (see figure 3.10). Moreover, the significantly lower HI values
depicted an additional increase to robustness compared to the conventional optimization, describing a
convergence of the target DVH curves to the ideal step-shape.
When target or OAR objectives are considered on their own, the plans created with the robust 4D ITV
approach confirmed the first hypothesis stated in section 3.1. However, in some cases it was not possible
for the robust optimizer to find robust solutions for both target and OAR objectives at the same time.
This tended to occur when the two objectives opposed each other too much for an optimal plan result, as,
in case of patient 23, caused by an partial overlap between the smaller airways and the tumor volume.
A possible solution to this case would be a revision to the optimization algorithm, to allow for voxels to
be assigned as both target and OAR voxels simultaneously. Such a possibility is not currently present in
TRiP4D.
The second hypothesis was only conditionally confirmed, as the results in figures 3.11 and 3.12 showed
indeed less dose delivered to the majority of the considered critical structures for the robust plans, but to
achieve the superior OAR sparing, the target dose needed to be compromised. This was especially true
for OARs close to the target. Although, a patient could benefit from single fraction treatments due to
the higher biological effective dose (BED), there is a great deal of uncertainty to whether so much target
coverage could be sacrificed. When the smaller airways dose exposure was dramatically decreased and
the tumor could not be controlled, the benefit to the patient is marginal at least.
Nonetheless, as the robustness analysis has shown, conventional plans can be highly affected from not
being robust. This was seen in patient 23, where the conventional plan looked reasonable in the nominal
scenario, but the results from a RA revealed that target coverage had actually been impeded and the dose
volume limit of the smaller airways was violated for a majority of uncertainty scenarios. Like the robust
approach, the 4D ITV method with conventional IMPT had its advantages and disadvantages. Yet, for
the robust 4D ITV optimization, as stated in the hypothesis, the nominal dose distribution might be
compromised, it does not degrade as much as the conventional plan in cases where setup or range
uncertainties exist. Additionally, the inherent possibility of OAR avoidance of carbon ions over photon
can still be exploited. But for particular patients this could require sacrificing some target coverage. In
the clinical setting, the requirements of the physician would need further deciding whether the robust
optimization approach would be beneficial to the patient treatment.
In contrast to the Champalimaud Center for the Unknown, lung cancer patients at the university hos-
pital in Marburg, Germany, are treated with stereo-tactic photon therapy without even considering the
smaller airways during treatment planning [Personal correspondence with Dr. Stefan Lautenschläger].
The different approaches of how and whether critical organs are take into consideration for plan op-
timization, exemplify discrepancies in the best practices for treatment planning at radiation oncology
centers.
If the smaller airways could truly be ignored as critical structures during optimization, there is even
more reason to use a treatment planning strategy such as the robust LOW optimization for patients, such
as patient 23, as this method significantly improves robustness of the target coverage in the majority of
considered uncertainty scenarios.
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4.1 Introduction
In this chapter, a robust version of conformal 4D optimization strategy is presented for a selected patient.
The approach is an extension of the 4D rescanning method described by Graeff [2014]. The basic idea is
to avoid the increased ITV-like volume which is necessary to cover the target in all motion states for both
the robust and the conventional version of the 4D ITV optimization presented in chapter 3. This can be
accomplished by creating a library of plans which consists of a conformal plan for each motion phase of
a 4DCT. This library of plans is further on called 4D RST.
For each motion phase, a conformal plan is optimized, which delivers the complete target dose . Using
a 4DCT with 10 motion states during treatment planning results in 10 corresponding phase treatment
plans. The irradiation of this 4D RST on a patient would result in a dose distribution 10 times higher
than the prescribed dose. In order to deliver the prescribed dose only, the particle numbers of the phase
plans need to be downscaled. The scaling factor is determined by the number of motion states of the
used 4DCT, which would result in a scaling factor of 1/10 for the given example. This downscaled 4D
RST creates a conformal dose distribution to the target volume, also when target motion is present. As
each of the unscaled phase plans would deliver the complete prescribed dose to the target, conformal
4D optimization is fully compatible with biological dose optimization and the concept of RBE, as the
accumulated particle spectra of all downscaled phase plans is similar to the particle spectra generated
by one of the unscaled phase plans.
Compared to the 4D ITV method presented in chapter 3, the conformal 4D optimization has the
disadvantage, that the delivery of a 4D RST requires synchronization of the irradiation with the patient
motion. Figure 4.1 schematically illustrates a 4D RST for a single IES, depicting how specific RST slices
from the 4D RST are assigned to the IES of the corresponding motion state.
In Graeff [2014], a combination of 4D rescanning with multiple SFUD fields is proposed in order to
increase robustness by avoiding inter-field dose gradients. The range ITV, as described by Graeff et al.
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Figure 4.1.: Illustration of a 4D RST for a single IES. For the considered IES, a corresponding RST slice exists
for each motion phase. Here, only 3 out of 10 CT phases are shown. During treatment, the delivery is
synchronized to the respiratory motion of the patient, which requires a dedicated TCS with a fast real-time
motion monitoring. Courtesy for 4D RST illustration: A. Eichhorn.
[2012], is used prior to the optimization in order to estimate the required size of the base RST which
serves as the starting point for further setup of the phase plans (a more detailed description of the base
RST is given in section 4.2). During the optimization of the phase plans, the target is set to the CTV
of the corresponding motion state plus additional isotropic safety margins. The described approach is
capable of accounting for range changes caused by patient motion. Within this approach, it is possible
to accomplish rudimentary OAR sparing by using a super-position of two or more SFUD fields, which,
however, requires further down scaling of the particle numbers in each phase plan. The scaling factor
is given by multiplying the number of treatment fields by the number of motion phases. For example,
using 3 SFUD fields on the same target with 10 motions states results in a scaling factor of 1/30.
The drawbacks of this method are, that the use of intensity modulated particle therapy (IMPT) is
prevented and the inclusion of additional field specific range margins is not possible. Here, the robust
optimization could provide new opportunities, as it enables the consideration of additional range changes
while keeping the target volumes constant which is required for a multiple field IMPT optimization
[Lomax, 1999]. Thus, robust IMPT within 4D rescanning should be able to account for field-specific
range uncertainties beyond those depicted in the 4DCT. Further details on the implementation of the
robust 4D rescanning approach are described in the following section.
For the treatment delivery of a 4D RST, a dedicated TCS which is capable of handling a plan library,
and a fast real-time motion monitoring system are required. So far, this system exists as a prototype at
GSI only and has been validated in 2D film experiments [Graeff, 2014].
4.2 Optimization method
For the 4D rescanning method each phase plan is optimized separately and independently of the re-
maining phase plans. However, due to the design of GSI’s TCS and the implementation of the 4D dose
calculation, the initial dimension of each phase RST grid has to be the same for all motion phases in
order to create a valid 4D RST. To provide an RST which is large enough and which contains the target
structure in all motion states, an empty base RST, containing zero particle numbers for each spot, is cre-
ated, which serves as the starting point for the further setup of the phase plans. This is done by creating
a range ITV of the target volume, extended by isotropic PTV margins. The resulting range ITV is used to
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set up the initial base RST. This procedure ensures that the dimensions of the base RST are large enough
to contain the target volume in all motion phases.	
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Figure 4.2.: The flowchart schematically shows the setup of the field dose correlations (FDC) matrices for
the robust conformal 4D optimization. For each of the 10 motion states of a 4DCT, the FDCs for each
pencil beam are calculated and stored, based on 9 uncertainty scenarios (as shown in fig. 2.5) and the
expanded base RST. This approach results in 10 separate robust optimization problems, each consisting
of 9 FDC matrices from which different dose scenarios can be calculated.
The schematic procedure of the optimization is shown in figure 4.2. The robust treatment fields are
set up as described in chapter 2 (see figure 2.5). The 9 uncertainty scenarios, including the stored
HLUT tables and transformation matrices (WEPL space ↔ patient CT), are used for the setup of the
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FDC matrices. In contrast to the 4D ITV approach, as described in chapter 3, each of the phase raster
grids (RSTs) corresponds to one motion state of the 4DCT only. As mentioned, this typically leads to
10 independent optimization problems, which each consist of 9 corresponding FDC matrices, in case of
robust optimization on 9 uncertainty scenarios. The final plan library is created by applying the scaling
factor, which was introduced in the introduction of this chapter.
It is to be noted, that the 4D rescanning method requires the minimum particle number to be increased
in order to generate valid phase treatment plans. As described in section 1.6.3, at GSI, the default value
for the minimum particle number Nmin is set to 5000. To maintain plan validity after downscaling of the
optimized particle numbers, Nmin needs to be increased to 50 000 during optimization. For low target
doses, in the order of some Gy, a minimal particle number of 50 000 can lead to suboptimal optimization
results, as the lowest possible dose value generated by a single beam spot is increased; however, for
single fraction doses beyond 20 Gy(RBE) this effect becomes negligible.
4.3 Treatment planning
For treatment planning with the conformal 4D optimization, the same parameters as for the 4D ITV
optimization were used, including target weights, OAR weights, and target doses as stated in table 3.1.
For the conventional optimization, 3 mm PTV margins were used as described in chapter 3. For the
robust optimization, the robust parameters were set to ±3 mm for setup uncertainty and to ±3.5 % for
range uncertainty. As described above, plan optimization of the 10 phase RSTs was performed separately.
The separate optimization of these phase plans also enables the handling of large CTVs by allowing to
increase the number of target voxels considered in the optimization of each phase plan. Compared with
4D ITV optimization, a similar increase in considered target voxels would exceed the working memory.
This was the case for patient 3, whose left lung lobe was afflicted with two tumors with volumes of
123 cm3 and 136 cm3). As described in chapter 3, including voxels from all 10 motion phases during
4D ITV optimization for patient 3, exceeded the allowed working memory and led to abortion of the
calculation. Only by reducing the number of considered motion states from 10 to 3, allowed for regular
execution of the 4D ITV optimization. In addition to the reduction of considered motion states, random
voxel subsampling was necessary for both the conventional and robust 4D ITV optimization. Especially
for the robust 4D ITV optimization, omitting the random voxel subsampling exceeded the assigned work-
ing memory which led to an abortion of the optimization algorithm. In order to maintain comparability
with the results from chapter 3, random voxel subsampling was also used for conventional and robust
4D rescanning.
As presented in the study in chapter 3, plans for the left and right lung lobes were optimized separately,
since the treatment fields, assigned to each lung lobe, overlapped only marginally.
4.4 4D dose calculation
In the ideal case of 4D rescanning, each motion phase is irradiated with a conformal dose distribution
provided by the corresponding phase plan. Thus, acting on the assumption of having perfect synchroniza-
tion between treatment delivery and respiratory motion, no further correlation between organ motion
and the scanned beam is considered. The contributions of all pencil beams from all motion states are
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transformed to the reference state of the 4DCT, on which the RBE-weighted LEM-based dose is calculated
from the accumulated particle spectra.
As in chapter 3, plan quality of the dose distributions was assessed with a RA which considered 21 dif-
ferent uncertainty scenarios, which resulted in a total of 21 different dose distributions. Dose measures,
such as V95, D95, D99, D5, and HI were used to asses target coverage, and Dmax, Dvol, and V5 were used
to determine dose exposure to critical structures. The statistical significance between different treatment
plans was calculated by performing an unsigned paired rank test. The resulting p-values are divided into
three different classes: ∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001.
4.5 Results
Patient 3 was selected for the 4D rescanning method, as this patient showed the highest motion am-
plitude of up to 17 mm, in combination with large tumor volumes in the left lung lobe (123 cm3 and
136 cm3) (see table 3.1). Hence, patient 3 was a promising candidate to benefit from the conformal
treatment delivery provided by the 4D rescanning approach, as less normal tissue would be harmed.
Dose distributions
To illustrate the differences between robust 4D rescanning and robust 4D ITV optimization, axial and
coronal dose distributions of the nominal dose scenario are presented in figure 4.3, for the left lung lobe
of patient 3. In general, the margins generated by the robust 4D rescanning plan were smaller as those
generated by the robust 4D ITV plan. The reduced margins due to the more conformal irradiation by
robust 4D rescanning, were most pronounced in CTV1. This can be seen in the coronal view of patient 3
in figure 4.3(a) and (c), where especially the margins on the superior and (patient) left portion of the
target volume are visibly smaller (indicated by red arrows).
The conformal irradiation with the robust 4D rescanning plan also enabled superior target coverage
of the medial area between CTV1 and the heart. Although CTV1 was in close proximity to the heart,
which was considered as critical organ during the optimization, the robust 4D rescanning approach was
able to generate at least small safety margins. For the robust 4D ITV plan, a similar low dose area,
as described for patient 23 in chapter 3, was visible between the heart and CTV1. Since there was no
overlap between heart and CTV1, this low dose area did not impede the target coverage as much as for
patient 23; however, not much safety margin was left to handle potential patient setup or range errors.
The reduced heart dose due to the robust 4D rescanning plan can also be seen in figure 4.6, where the
DVHs for the left lung lobe of patient 3 are depicted for robust 4D ITV plan and the robust 4D rescanning
plan.
figure 4.4 shows the deteriorated dose distributions for the robust and the conventional 4D rescanning
plans, caused by the presence of setup and range uncertainties. The depicted uncertainty scenario is a
superposition of increased CT density, which causes range undershoots, and a setup error, which shifts
the patient’s isocenter in direction of the heart. Comparison between the resulting dose distributions of
both plans showed cold spots in the dose distribution of the conventional 4D rescanning plan, whereas
the dose distribution of the robust 4D rescanning plan still provided sufficient target coverage.
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(a) robust 4D rescanning (b) robust 4D rescanning
(c) robust 4D ITV (d) robust 4D ITV
Heart
Heart
CTV3
CTV1
CTV1
Figure 4.3.: Dose distribution of the nominal dose scenario for patient 3, showing (a) the axial view and
(b) the coronal view of the robust 4D rescanning plan, whereas (c) shows the axial view and (d) the
coronal view of the robust 4D ITV plan.
(a) conv. 4D rescanning (b) robust 4D rescanning
Heart
CTV1
Figure 4.4.: Coronal dose distribution of patient 3, exemplarily showing the deteriorated dose distribution
of the conventional 4D rescanning plan (a), compared to the robust 4D rescanning plan (b), in the pres-
ence of range undershoot (increased CT density) and a horizontal setup shift in direction of the heart.
The conventional 4D rescanning plan produces cold spots and fails to cover the complete target with
dose.
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As these dose cuts depict examples of the generated dose distributions only, the DVHs shown in the
next section give a more comprehensive picture of how dose coverage and OAR exposure are affected by
range and setup uncertainties.
DVHs
The DVHs for the conventional 4D rescanning plan for patient 3 are shown in figure 4.5, for the left
and the right lung lobe separately. For the conventional 4D rescanning approach, IMPT with 3 mm PTV
margins was used. The RA on 21 uncertainty scenarios revealed a huge uncertainty in target coverage.
For the left lung lobe of patient 3, conventional 4D rescanning generated excessive overdose, especially
for CTV3, while in the right lung lobe, underdosage of the target was the major issue, in particular for
CTV2. For the right lung lobe, a dose volume constraint of D0.5cc < 12.4 Gy(RBE)was used for the smaller
airways. As described in chapter 3, the Dvol was normalized to the above stated limit and the constraint
was counted as violated, when the 100 % mark was exceeded. For conventional 4D rescanning, the
constraint is fulfilled in 90.5 % of the uncertainty scenarios, with D0.5cc = (77.0± 12.0)%.
To assess the size of the uncertainty bands, the D50 spread is stated for all 5 CTVs of patient 3 in
table 4.1. When compared to robust 4D rescanning plan, the average D50 spread is larger for the
conventional 4D rescanning plan by a factor of about 14 . The table also shows the D50 values for the
conventional and the robust 4D ITV plan. In comparison to robust 4D rescanning, the increase in average
dose spread is less than a factor 2. Compared to the conventional 4D rescanning plan, the D50 spread of
the conventional 4D ITV plan is 1/3 smaller, but is still considerably larger than for the two robust plans.
Target
D50 spread in [%]
conventional robust
4D rescanning 4D ITV 4D rescanning 4D ITV
CTV 1 10.90 6.33 0.64 1.20
CTV 3 8.01 6.52 0.70 1.14
CTV 2 7.28 4.60 0.73 0.96
CTV 4 7.75 5.15 0.46 1.09
CTV 5 8.88 4.81 0.55 1.03
CTVavg ± std 8.6± 1.4 5.5± 0.9 0.6± 0.1 1.1± 0.1
Table 4.1.: Width of D50 dose spread for all 5 targets of patient 3, stating results for 4 different 4D
optimization approaches.
The DVHs of the robust 4D ITV plan for patient 3 are shown in figure 4.6(a) for the left lung lobe
and in figure 4.7(a) for the right lung lobe. Figures 4.6(b) and 4.7(b) show the DVHs of the robust
4D rescanning plan for the left and right lung lobe of patient 3. When compared to the robust 4D ITV
plan, the robust 4D rescanning plan reduced target overdose, as steeper dose fall-offs were generated.
The reduction of target overdose due to robust 4D rescanning was more pronounced for the right lung
lobe, whereas the width of the uncertainty band around 100 % of the target dose was on a similar level.
For the left lung lobe, the dose distributions generated from the robust 4D rescanning plan improved
the avoidance of target underdosage, as can be seen in the tighter curvature of the uncertainty band in
figure 4.6(b).
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(a) Left lung lobe.
(b) Right lung lobe. Star symbol denotes the dose volume constraint for the smaller
airways (D0.5cc ≤ 12.4GyE), which is fulfilled in 90.5% of uncertainty scenarios.
Figure 4.5.: DVHs with uncertainty bands resulting from robustness analysis for patient 3, using confor-
mal 4D rescanning with conventional IMPT with 3mm PTV margins. The solid lines are average DVH
curves and the light colored areas are uncertainty bands, depicting the envelope of all 21 4D dose distri-
butions. All target DVHs are normalized to respective target doses and OAR DVHs are normalized to the
corresponding limit value of the DVH constraints from Benedict et al. [2010].
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Comparing the dose exposure to the smaller airways in the right lung lobe, robust 4D rescanning
could further reduce the volume dose from (84.9± 6.5) % to (76.3± 7.5) % of the corresponding limit,
which led to a fulfillment of the OAR constraint in 98.8 % and 100.0 % of the scenarios, respectively.
Although both robust optimization methods fulfilled the volume dose constraint for the smaller airways
in the majority of uncertainty scenarios, only the robust 4D rescanning plan allowed for an additional
improvement to the dose exposure by shifting the DVH curves to lower dose values (for values below
about 30 % of the target dose).
CTV coverage
Figure 4.8 shows the summarized CTV coverage for patient 3 as boxplots for the 4 aforementioned
optimization approaches. The same dose measurements as in chapter 3 were evaluated, namely V95,
D95, D99, D50 and the homogeneity index (HI). In the boxplots, the black lines indicate the median
values, and the black X’s symbols denote the average values. The boxes describe the 1st and 3rd quantiles,
and the whiskers represent 3 standard deviations, including approximately 1 % to 99 % of all values in
the distribution of a dose measurement. Outliers are represented by crosses. Since the distribution of
these values is not Gaussian, statistical significance has been calculated by using an unsigned rank test.
The resulting p-values are divided into three different classes: ∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p <
0.001.
As already shown in the DVH plots, for the conventional 4D rescanning plan, the RA revealed a sig-
nificantly reduced dose coverage. In comparison to the two robust plans and the conventional 4D ITV
plan, especially the median values for V95, D95 and D95 were considerably lower for the conventional
4D rescanning. The conventional 4D rescanning plan also showed significantly longer bottom whiskers.
Considering V95, the two 4D ITV plans and the robust 4D rescanning plan yielded similar results. For
the D95 values, the robust 4D rescanning plan was significantly better than all other plans. For the D99
values, the robust 4D rescanning yielded significantly better results compared to the conventional 4D
rescanning plan and robust 4D ITV plan. Compared to the conventional 4D ITV, the distribution of D99
values was at least on a similar level. Although, the bottom whisker limit was slightly lower at 90.5 %,
compared to the robust and conventional 4D ITV plans, with 92.6 % and 93.6 %, respectively.
Compared to the conventional 4D rescanning plan, the two robust approaches showed narrower dis-
tributions of the D50 values and smaller HI values, which illustrates the efficacy of robust optimization
against dose deterioration due to potential error scenarios. Smaller uncertainty bands and improved
homogeneity are also visible in the DVH plots of both robust plans in figures 4.6 and 4.7, compared to
the DVH of the conventional 4D rescanning plan in figure 4.5. While for both robust plans, the whiskers
were close to the D50 median value, the width of D50 distribution for conventional 4D rescanning plan
was 12.9 %, and the distribution contained values from 97.7 % to 110.6 %. For the conventional 4D ITV
plan, the width of the D50 distribution was slightly smaller at 6.4 %, and contained values from 103.4 %
and 109.8 %.
For the HI values, the difference between the conventional 4D rescanning plan and the 3 other plans
was even more pronounced: apart from the increased upper limit of the whisker above 45 %, also
the median HI value was significantly higher at 11.6 % for the conventional 4D rescanning plan. The
other plans resulted in HI median values of 3.4 %, 3.4 % and 5.8 % for the robust 4D rescanning plan, the
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(a) Robust 4D ITV plan.
(b) Robust 4D rescanning plan.
Figure 4.6.: DVHs with uncertainty bands for the left lung lobe of patient 3, comparing robust 4D ITV
and robust 4D rescanning. Robustness parameters were in both cases ±3mm setup and ±3.5% range
uncertainty. The solid lines are average DVH curves and the light colored areas are uncertainty bands,
depicting the envelope of all 21 4D dose distributions. All target DVHs are normalized to respective
target doses and OAR DVHs are normalized to the corresponding limit value of the DVH constraints from
Benedict et al. [2010].
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(a) Robust 4D ITV plan. The SA dose volume constraint is fulfilled in 98.8% of un-
certainty scenarios.
(b) Robust 4D rescanning plan. The SA dose volume constraint is fulfilled in 100.0%
of uncertainty scenarios.
Figure 4.7.:DVHs with uncertainty bands for the right lung lobe of patient 3, comparing (a) robust 4D ITV
and (b) robust 4D rescanning. Robustness parameters were in both cases ±3mm setup and ±3.5% range
uncertainty. The solid lines are average DVH curves and the light colored areas are uncertainty bands,
depicting the envelope of all 21 4D dose distributions. Star symbols denote the dose volume constraint
for the smaller airways (D0.5cc ≤ 12.4GyE). All target DVHs are normalized to respective target doses and
OAR DVHs are normalized to the corresponding limit value of the DVH constraints from Benedict et al.
[2010].
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Figure 4.8.: Summarized CTV coverage of patient 3 shown as boxplots of V95, D95, D99, D5 and HI
for the robust and conventional 4D ITV plans and for the robust and conventional 4D rescanning
plans. The black lines indicate the median values, whereas the black X’s denote the average values.
The boxes represent the 1st and 3rd quantiles, while the whiskers represent the environment of 3 stan-
dard deviations. Statistical significance, calculated with an unsigned rank test, is indicated by a p-value
(∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001).
robust 4D ITV plan, and the conventional 4D ITV plan, respectively. The significantly smallest distribution
of HI values was generated by the robust 4D rescanning plan. In summary, the robust 4D rescanning
plan provides the most robust target coverage, as also the D50 dose spread was the smallest.
OAR exposure
For patient 3, the dose exposure to several OARs is depicted in figures 4.9 and 4.10. The distributions
of volume dose values Dvol, maximal point dose values Dmax, and V5 values are shown as boxplots. Since
Dvol and Dmax were normalized to the limit values of the corresponding DVH constraints from Benedict
et al. [2010], a constraint was counted as violated, when the value did exceed the 100 % mark. As can
be seen in figure 4.9, no constraints were violated for esophagus, aorta, and trachea. For the majority
of dose measurements and OARs, the conventional 4D rescanning plan yielded the lowest dose values,
followed by the robust 4D rescanning plan, which yielded the second lowest dose values. There was no
discernible trend for the robust and conventional 4D ITV plans, whose dose distributions consisted of
higher values than for the two 4D rescanning plans for most of the OARs.
For the smaller airways, only the robust 4D rescanning plan could fulfill the dose volume constraint
in all uncertainty scenarios, whereas the remaining plans violated the DVH constraint in at least some
uncertainty scenarios: for the conventional 4D rescanning plan the DVH constraint was violated in 8.5 %
of the scenarios and in 1.2 % for both the robust and the conventional 4D ITV plans. Although the
maximal dose constraint was neglected for the original SBRT treatments of patient 3, both robust plans
yielded lower Dmax distributions than both conventional plans.
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Figure 4.9.: OAR doses of patient 3 shown as boxplots of Dvol, Dmax and V5. Results are shown for the
robust 4D ITV plan and for the robust and conventional 4D rescanning plan. The black lines indicate the
median values, whereas the black X’s denote the average values. The boxes represent the 1st and 3rd
quantiles, while the whiskers represent the environment of 3 standard deviations. Statistical significance,
calculated with an unsigned rank test, is indicated by a p-value (∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p <
0.001).
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Apart from the conventional 4D ITV plan, the volume dose values of the heart were below the con-
straint for all three remaining methods, where the conventional 4D rescanning plan achieved the lowest
values at a median Dvol of 34.5 %, followed by 57.0 % and 66.0 % for the robust 4D rescanning and the
robust 4D ITV plans, respectively. The conventional 4D ITV plan violated the dose volume constraint
for the heart in 52.4 % of the uncertainty scenarios, with a median Dvol value at 99.0 %. Except for the
conventional 4D rescanning plan, the maximal dose constraint for the heart was violated for all three
remaining plans in all considered uncertainty scenarios. It is to note, that the robust 4D rescanning plan,
though violating the Dmax constraint, still generated a significantly lower dose distribution than both the
robust and the conventional 4D ITV plans.
For the spinal cord, the most unfavorable dose distribution was generated by the conventional 4D
ITV plan. For conventional 4D ITV plan, the DVH constraints for Dvol and Dmax were violated in 3.6 %
and 23.8 % of the uncertainty scenarios, respectively. All other plans fulfilled the DVH constraints in all
considered uncertainty scenarios with dose distributions significantly below the 100 % mark. The lowest
dose exposures to the spinal cord were provided by both the conventional and the robust 4D rescanning
plans, where the conventional 4D rescanning plan provided even lower dose values.
In absence of a maximal dose limit for the lung, the Dmax values were normalized to the highest
target dose in the corresponding lung lobe, which resulted in the following distributions as shown in
figure 4.10. The lung doses were calculated for the lung volume minus the CTV volumes. In addition,
values for V20 and V90 were stated in order to assess the low and high dose exposure to the lung. Since,
as mentioned in chapter 3, the lung is a parallel organ, no limit is stated for the Dmax values in Benedict
et al. [2010], and the Dmax values were normalized to the target doses. Although Dmax values are not
that important, the most favorable distribution of Dmax values was generated by the conventional 4D
ITV plan, while the most unfavorable distribution was yielded by the conventional 4D ITV plan. The
V20 distributions were on similar levels for both the robust and the conventional 4D rescanning plans at
about 25 %, and ther were significantly lower than both the robust and the conventional 4D ITV plans.
Nonetheless, the significantly lowest distribution was generated by the robust 4D rescanning plan. The
V90 values were on similar low levels for all 4 plans, where both 4D rescanning plans yielded the lowest
values.
4.6 Discussion
Regarding the results for target coverage in context with OAR exposure, the use of 4D rescanning with
conventional IMPT could not be recommended for patient 3. The uncertainty bands, as can be seen in the
DVH in figure 4.5, were too large to ensure safe delivery of the prescribed dose to the target in presence
of setup of range uncertainties. Although, compared to both robust plans and the conventional 4D ITV
plan, the dose exposure to the critical organs was significantly lower for the conventional 4D rescanning
plan, the huge uncertainties in target coverage neutralized this advantage. For the smaller airways,
which have been the most critical organ in the studies performed by Anderle et al., both 4D rescanning
methods fulfilled the volume dose constraint in more than 90 % of the considered uncertainty scenarios.
When taking into account the significantly better target coverage provided by the robust 4D rescanning
plan, patient 3 would profit even more from the robust 4D rescanning plan.
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Figure 4.10.: Dose exposure of the ipisilateral lung of patient 3 as boxplots of Dmax, V20 and V90. Re-
sults are shown for the robust 4D ITV plan and for the robust and conventional 4D rescanning plan.
The black lines indicate the median values, whereas the black X’s denote the average values. The
boxes represent the 1st and 3rd quantiles, while the whiskers represent the environment of 3 stan-
dard deviations. Statistical significance, calculated with an unsigned rank test, is indicated by a p-value
(∗ 7→ p < 0.05, ∗∗ 7→ p < 0.01, ∗∗∗ 7→ p < 0.001).
As shown in figure 4.3, the application of the conformal 4D rescanning strategy resulted in reduced
safety margins around the CTVs, which led to reduced normal tissue dose. For the right lung lobe of
patient 3, the shape of DVH curves of the smaller airways were even further improved, since there was
a visible shift of the dose curves towards lower doses below 40 % of the target dose. As target coverage
was almost not affected by the improved OAR sparing, robust 4D rescanning yielded a more favorable
plan than robust 4D ITV optimization.
For the 4D dose calculations for the 4D rescanning plans, further consideration of residual motion
is neglected, which could mean an overestimation of the plan quality. Nevertheless, for patient 3, the
comparison between the robust 4D ITV plan and the robust 4D rescanning plan, showed only a small
difference in D50 dose spread (as can be seen in table 4.1). This suggests, that including residual
motion into 4D dose calculation for robust 4D rescanning plans would only increase the extension of
the uncertainty bands to the level of D50 values yielde with the robust 4D ITV plan, which was still
considerably lower than for both conventional plans.
The large values for the maximal point dose delivered to the heart were an issue for all 4 treatment
planning strategies. In comparison to patient 23 presented in chapter 3, treatment planning for patient
3 showed a similar level of complexity: Due to the close proximity of the 2 left-sided tumors to the heart,
the two objectives to reach high target coverage with D99 > 100 %, and to stay below the Dmax limit for
the heart, were found to be competitive. It was not possible to sufficiently accomplish both objectives
simultaneously. Except for the conventional 4D rescanning plan, the corresponding DVH constraint was
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violated for the other 3 plans in all uncertainty scenarios considered in the robustness analysis. Even
for the conventional 4D rescanning plan, the Dmax limit was still exceeded in 14.3 % of the uncertainty
scenarios. As the chosen voxel weights were smaller for CTV voxels than for heart voxels, and the OAR
dose limit Dlimit was set to 88 % of the prescribed dose, the sparing of the heart was expected to improve;
however, the optimization resulted in treatment plans, which favored the fulfillment of the CTV objective.
To maintain comparability, the same voxel weights and Dlimit were used for all 4 optimization strategies,
but as only the conventional plan generated reasonable sparing for the heart, further reduction of the
OAR dose limit and higher heart voxel weights must be considered. However, as already suggested
by the conventional 4D rescanning plan, further improvement of the heart spearing will be possibly
achievable at the cost of CTV target coverage only. It is to mention, that both robust treatment planning
strategies still yielded lower maximal heart doses than the conventional 4D ITV approach, given the
same voxel weights and the for robust optimization empirically increased planned dose (as shown in
table 3.1); however, the use of a fractionated treatment might be reasonable, at least for the left lung
lobe of patient 3 with a prescribed dose of 27 Gy.
4.7 Conclusion
The robust 4D rescanning method, which relies on a library of robust treatment plans for each motion
phase, enabled an increase of target coverage of moving tumors due to a more conformal irradiation,
while simultaneously improving OAR sparing. Using the 4D rescanning approach with conventional
IMPT, which relies on PTV margins, failed to provide sufficient target coverage, since large uncertainty
bands were emanating in the DVHs in presence of patient setup errors or range uncertainties.
That conventional IMPT without range correction will tend to fail target coverage, was already shown
by Graeff et al. This conclusion was the rationale for the proposal of 4D rescanning with SFUD on
range specific ITVs [Graeff et al., 2012]. Robust 4D rescanning provides the benefit of straightforwardly
using IMPT optimization, which allows to account for additional range uncertainties beyond the motion
induced range changes implicitly considered via the different motion states of a 4DCT. In addition,
robust optimization enables the reduction of dose gradients between treatment fields, which considerably
increases treatment plan robustness against patient setup errors or particle range changes.
Although, the method has been only tested in-silico for a single patient, the trend for improved plan
quality is already evident. Compared to the robust 4D ITV method, the translation of 4D rescanning to
be used in a clinical setting is more complicated, since also changes to the treatment control system are
required. So far, this method has been only implemented at GSI [Graeff et al., 2013]; however, there
is an ongoing cooperation with National Center of Oncological Hadrontherapy, Pavia, Italy (CNAO) to
update the medical cave at GSI with the latest TCS of the CNAO facility, and to implement 4D rescanning
into the CNAO TCS. On a long-term view, this cooperation could facilitate the use of 4D rescanning in
clinical trials.
In particular, when a particle therapy facility does not have an exceptional accelerator, such as HIMAC
(in Chiba, Japan), which provides extremely fast gating and rescanning, the approach of robust 4D
rescanning could be a promising method to treat moving tumors. As shown in this chapter, robust
4D rescanning could accomplish beneficial treatment delivery with significantly improved OAR sparing,
while providing sufficient target coverage.
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5 Discussion
In this chapter, the results of the previous chapters 2, 3 and 4 are discussed in a comprehensive perspec-
tive.
5.1 Robust optimization for carbon ions
As described in the introduction of chapter 2, a variety of different robust optimization methods currently
exists for proton therapy. That carbon therapy shares the same susceptibilities to patient setup errors and
particle range changes as proton therapy, was the main rationale of transferring those robust optimization
methods to carbon ion therapy. In addition, robust optimization methods provide smoothing of internal
dose gradients, which can occur when MFO IMPT optimization is used.
Although the physical principals are the same for proton and carbon ion therapy, the consideration of
a variable RBE during treatment planning for carbon ion therapy does increase the complexity of the bi-
ological dose calculation, and requires the use of nonlinear optimization algorithms. Thus, compatibility
with biological dose optimization led to the decision of adapting a voxel-wise worst-case optimization
method for the GSI in-house TPS, TRiP4D. The implemented worst-case optimization is currently based
on the consideration of 9 uncertainty scenarios in total, including a nominal scenario, two range uncer-
tainty scenarios with rang overshoots and range undershoots, and six setup error scenarios where the
patient’s isocenter is shifted in direction of the major anatomical axis.
As shown for a RA in chapter 2, the treatment plans generated with robust optimization showed in-
creased robustness, not only against the 9 uncertainty scenarios, which were already considered in the
worst-case optimization, but also against the superposition of range changes and setup errors, which
resulted in a total of 21 uncertainty scenarios. Compared to conventional optimization, robust optimiza-
tion increased the robustness of the target dose distribution, which was expressed by a considerable
reduction of the uncertainty bands around the average DVH curve and an improvement of the HI val-
ues, showing convergence of the DVHs to the ideal step shape. These results were expected, as the
worst-case method has already been successfully used for proton plan optimization. Nonetheless, using
the plain worst-case cost function as proposed for robust optimization of proton treatment plans, led
to considerable overdosage of the target volume for carbon ions. In the basic version of the worst-case
cost function, as shown in equation (2.2), the scenario with the lowest dose is selected for target voxels
and the scenario with the highest dose is selected for OAR voxels. The explanation for the generation of
overdosage in the target volume was found to be the absence of a correction term for the maximum dose
in the robust cost function. Due to the selection of the scenario delivering the lowest dose to a corre-
sponding target on a voxel-wise basis, the robust optimizer only adapts particle numbers for underdosed
target voxels, which will typically result in an increase of particle numbers, and therefore in an increase
of dose delivered to the target volume. At least for the conjugate gradient optimization algorithm used
in TRiP4D, the robust cost function presented in equation (2.2) prevents a reasonable limitation of the
maximum dose delivered to the target volume.
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The generation of target overdosage can be suppressed by introducing an additional maximum dose
term into the robust cost function, as described in equation (2.3). For robust proton plan optimization,
such a maximum dose term has been originally proposed by Liu et al. [2012] as an optional measure to
avoid hot spots within the target dose distribution. For the robust optimization of carbon ion treatment
plans, this maximum dose term is no longer optional and becomes vital in order to generate robust
treatment plans without unrestricted overdosage, and is therefore highly recommended. Consequently,
the maximum dose term was used for robust 4D ITV optimization in the patient study presented in
chapter 3, and for robust 4D rescanning in chapter 4.
5.2 Robust optimization with opposing objectives
In chapter 3, a robust version of the 4D ITV optimization approach, as proposed by [Anderle, 2016],
based on the work of [Graeff, 2014], was presented. The robust 4D ITV strategy used the worst-case
cost function as presented in chapter 2, including the maximum dose term and was tested on a cohort
of 8 complex lung cancer patients. These patients were the same 8 lung cancer patients as described in
the study by Anderle et al. [2018]. To maintain compatibility, the same objectives for target coverage
and OAR sparing have been adopted from Anderle et al. [2018]. For target volumes, the objective was
to provide D99 values ≥ 100 %, and for critical organs, the objective was to meet the OAR dose limits
described by [Benedict et al., 2010].
Huge effort was put by Anderle et al. into the treatment planning, and into the treatment planning
software TRiP4D, in order to achieve these objectives as best as possible. This included the implementa-
tion of multiple target optimization and the implementation of objective optimization, where the entire
optimization is repeated several times adapting weights and planned dose on a voxel-wise basis, until
the desired objective is fulfilled. In the study of Anderle et al., plan robustness was tested for 4 res-
piratory motin patterns only. Although 4D dose calculation implicitly considered temporal changes of
patient anatomy, the dose calculation was performed on a nominal case only, not considering any further
uncertainties. A robustness analysis, as described in chapter 2, revealed that in presence of patient setup
errors and range uncertainties, the delivered dose distributions can be considerably deteriorated.
Using the robust 4D ITV planning strategy, uncertainty in dose distributions could be reduced in many
cases, improving target coverage and OAR sparing simultaneously. Over all patients, the plan acceptance
rate for fulfillment of the smaller airways DVH constraint could be raised from 79.8 % of the considered
uncertainty scenarios for the conventional 4D ITV plans to 98.8 % for the robust 4D ITV plans. It is to
note, that there are cases, where the robust 4D ITV approach reaches its limits, for example when a target
volume overlaps with a critical organ. This situation was found in patient 23, where the tumor volume
overlapped with the smaller airways. Here, the current implementation of the robust optimization was
only able to fulfill one of the two required objectives: when robustness was increased for the target
coverage, the OAR exposure was considerably increased simultaneously and vice versa. Unless this issue
is overcome, for complex cases, the robust treatment planning using the worst-case method will result
in two extreme kinds of treatment plans, one favoring robust target coverage, the other providing robust
OAR sparing. Here, the experienced decision of a physician, on which of both objectives it to prioritize,
is required. Possible improvements to the presented robust optimization algorithms are mentioned in
the outlook chapter.
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5.3 Study limitations
The 4D dose calculations presented in chapter 3, were based on regular respiratory motion patterns,
which are typically not present during real patient treatments, where respiratory amplitude and period
are most likely to vary over time, between 4DCT acquisition and actual treatment, and during the treat-
ment delivery itself. The topic of irregular patient motion is currently investigated at GSI: an adapted
4D dose calculation algorithm has recently been implemented and is currently undergoing tests. This
algorithm relies on a huge series of 4DCT data, which represent the temporal changes in patient anatomy
over numerous respiration cycles. So far, it is still unclear how to reasonably produce comparable data
for real patients. As a substitute for current testing purposes, these image data sets are artificially gen-
erated with the XCAT phantom. A potential solution for the generation of real patient data could be the
use of 4D MRI images which are registered on a CT image [Boye et al., 2013]. Hence, the results of the
robust 4D ITV optimization are so far only valid for regular motion.
A further limitation of this study is caused by the deformable image registration (DIR), which is used
for contour propagation or transformation of pencil beam contributions of different motion phases to
the reference phase. As shown in [Anderle, 2016], DIR can generate errors such as deficient inverse
consistency, where the initial starting point is not recovered, when first using the forward transformation
map, which leads from the moving frame to the reference frame, and subsequent use of the correspond-
ing backward transformation map, which leads from the reference frame to the moving frame. When
comparing conventional and robust treatment plans which used the same deformation maps during op-
timization and 4D dose calculation, those errors due to DIR should be marginal extent; however, this
has to be kept in mind, when results of carbon ion treatment planning is compared to photon therapy, as
done in Anderle et al. [2018]. To mitigate these potential errors, Kristjan Anderle proposed a strategy for
quality assurance of image registrations, which is already published as a module for Slicer3D [Anderle,
2016].
5.4 Robust methods for conformal 4D optimization
The use of the worst-case method to optimize robust carbon ion treatment plans was successfully used
for the 4D ITV and for the 4D rescanning approach. For both strategies, robustness against patient
positioning errors and range changes could be increased. Both strategies allowed for generation of
field-specific range margins which were beyond the motion induced range changes, which are implicitly
accounted for by using the information on temporal changes of a patient’s anatomy provided by 4DCTs.
For the patient study presented in chapter 3, where the 4D ITV approach was compared for robust
and conventional optimization, the issue with opposing objectives (as described in the previous section)
appeared in cases of close proximity between target volumes and critical structures. In these cases, the
robust 4D ITV approach reached its limits.
This is where robust 4D rescanning could be advantageous due to the more conformal irradiation of
the moving target. At least for patient 3, which was exemplarily presented in chapter 4, the robust 4D
rescanning plan yielded a similar target coverage while OAR doses were decreased in the majority of
critical organs, compared to the robust 4D ITV method. The dose reduction was especially pronounced
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for the smaller airways and the heart. It is to note that, although robust 4D rescanning yielded promising
results, the 4D dose calculation for this method assumes perfect delivery of each phase RST to the
corresponding motion state. As perfect delivery is unlikely to occur, further degradation of the dose
distributions for real patient treatments must be expected.
5.5 Robust optimization allows safe IMPT for complex patients
As shown in chapters 2, 3 and 4, the assumption of a static dose cloud is not given. In presence of
patient setup errors and range uncertainties, the deterioration of the delivered dose distribution can
not be mitigated by conventional, isotropic PTV margins, as used in photon radiotherapy. In these
cases, robust optimization allows for the safe application of IMPT in carbon ion therapy, also when dose
gradients are present in the target area.
In case of 4D treatment planning, the use of robust optimization is even more beneficial, as con-
ventional 4D optimization enables the consideration of motion induced range changes, but leads to
field-specific changes of the treatment volume at the same time, when range margins are applied; how-
ever, congruent treatment volumes are a requirement for safe IMPT. The robust optimization algorithm
allows for the incorporation of field-specific range changes and simultaneous IMPT optimization on con-
gruent target volumes. Robust 4D optimization additionally enables the consideration of global range
changes due to respiratory motion.
Only with robust 4D optimization strategies, as presented in this thesis, it is possible to safely plan
carbon ion treatments with IMPT for complex lung cancer patients with large tumor motion and OARs
in close proximity.
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6 Outlook
A first topic, which could be investigated in further studies, is the elimination of the exclusive assignment
of voxel as target or OAR in TRiP4D. This approach could improve the robustness of treatment plans in
patient cases, were the target is in close proximity to a critical structure. Potentially, this modification
could also enable multi criteria objective optimization with opposing objectives, as presented in chapter 3
and 4.
Similar effects could be tested by implementing an all-plan or minimax optimization, which would
avoid the overly conservative plans which are generated by the worst-case method. Especially the
implementation of a minimax approach, as proposed by Fredriksson et al. [2011], should be fairly
straightforward to implement into TRiP4D by a rearrangement of sub parts of the optimization algo-
rithm. To achieve a minimax optimization, the step in the algorithm, where the worst-case is selected
from a set of scenarios on a voxel-wise basis, would need to be shifted to the level of the cost function
itself. For a set of cost functions, which are established from a set of uncertainty scenarios, the worst-case
is the cost function generating the highest value. When in each iteration step of the optimization the
cost-function with the highest value is selected, this leads to a minimization of the maximum value of
the cost-function, which also describes the name origin of this method.
The all-plan approach would base on the 4D optimization introduced into TRiP4D by Graeff et al.
Already in the non-robust 4D optimization, there is a distinctive field dose correlation (FDC) matrix for
each motion state, set to be independent and of equal weights. These motion-state-specific FDC matrices
are co-existing during the optimization, all contributing to the calculation of gradient of the cost function
which determines the next optimization step. By also considering all uncertainty scenarios per motion
phase as equal and independent possibilities, a (robust) all-plan optimization could be achieved.
An interesting approach has been proposed by Engwall et al. [2018], where temporal uncertainties
during delivery are already accounted for during the plan optimization. Partial doses of pencil beams
in different motion states are calculated and transformed to a reference phase, using the transformation
maps from a deformable image registration, which is done for different respiratory cycles. Further on,
these results are used as input for a robust optimization using the minimax method. Engwall et al.
have shown for 3 NSCLC stage IV patients, that their proposed method can reduce the dose degradation
caused by interplay. Due to the nonlinearity of the RBE-weighted biological dose calculation in TRiP
and the complexity of the temporal correlation between treatment delivery and respiratory motion, the
implementation of the approach proposed by Engwall et al. into TRiP4D could become difficult.
Eventually, the robust optimization methods could be tested on consecutive patient data sets, such
as weekly re-CTs, which describe anatomical variations of the patient in a more realistic manner. In
particular, when compared to the simplified approach of shifting the isocenter or globally manipulating
CT density to generate range changes. Weekly 4DCTs with clinical high precision patient positioning are
currently quite rare; however, by future cooperation with the particle therapy center in Marburg and
Dresden, suitable patient data sets should be soon available.
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A Appendix of Chapter 2
A.1 TRiP commands for robust optimization
A.1.1 Robust field setup
Before performing a robust optimization in TRiP4D, the uncertainty parameters for the robust fields
which will include the different uncertainty scenarios have to be stated. This step is done during the
normal field setup. There are two basic commands (the *-symbol indicates the minimum characters
required for TRiP4D to identify the command):
• robustrange*shift(∆range): add 2 range scenarios with shifted CT density (by ±∆range [%]).
• robustrange*shift(∆position): add 6 position scenarios with a shifted iso-center in all major direc-
tions (by ±∆position [%])
If these two commands are appended to the normal field commands with typical parameters like
∆range = 3.5 % ∆position = 3 mm, 8 additional uncertainty scenarios are generated on top of the nominal
case, resulting in 9 possible scenarios per field. It is important, that all treatment fields used in an
optimization contain the same number of scenarios. Otherwise the optimization will interrupt. The
combination of robust and non-robust fields is not possible in TRiP4D so far, although the question arises
if it would be reasonable at all. It is also recommended to use the same robust parameters for all field
targeting the same CTV.
Besides the basic setup of robust fields the commands already mentioned have also the ability of
processing additional parameters: The additional parameters for the robustrangeshift command is a
systematic H2O offset in mm, which gets added onto the H2O range of the high CT density scenario and
gets subtracted from the low CT density scenario:
• robustrange*shift(∆range,∆H2O): add 2 range scenarios with shifted CT density (by ±∆range [%])
with an additional H2O offset of ±∆H2O [mmH2O].
The robustpositionshift command generates an isotropic shift of the iso-center in all major directions.
If more anisotropic shifts are desired, this can be done by append more parameters, affecting the major
CT directions independently:
• robustpos*itionshift(∆x ,∆y,∆z): add 6 position scenarios with a shifted iso-center by ±∆x in
x-, ±∆y in y- and ±∆z in z-direction, respectively.
For completely independent anisotropic position shifts, the parameters for each direction can also be
split up in two values, one in the positive direction of the chosen axis, the other in negative direction:
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• robustpos*itionshift(−∆x ,+∆′x ,−∆y,+∆′ y,−∆z,+∆′z): add 6 position scenarios with a
shifted iso-center by −∆x and +∆′x in x-, −∆y and +∆′ y in y- and −∆z and +∆′z in z-direction,
respectively.
As described in chapter 2 it is also possible to create an additional RBE scenario for the robust opti-
mization, which is generated by the following command:
• robustRBE*uncertainty(∆RBE): adds a robust scenario with RBE uncertainty, scaling the RBE
values by +∆RBE[%] for OAR voxel and −∆RBE[%] for target voxel.
A.1.2 Robust optimization
If robust treatment fields are set up, TRiP4D automatically performs a robust optimization. Robust op-
timization is available for physical and biological plan optimization using the Fletcher-Reeves conjugate
gradient algorithm (FR) or the most recent and faster implementation of Fletcher-Reeves (FDCS).
The robust optimization supports multi threading, which is recommended to use, to save computation
time. The number of threads can be requested by the already existing command maxthreads(Nmax).
The default value is 1 thread.
An additional parameter for robust optimization is the dose weight for the maximal dose term of the
cost function (as described in section 2.2.3):
• maxdosew*eightfactor(wMDW): which can be any positive real number. The default value is 1.0.
As described in chapter 2 it is recommended to always use the maximal dose term in the cost function
for the robust optimization, since it significantly reduces over dose in the target volume.
A.1.3 Additional commands for robustness analysis
For the insertion of patient setup errors or range uncertainties into the dose calculation, the following
commands can be used.
To affect the particle ranges, the CT density can be altered by shifting the value of the Hounsfield unit
lookup (as described in chapter 2). After the HLUT is loaded for a dose calculation, it can be shifted by
the following command:
• hlut / s*hift(∆range):, which shifts the value by ∆range [%].
To model a patient setup error, the target point of the assigned field is shifted, i.e. the patient’s
iso-center, while the treatment fields are loaded:
• field / sh*ifttarget(∆x ,∆y,∆z) shifts the patient’s iso-center in the field by ∆x ,∆y and ∆z in
[mm].
So far the shifttarget command is field specific, meaning, that in the case of a multiple field optimiza-
tion, the same shift must be applied in all corresponding fields.
118
B Appendix of Chapter 3
B.1 Dose limits for organs at risk
OAR dose limits used in SBRT and PT treatment planning for different fractionation schemes are shown
in table B.1. Two limits were used: The first limitation was a maximum dose to single voxel DMax and
the second a maximum dose deposited to a specific OAR volume DVolume.
Organ
Critical
volume [cc]
Volume dose [Gy] Maximum point dose [Gy]
1 3 5 1 3 5
Heart 15.0 16.0 22.0 24.0 30.0 32.0 38.0
Spinal cord 0.35 10.0 14.0 18.0 21.9 23.0 30.0
Smaller airways 0.5 12.4 13.3 18.9 23.1 21.0 33.0
Esophagus 5.0 11.9 15.4 17.7 25.2 19.5 35.0
Trachea 4.0 10.5 20.2 15.0 30.0 16.5 40.0
Aorta 10.0 31.0 37.0 39.0 45.0 47.0 53.0
Stomach 10.0 11.2 12.4 16.5 22.2 18.0 32.0
Table B.1.: Dose constraints for various OARs for 1, 3 and 5 fractions, denoted as respective numbers.
Limits were used in SBRT and PT treatment planning. Data taken from [Benedict et al., 2010].
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